Assessment of Evidence for COVID-19-Related Treatments 08/19/2021

The information contained in this evidence table is emerging and rapidly evolving because of ongoing research and is subject to the professional judgment and interpretation of the practitioner due to the uniqueness of each medical facility’s approach to the care of patients with COVID-19 and the needs of individual patients. ASHP provides this evidence table to help practitioners better understand approaches related to treatment and care. ASHP has made reasonable efforts to ensure the accuracy and appropriateness of the information presented. However, any reader of this information is advised ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the evidence table in any and all practice settings. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this evidence table and will bear no responsibility or liability for the results or consequences of its use.

For the most up-to-date information on treatment and prevention of COVID-19, consult current guidelines published by NIH, IDSA, WHO, Medical Letter, and others and consult current FDA information, including FDA documents for drugs available under an emergency use authorization (EUA).

TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>ANTIVIRAL AGENTS</th>
<th>SUPPORTING AGENTS</th>
<th>OTHER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baloxavir</td>
<td>Anakinra (Kineret®)</td>
<td>Ace inhibitors, angiotensin II receptor blockers (ARBs)</td>
</tr>
<tr>
<td>Chloroquine Phosphate</td>
<td>Ascorbic Acid</td>
<td>Anticoagulants</td>
</tr>
<tr>
<td>Favipiravir (Avigan®, Avifavir®, Favilavir)</td>
<td>Azithromycin</td>
<td>Covid-19 convalescent plasma</td>
</tr>
<tr>
<td>HIV Protease Inhibitors (e.g., LPV/RTV, Kaletra®)</td>
<td>Baricitinib (Olumiant®)</td>
<td>Famotidine</td>
</tr>
<tr>
<td>Hydroxychloroquine (Plaquenil®)</td>
<td>Colchicine</td>
<td>Fluvoxamine (Luvox CR®)</td>
</tr>
<tr>
<td>Neuraminidase Inhibitors (e.g., oseltamivir)</td>
<td>Corticosteroids (systemic)</td>
<td>HMG-CoA reductase inhibitors (statins)</td>
</tr>
<tr>
<td>Remdesivir (Veklury®)</td>
<td>Corticosteroids (inhaled)</td>
<td>Immune globulin</td>
</tr>
<tr>
<td>SARS-CoV-2-Specific Monoclonal Antibodies</td>
<td>Inhaled Prostacyclins</td>
<td>Ivermectin</td>
</tr>
<tr>
<td>Umifenovir (Arbidol®)</td>
<td>Interferons</td>
<td>Nebulized Drugs</td>
</tr>
<tr>
<td></td>
<td>Nitric oxide (inhaled)</td>
<td>Niclosamide</td>
</tr>
<tr>
<td></td>
<td>Ruxolitinib (Jakafi®)</td>
<td>Nitazoxanide (Alinia®)</td>
</tr>
<tr>
<td></td>
<td>Sarilumab (Kevzara®)</td>
<td>Nonsteroidal anti-inflammatory agents (NSAIDs)</td>
</tr>
<tr>
<td></td>
<td>Siltuximab (Sylvant®)</td>
<td>Tocilizumab (Actemra®)</td>
</tr>
<tr>
<td></td>
<td>Sirolimus (Rapamune®)</td>
<td>Thrombolytic agents (t-PA)</td>
</tr>
<tr>
<td></td>
<td>Tocilizumab (Actemra®)</td>
<td>alteplase], tenecteplase)</td>
</tr>
<tr>
<td></td>
<td>Vitamin D</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zinc</td>
<td></td>
</tr>
</tbody>
</table>
## Antiviral Agents

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baloxavir</td>
<td>8:18.92</td>
<td>Antiviral active against influenza viruses</td>
<td>Only very limited data available regarding use of baloxavir for treatment of COVID-19</td>
<td>A baloxavir marboxil dosage of 80 mg on day 1 and on day 4, and another dose of 80 mg on day 7 (as needed; not to exceed 3 total doses) was used in one open-label COVID-19 study in adults in China.</td>
<td>Although investigated as a potential treatment during the early stages of the COVID-19 pandemic, in vitro antiviral activity against SARS-CoV-2 was not confirmed and there are no data to support the use of baloxavir in the treatment of COVID-19.</td>
</tr>
<tr>
<td><strong>Updated 1/14/21</strong></td>
<td></td>
<td>Conflicting data regarding possible in vitro antiviral activity against SARS-CoV-2</td>
<td>Exploratory, open-label, randomized controlled study at a single center in China (ChicTR20000295444): 29 adults hospitalized with COVID-19 receiving antiviral treatment with lopinavir/ritonavir, darunavir/cohbicistat, or umifenovir (Arbidol&lt;sup&gt;b&lt;/sup&gt;), in combination with inhaled interferon-α, were randomized to treatment with baloxavir marboxil (80 mg orally on day 1 and on day 4, and 80 mg orally on day 7 as needed) (n=10), favipiravir (1600 or 2200 mg orally on day 1, followed by 600 mg three times daily for up to 14 days) (n=9), or control (standard antiviral treatment) (n=10). Results did not indicate a benefit of adding baloxavir to the treatment regimen. Percentage of pts with viral conversion (2 consecutive tests with undetectable viral RNA results) after 14 days of treatment was 70%, 77%, and 100% in the baloxavir, favipiravir, and control groups, respectively, with median time to clinical improvement of 14, 14, and 15 days, respectively.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloroquine Phosphate</td>
<td>8:30.08</td>
<td>In vitro activity against various viruses, including coronaviruses</td>
<td>Only limited clinical trial data available to date to evaluate use of chloroquine for treatment or prevention of COVID-19</td>
<td>Consider: 500 mg of chloroquine phosphate is equivalent to 300 mg of chloroquine base&lt;sup&gt;17&lt;/sup&gt;</td>
<td>Efficacy and safety of chloroquine for treatment or prevention of COVID-19 not established&lt;sup&gt;10, 24, 39&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Updated 2/25/21</strong></td>
<td></td>
<td>In vitro activity against SARS-CoV-2 in infected Vero E6 cells reported; some evidence it may block infection in Vero E6 cells exposed to SARS-CoV-2&lt;sup&gt;1-3, 13, 14&lt;/sup&gt;</td>
<td>Small, randomized study in hospitalized adults in China compared chloroquine with LPV/RTV (Huang et al): 10 pts (7 with moderate and 3 with severe COVID-19) received chloroquine (500 mg twice daily for 10 days) and 12 pts (7 with moderate and 5 with severe COVID-19) received LPV/RTV (lopinavir 400 mg/ritonavir 100 mg twice daily for 10 days). All 10 pts treated with chloroquine had negative RT-PCR results for SARS-CoV-2 by day 13 and were discharged from the hospital by day 14; 11/12 pts (92%) treated with LPV/RTV were negative for SARS-CoV-2 at day 14 and only 6/12 (50%) were discharged from</td>
<td>Oral chloroquine phosphate dosage suggested in the EUA (now retracted): For treatment of hospitalized adults and adolescents weighing 50 kg or more, suggested dosage was 1 g on day 1, then 500 mg daily for 4-7 days of total treatment based on clinical evaluation.</td>
<td>No data to date indicating that in vitro activity against SARS-CoV-2 corresponds with clinical efficacy for treatment or prevention of COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Active in vitro against SARS-CoV-1 and MERS-CoV&lt;sup&gt;2, 3, 5, 9&lt;/sup&gt;</td>
<td></td>
<td>FDA now states that this dosage regimen is unlikely to have an antiviral effect in pts with COVID-19 based on a reassessment of in vitro EC&lt;sub&gt;50&lt;/sub&gt;/EC&lt;sub&gt;90&lt;/sub&gt; data and calculated lung concentrations; it is unclear whether this dosage regimen would provide any beneficial immunomodulatory effects.</td>
<td>Data from various published randomized, controlled clinical trials and retrospective, cohort studies have not substantiated initial reports of efficacy of 4-aminooquinoline antimalarials for treatment of COVID-19. (See Hydroxychloroquine in this Evidence Table.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Has immunomodulatory activity that theoretically could contribute to an anti-inflammatory response in</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>See Neuraminidase Inhibitors in this Evidence Table.<sup>11</sup>  
<sup>b</sup>Arbidol<sup>®</sup> is the same in all pts regardless of SARS-CoV-2 coinfection.  
<sup>1</sup>See Neuraminidase Inhibitors in this Evidence Table.  
<sup>2</sup>COVID-19 treatment or prevention of COVID-19.  
<sup>3</sup>NIAID guidelines and recommendations regarding antiviral therapy for COVID-19.  
<sup>4</sup>May cause QT prolongation and torsades de pointes; use with caution in pts with ECG abnormalities or risk factors for these adverse effects.  
<sup>5</sup>Consider: 500 mg of chloroquine phosphate is equivalent to 300 mg of chloroquine base.  
<sup>6</sup>Only limited clinical trial data available to date to evaluate use of chloroquine for treatment or prevention of COVID-19.  
<sup>7</sup>Small, randomized study in hospitalized adults in China compared chloroquine with LPV/RTV (Huang et al): 10 pts (7 with moderate and 3 with severe COVID-19) received chloroquine (500 mg twice daily for 10 days) and 12 pts (7 with moderate and 5 with severe COVID-19) received LPV/RTV (lopinavir 400 mg/ritonavir 100 mg twice daily for 10 days). All 10 pts treated with chloroquine had negative RT-PCR results for SARS-CoV-2 by day 13 and were discharged from the hospital by day 14; 11/12 pts (92%) treated with LPV/RTV were negative for SARS-CoV-2 at day 14 and only 6/12 (50%) were discharged from |
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>patients with viral infections 1-3, 13, 15-16</td>
<td>Known pharmacokinetics and toxicity profile based on use for other indications 13, 17</td>
<td>the hospital by day 14. <strong>Note:</strong> Results suggest that chloroquine was associated with shorter time to RT-PCR conversion and quicker recovery than LPV/RTV; however, this study included a limited number of pts and the median time from onset of symptoms to initiation of treatment was shorter in those treated with chloroquine than in those treated with LPV/RTV (2.5 vs 6.5 days, respectively). 20</td>
<td>Oral chloroquine phosphate dosage in Chinese guidelines: 500 mg twice daily for 7 days (adults 18-65 years weighing &gt;50 kg); 500 mg twice daily on days 1 and 2, then 500 mg once daily on days 3-7 (adults weighing &lt;50 kg) 11</td>
<td>chloroquine (with or without azithromycin) for the treatment of COVID-19 in hospitalized pts and <strong>recommends against</strong> use of chloroquine (with or without azithromycin) for the treatment of COVID-19 in nonhospitalized patients, except in a clinical trial. The panel also <strong>recommends against</strong> use of high-dose chloroquine (i.e., 600 mg twice daily for 10 days) for the treatment of COVID-19 because such dosage has been associated with more severe toxicities compared with lower-dose chloroquine. 35</td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage*</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
</tbody>
</table>

should be used concomitantly with drugs that pose a moderate to high risk for QT prolongation (e.g., antiarrhythmics, antipsychotics, antifungals, fluoroquinolones, macrolides [including azithromycin]) only if necessary. The panel states that use of doxycycline (instead of azithromycin) should be considered for empiric therapy of atypical pneumonia in COVID-19 pts receiving chloroquine (or hydroxychloroquine).  

FDA issued a safety alert regarding adverse cardiac effects (e.g., prolonged QT interval, ventricular tachycardia, ventricular fibrillation) reported with use of chloroquine or hydroxychloroquine (either alone or in conjunction with azithromycin or other drugs known to prolong QT interval) in hospital and outpatient settings; FDA cautions against use of chloroquine or hydroxychloroquine outside of a clinical trial or hospital setting and urges healthcare professionals and pts to report adverse effects involving these drugs to FDA MedWatch.  

Emergency use authorization (EUA) for chloroquine (now revoked): Effective June 15, 2020, FDA has revoked the EUA for chloroquine and hydroxychloroquine previously issued on March 28, 2020 that permitted distribution of the drugs from the strategic national stockpile (SNS) for use in adults and adolescents weighing 50 kg or more hospitalized with COVID-19 for whom a clinical trial was not available or participation not feasible. Based on a review of new information and reevaluation of information available at the time the EUA was issued, FDA concluded that the original criteria for issuance of the EUA for these drugs are no longer met. Based on the totality of scientific evidence available, FDA concluded that it is unlikely that chloroquine and hydroxychloroquine may be effective in treating COVID-19 and, in light of ongoing reports of serious cardiac adverse events and several newly reported cases of methemoglobinemia in COVID-19...
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favipiravir</td>
<td>8:18.32</td>
<td>Antiviral</td>
<td>Nucleoside analog pro-drug; RNA polymerase inhibitor 2,11,14</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Broad-spectrum antiviral with in vitro activity against various viruses, including coronaviruses 1-5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In vitro evidence of activity against SARS-CoV-2 in infected Vero E6 cells reported with high concentrations of the drug 1,5,16</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Licensed in Japan and China for treatment of influenza 7,4,6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Some data regarding use of favipiravir for the treatment of COVID-19 are available from open-label, randomized or nonrandomized studies and prospective or retrospective observational studies performed in various countries.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Open-label, prospective, randomized, multicenter study in 236 adults with COVID-19 pneumonia in China (ChiCTR2000030254): Favipiravir (1600 mg orally twice daily on day 1, then 600 mg orally twice daily thereafter for 7–10 days) was associated with greater clinical recovery rate at 7 days (61 vs 52%) compared with the control group treated with umifenovir (Arbidol®; 200 mg 3 times daily for 7–10 days). Stratified by disease severity, clinical recovery rate at day 7 in pts with moderate COVID-19 pneumonia was 71% in the favipiravir group vs 56% in the umifenovir group; clinical recovery rate in those with severe to critical COVID-19 pneumonia was 6% vs 0%, respectively. Twice as many pts in the favipiravir group had severe to critical disease compared with the group receiving umifenovir. 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Open-label, prospective, randomized, multicenter study in 60 hospitalized adults with moderate COVID-19 pneumonia in Russia (NCT04434248): Favipiravir (1600 mg orally twice daily on day 1, then 600 mg twice daily on days 2–14 or 1800 mg twice daily on day 1, then 800 mg twice daily on days 2–14) was associated with higher rate of viral clearance at 10 days (92.5 vs 80%) compared with the control group receiving the standard of care. Favipiravir also was associated with decreased median time to normalization of body temperature (2 vs 4 days) and higher improvement rate on chest CT imaging on day 15 (90 vs 80%) compared with the control group. Data are based on interim results of the pilot stage of the study. 24</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A favipiravir dosage of 1600 mg twice daily on day 1, then 600 mg twice daily thereafter for 7–10 or 14 days was used in several open-label COVID-19 studies in adults and adolescents ≥16 years of age in other countries 5,13,24</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Protocols in many registered trials generally specify a favipiravir dosage of 1600 or 1800 mg twice daily on day 1, then a total daily dosage of 1200–2000 mg in 2, 3, or 4 divided doses for 4–13 days for treatment of COVID-19 in adults 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Protocol in one trial (NCT04448119) specifies a prophylactic favipiravir dosage of 1600 mg twice daily on day 1, then 800 mg twice daily on days 2–25 and a treatment favipiravir dosage of 2000 mg twice daily on day 1, then 1000 mg twice daily on days 2–14 in older adults in long-term care homes experiencing COVID-19 outbreaks. The prophylactic regimen is considered pre-exposure prophylaxis, post-exposure prophylaxis, or preemptive therapy in this setting; those diagnosed with COVID-19 will be offered the treatment regimen 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Because high favipiravir concentrations are required for in vitro activity against SARS-CoV-2, 1,5,11 it has been suggested that high favipiravir dosages, like those used in the treatment of Ebola virus disease, should be considered for the treatment of COVID-19. 11,19,20 One such favipiravir regimen used in the treatment of Ebola virus disease includes a loading dosage of 6000 mg (doses of 2400 mg, 2400 mg, and 1200 mg given 8 hours apart on day 1), then a maintenance dosage of 1200 mg every 12 hours on days 2–10. 12,13</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Not commercially available in the US</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Efficacy and safety of favipiravir for treatment of COVID-19 not established</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Additional data needed to substantiate initial reports of efficacy for treatment of COVID-19 and identify optimal dosage and treatment duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Given the lack of pharmacokinetic and safety data for the high favipiravir dosages proposed for treatment of COVID-19, the drug should be used with caution at such dosages. 19,20 There is conflicting evidence as to whether favipiravir is associated with QT prolongation. 21,41 Some have suggested close cardiac and hepatic monitoring during treatment, as well as monitoring of plasma and tissue concentrations of the drug and, if possible, the active metabolite. 19,20,21 Some data suggest that favipiravir exposure may be greater in Asian populations. 17,19</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Early embryonic deaths and teratogenicity observed in animal studies. Favipiravir is contraindicated in women with known or suspected pregnancy and precautions should be taken to avoid pregnancy during treatment with the drug. 14</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Based on a pharmacokinetic interaction, if favipiravir is used in pts receiving acetaminophen, the maximum recommended daily dosage of acetaminophen is 3 g. 17,18 Note that favipiravir-induced fever has been described in several COVID-19 pts receiving the drug. 30,40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage*</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Favipiravir</td>
<td></td>
<td></td>
<td><strong>Open-label, prospective, randomized, multicenter study</strong> in patients hospitalized with asymptomatic or mild COVID-19 in Japan (jRCTs041190120): Early treatment (beginning on day of hospital admission) with favipiravir (two 1800-mg doses given orally at least 4 hours apart on day 1, then 800 mg orally twice daily for a total of up to 19 doses over 10 days) (n=36) was not associated with significant improvement in viral clearance compared with late treatment with favipiravir (same regimen beginning day 6 after admission) (n=33). Viral clearance occurred by day 6 in 66.7 and 56.1% of patients in the early and late treatment groups, respectively. Viral clearance was assessed by RT-PCR of nasopharyngeal specimens. Most common adverse effect was transient hyperuricemia (84.1% of patients). 29</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In an <strong>open-label, randomized controlled trial</strong> in Oman in 89 adults (≤75 years of age) hospitalized with moderate to severe COVID-19 pneumonia (NCT04385095), pts received favipiravir (1800 mg on day 1, then 600 mg twice daily for a maximum of 10 days) in combination with inhaled interferon β-1b (n=44) or standard of care (which included hydroxychloroquine) (n=45). At interim analysis, there were no differences between the groups in improvement in inflammatory markers or other clinical outcomes (e.g., hospital length of stay, hospital discharge, 14-day mortality); however, the study lacked sufficient power to detect such differences. 43</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In an <strong>open-label, randomized controlled trial</strong> in India in 150 adults with asymptomatic, mild, or moderate COVID-19, pts received favipiravir (1800 mg twice daily on day 1, then 800 mg twice daily for up to 14 days total) plus standard care (n=75) or standard care alone (n=75). The median time to cessation of oral viral shedding of SARS-CoV-2 (primary end point) was 5 days in the favipiravir group compared with 7 days in the control group; this was numerically lower but not statistically significant. The median time to clinical cure among pts who were symptomatic at baseline was significantly faster in the favipiravir group (3 days) compared with the control group For the treatment of COVID-19, one pharmacokinetic simulation model suggested that a dosage of 2400 mg twice daily on day 1, followed by 1600 mg twice daily on days 2–10 should achieve adequate favipiravir trough plasma concentrations and may be more pharmacologically relevant than lower dosages. 35</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Dosages of the drug were similar to those reported in nondialysis pts. Weekly doxorubicin regimens of the drug were similar to those reported in healthy individuals who received the same dosage.

Another pharmacokinetic simulation model suggested that, despite rapid clearance of the parent drug from plasma, a favipiravir dosage of 1600 mg twice daily on day 1 followed by maintenance doses of 800 or 1200 mg twice daily may be sufficient to provide therapeutic intracellular concentrations of the favipiravir metabolite across the dosing interval, owing to its long intracellular half life. 46

Pharmacokinetic data are available from a study in critically ill pts with COVID-19 requiring mechanical ventilation who received a favipiravir dosage of 1600 mg twice daily on day 1, then 600 mg twice daily on days 2–5 (or longer if needed) via NG tube. Trough serum concentrations of the drug in most samples were lower than the lower limit of quantification and lower than the in vitro EC_{50} of the drug reported for SARS-CoV-2; trough concentrations in these critically ill pts also were much lower than those previously reported in healthy individuals who received the same dosage. 55

While its molecular weight, protein binding rate, and volume of distribution suggest that favipiravir would be eliminated by dialysis, data from a COVID-19 pt treated with favipiravir (1800 mg twice daily on day 1, then 800 mg twice daily) who was undergoing hemodialysis (2 or 3 times weekly) indicated that blood concentrations of the drug were similar to those reported in nondialysis pts. 56

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trials or Clinical Experience</td>
<td>Dosage&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Comments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(5 days). The authors noted that the lack of statistical significance of the primary end point may be attributable to limitations of the RT-PCR assay. 47</td>
<td>Data from 4 critically ill pts with COVID-19 who received favipiravir 1600 mg twice daily on day 1, then 600 mg twice daily on days 2–7 (a dosage considered to be “low dose”) indicate that the drug was well-tolerated in these pts. 39</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In a randomized multicenter trial in Egypt in 96 adults with mild or moderate COVID-19, pts received favipiravir (1600 mg twice daily on day 1, then 600 mg twice daily on days 2–10) (n=48) or chloroquine (600 mg twice daily for 10 days) (n=48) in addition to standard care. Pts in the favipiravir group had a lower, though not statistically significant, mean duration of hospital stay compared with pts in the chloroquine group (13.3 versus 15.9 days). No pts in the favipiravir group required mechanical ventilation compared with 4 pts in the chloroquine group. 48</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In a small, open-label, nonrandomized study in patients with non-severe COVID-19 in China (ChiCTR2000029600), favipiravir (1600 mg orally twice daily on day 1, then 600 mg orally twice daily on days 2–14) (n=35) was associated with decreased median time to viral clearance (4 vs 11 days) and higher improvement rate on chest CT imaging on day 14 (91 vs 62%) compared with the control group receiving lopinavir/ritonavir (n=45); both groups also received aerosolized interferon α-1b. 15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In a prospective, observational, single-center study in 174 adults in Turkey with probable or confirmed COVID-19 (20.1% with mild disease, 61.5% with moderate disease, 18.4% with severe pneumonia) admitted to the hospital within a median of 3 days after symptom onset, 32 pts received a regimen that included favipiravir. Most pts who received favipiravir (93.8%) received the drug either in combination with, or as sequential therapy to, hydroxychloroquine with or without azithromycin. In pts who received a favipiravir-containing regimen, the median time to defervescence and to clinical improvement on therapy was 3 and 6 days, respectively. Critically ill pts with sepsis and/or ARDS at the time of admission were excluded. 31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In a small, observational study in Turkey in 107 critically ill adults with COVID-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>---------------------</td>
<td>----------</td>
</tr>
</tbody>
</table>

- **pneumonia, 65 pts received favipiravir (1600 mg twice daily on day 1, then 600 mg daily for 4 days) and 42 pts received lopinavir/ritonavir. While length of hospital stay in the favipiravir group was decreased (6.6 vs 9 days), mortality in the favipiravir group was increased (66.2 vs 54.8%).**  

  **In an open-label, prospective, nonrandomized, observational, single-center sequential cohort study** in Hungary, 150 hospitalized adults with moderate to severe COVID-19 received treatment with favipiravir (n=75) or other antivirals (n=75). Disease progression, 14-day all cause mortality, requirement for mechanical ventilation, and PCR negativity rate were unaffected in pts receiving favipiravir (1600 mg twice daily on day 1, then 600 mg twice daily for a total course of at least 10 days) compared with those receiving other antivirals (i.e., chloroquine/hydroxychloroquine, oseltamivir, or LPV/RTV).  

  **In a prospective, single-center study** in 13 pts requiring mechanical ventilation for severe COVID-19 in Japan, pts received favipiravir (3600 mg orally on day 1, then 1600 mg orally on days 2–14), along with methylprednisolone, and low molecular weight heparin (LMWH) or unfractionated heparin. Improvements in PaO<sub>2</sub>/FiO<sub>2</sub> (P/F ratio), interleukin-6 concentration, and prepsepsin concentration suggested that favipiravir may have some effect on inflammatory mediators, but could not completely control inflammatory mediators or respiratory status.  

  **In a retrospective, observational, multicenter study** in 63 adults with COVID-19 in Thailand who received favipiravir (median loading dose of 47.4 mg/kg on day 1 and median maintenance doses of 17.9 mg/kg per day for a median total duration of 12 days), clinical improvement at day 7 was reported in 66.7% of patients (92.5% in patients not requiring oxygen supplementation, 47.2% in patients requiring oxygen supplementation) and clinical improvement at day 14 was reported in 89.7% of patients (100% in patients not requiring oxygen supplementation, 75% in patients requiring oxygen supplementation).
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Protease Inhibitors</td>
<td>8:18.08.08 HIV Protease Inhibitors</td>
<td>Updated 2/25/21</td>
<td>Lopinavir (LPV): Some evidence of in vitro activity against SARS-CoV-2 in Vero E6 cells; evidence of in vitro activity against SARS-CoV-1 and MERS-CoV; some evidence of benefit in animal studies for treatment of MERS-CoV</td>
<td>LPV/RTV (COVID-19): LPV 400 mg/RTV 100 mg orally twice daily for up to 14 days with or without other antivirals (e.g., interferon, umifenovir) has been used.</td>
<td>LPV/RTV: Efficacy for the treatment of COVID-19, with or without other antivirals, not established. Results of several large, randomized trials evaluating LPV/RTV in pts with COVID-19 have not revealed evidence of clinical benefit. Darunavir: Manufacturer states they have no clinical or pharmacologic evidence to support use of DRV/c for treatment of COVID-19. Results of an open-label, controlled study in China indicated that a 5-day regimen of DRV/c was not effective for treatment of</td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage*</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>------------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>cells, 17, 19 human epithelial pulmonary cells (A549), 17 and human monocytes 17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir (DRV): In one study, DRV with cobicistat had no in vitro activity against SARS-CoV-2 at clinically relevant concentrations in Caco-2 cells; 18 in another study, high DRV concentrations were required for in vitro inhibition of SARS-CoV-2 in Vero E6 cells 19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nelfinavir (NFV), 19, 28 Ritonavir (RTV), 19 Saquinavir (SQV), 19 and Tipranavir (TPV) 19: Some evidence of in vitro activity against SARS-CoV-2 in Vero cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LPV/RTV: Some evidence of clinical benefit when used in conjunction with ribavirin and/or interferon in pts with SARS or MERS. 1, 8, 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 days in LPV/RTV group and 16 days in standard care only group. The 28-day mortality rate was numerically lower in LPV/RTV group (19.2% vs 25% in ITT population; 16.7% vs 25% in modified ITT population). Some evidence that LPV/RTV initiation within 12 days after symptom onset is associated with shorter time to clinical improvement. No significant differences in reduction of viral RNA load, duration of viral RNA detectability, duration of oxygen therapy, duration of hospitalization, or time from randomization to death. LPV/RTV stopped early in 13 pts because of adverse effects. 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LPV/RTV vs chloroquine in small, randomized study in hospitalized adults with COVID-19 in China (Huang et al): 10 pts (7 with moderate and 3 with severe disease) received chloroquine (500 mg twice daily for 10 days) and 12 pts (7 with moderate and 5 with severe disease) received LPV/RTV (lopinavir 400 mg/ritonavir 100 mg twice daily for 10 days). All 10 pts treated with chloroquine had negative RT-PCR results for SARS-CoV-2 by day 13 and were discharged from the hospital by day 14; 11/12 pts (92%) treated with LPV/RTV were negative for SARS-CoV-2 at day 14 and only 6/12 (50%) were discharged from the hospital by day 14. Note: Results suggest that chloroquine was associated with shorter time to RT-PCR conversion and quicker recovery than LPV/RTV; however, this study included a limited number of pts and the median time from onset of symptoms to initiation of treatment was shorter in those treated with chloroquine than in those treated with LPV/RTV (2.5 vs 6.5 days, respectively). 24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LPV/RTV with ribavirin and interferon β-1b vs LPV/RTV alone in open-label, randomized trial in adults with mild to moderate COVID-19 in Hong Kong (Hung et al; NCT04276688): 127 pts were randomized 2:1 to receive LPV/RTV (LPV 400 mg/RTV 100 mg) twice daily for 14 days) with ribavirin (400 mg twice daily) and interferon β-1b (8 million IU sub-Q on alternate days for up to 3 doses depending on how soon treatment initiated after symptom onset) or a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>orally twice daily with interferon β-1b (0.25 mg/mL sub-Q on alternate days) for 14 days 1, 4, 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19 22, 26 and there are no published clinical studies that have evaluated efficacy and safety of DRV/RTV or the fixed combination of DRV, cobicistat, emtricitabine, and tenofovir alafenamide for treatment of COVID-19. 21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir, Nelfinavir, Saquinavir, Tipranavir: No clinical trial data to support use in the treatment of COVID-19 22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIH COVID-19 Treatment Guidelines Panel recommends against the use of LPV/RTV or other HIV protease inhibitors for the treatment of COVID-19 in hospitalized and nonhospitalized patients. The panel states that, based on the pharmacodynamics of LPV/RTV, there are concerns whether it is possible to achieve drug concentrations that can inhibit SARS-CoV-2 proteases. In addition, results of large randomized clinical trials evaluating LPV/RTV in hospitalized COVID-19 patients did not demonstrate efficacy and data are lacking regarding use in nonhospitalized COVID-19 patients. 22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDSA recommends against use of LPV/RTV for the treatment of COVID-19 in hospitalized pts. 23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: Results suggest that chloroquine was associated with shorter time to RT-PCR conversion and quicker recovery than LPV/RTV; however, this study included a limited number of pts and the median time from onset of symptoms to initiation of treatment was shorter in those treated with chloroquine than in those treated with LPV/RTV (2.5 vs 6.5 days, respectively). 24*

Copyright © 2021, American Society of Health-System Pharmacists, Inc. All rights reserved. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>14-day regimen of LPV/RTV alone. Median time to negative RT-PCR results for SARS-CoV-2 in nasopharyngeal samples was 7 days in pts treated with the 3-drug regimen vs 12 days in those treated with LPV/RTV alone; median duration of hospitalization was 9 or 14.5 days, respectively. Adverse effects reported in 48% of those treated with the 3-drug regimen and in 49% of those treated with LPV/RTV alone. <strong>Note:</strong> Results indicate a 3-drug regimen that included LPV/RTV, ribavirin, and interferon β-1b was more effective than LPV/RTV alone in pts with mild to moderate COVID-19, especially when treatment was initiated within 7 days of symptom onset. 85</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LPV/RTV retrospective cohort study in China [Deng et al] evaluated use of LPV/RTV with or without umifenovir (Arbidol®) in adults. Primary end point was negative conversion in nasopharyngeal samples and progression or improvement of pneumonia. At 7 days, SARS-CoV-2 undetectable in nasopharyngeal specimens in 6/17 pts (35%) treated with LPV/RTV alone vs 12/16 (75%) treated with both drugs; chest CT scans were improving in 29% of pts treated with LPV/RTV alone vs 69% of pts treated with both drugs. (See Umifenovir in this Evidence Table.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LPV/RTV in randomized, controlled, open-label, platform trial (NCT04381936; RECOVERY): This study is enrolling pts with suspected or confirmed COVID-19 from 176 hospitals in the UK. In the LPV/RTV arm (now terminated), 1616 pts were randomized to receive LPV/RTV (LPV 400 mg/RTV 100 mg every 12 hours for 10 days or until discharge, whichever came first) plus standard of care and 3424 pts were randomized to standard of care alone. At the time of study enrollment, 26% of pts did not require oxygen support, 70% required oxygen support, and only 4% were on mechanical ventilation. The primary outcome was all-cause mortality at day 28. Results of this study indicated that LPV/RTV is not an effective treatment for COVID-19 in hospitalized pts. Mortality rate at 28 days was 23% in those treated with LPV/RTV plus standard of care vs 22% in those treated</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
with standard of care alone. In addition, LPV/RTV did not reduce the time to hospital discharge (median length of stay was 11 days in both groups) and, in those not requiring mechanical ventilation at baseline, LPV/RTV did not decrease the risk of progression to mechanical ventilation (10% in the LPV/RTV group vs 9% in standard of care alone group). Results were consistent across all prespecified pt subgroups (age, sex, ethnicity, level of respiratory support, time since symptom onset, and predicted 28-day mortality risk at time of randomization). 27

Large, multinational, open-label, randomized, adaptive trial launched by the World Health Organization (WHO) to evaluate effects of 4 different treatments compared with local standard of care in adults hospitalized with COVID-19 and not previously treated with any of the study drugs (SOLIDARITY): The protocol-specified primary outcome is in-hospital mortality; protocol-specified secondary outcomes are initiation of ventilation and duration of hospitalization. 29,30 From March 22 to July 4, 2020, 1411 pts were randomized to receive LPV/RTV (two tablets containing LPV 200 mg/RTV 50 mg orally twice daily for 14 days) with local standard of care and 1380 pts were randomized to LPV/RTV control (i.e., local standard of care only). Clinical characteristics at baseline were well balanced between groups. Data analysis for the intention-to-treat (ITT) population (1399 pts in LPV/RTV group and 1372 pts in standard of care group) indicated that LPV/RTV did not reduce in-hospital mortality (either overall or in any subgroup defined by age or ventilation status at study entry) and did not reduce the need for initiation of ventilation or the duration of hospitalization. The log-rank death rate ratio for LPV/RTV in the ITT population was 1.00; 148/1399 pts treated with LPV/RTV (9.7%) and 146/1372 pts treated with standard of care (10.3%) died. Ventilation was initiated after randomization in 126 pts receiving LPV/RTV and 121 pts receiving standard of care. 29
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darunavir and cobicistat (DRV/c) randomized, open-label trial in China (Chen et al; NCT04252274):</td>
<td></td>
<td></td>
<td>A total of 30 adults with mild, laboratory-confirmed COVID-19 were randomized 1:1 to receive DRV/c (fixed combination darunavir 800 mg/cobicistat 150 mg once daily for 5 days) or no DRV/c (control group); all pts received interferon alfa-2b and standard of care. The primary end point was viral clearance rate at day 7 (defined as RT-PCR negative for SARS-CoV-2 in at least 2 consecutive oropharyngeal swabs collected at least 1-2 days apart). At day 7, viral clearance rate in the intention-to-treat (ITT) population was 47% in those treated with DRV/c and 60% in the control group. In the per-protocol (PP) population, viral clearance rate at day 7 was 50% in those treated with DRV/c and 60% in the control group. The median time from randomization to negative RT-PCR result was 8 and 7 days, respectively. This study indicated that a 5-day regimen of DRV/c in pts with mild COVID-19 did not provide clinical benefits compared with use of standard care alone.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Several clinical trials evaluating LPV/RTV for treatment of COVID-19 are registered at clinicaltrials.gov.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxychloroquine</td>
<td>8:30.08</td>
<td>Antimalarial (4-aminoquinoline derivative)</td>
<td>Clinical experience in treating pts with COVID-19: Majority of data to date involves use in pts with mild or moderate COVID-19; only limited clinical data on use in pts with severe and critical disease.**</td>
<td>Oral hydroxychloroquine sulfate dosage suggested in the EUA (now revoked): For treatment of hospitalized adults and adolescents weighing 50 kg or more, suggested dosage was 800 mg on day 1, then 400 mg daily for 4-7 days of total treatment based on clinical evaluation. 26 FDA now states that this dosage regimen is unlikely to have an antiviral effect in pts with COVID-19 based on a reassessment of in vitro EC50/EC90 data and calculated lung concentrations; it is unclear whether this dosage regimen would provide any beneficial immunomodulatory effects. 57</td>
<td>Efficacy and safety of hydroxychloroquine for treatment or prevention of COVID-19 not established 10, 24, 35, 38, 39</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Has immunomodulatory activity that theoretically could contribute to an anti-inflammatory response in patients with viral infections 3, 8, 13, 15, 16</td>
<td></td>
<td>No data to date indicating that in vitro activity against SARS-CoV-2 corresponds with clinical efficacy for treatment or prevention of COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Known pharmacokinetics and toxicity profile based on use for other indications 11</td>
<td></td>
<td>Data from various published randomized, controlled clinical trials and retrospective, cohort studies have not substantiated initial reports of efficacy of 4-aminoquinoline antimalarials (with or without azithromycin) for the treatment of COVID-19; a few studies reported benefits when hydroxychloroquine was used in pts with COVID-19 35, 38, 58</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hydroxyl analog of chloroquine with similar mechanisms of action and adverse effects; 13, 14 may have more favorable dose-related toxicity profile than chloroquine, 13,16 but cardiotoxicity (e.g., prolonged QT interval) is a concern with both drugs 13, 35</td>
<td></td>
<td>There has been concern about limitations related to trial design of some studies evaluating efficacy of hydroxychloroquine (e.g., lack of blinding and/or randomization, retrospective and/or observational nature, insufficient statistical power, inconsistency regarding concomitant therapy, and there are some ongoing studies 10, 35, 38</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hydroxychloroquine randomized, parallel-group study in adults in China (ChiCTR2000029559): 31 pts with COVID-19 and pneumonia received hydroxychloroquine sulfate (200 mg twice daily for 5 days) and standard treatment (O2, antiviral agents, antibacterial agents, immunoglobulin, with or without corticosteroids) and 31 other pts received standard treatment alone (control group). Exclusion criteria included severe and critical illness.Pts assessed at baseline and 5 days after treatment initiation for time to clinical recovery (TTCR; defined as normalization of fever and cough relief maintained for &gt;72 hours), clinical characteristics, and changes on chest CT. It was concluded that hydroxychloroquine was associated with symptom relief since time to fever normalization was shorter in hydroxychloroquine group (2.2 days) vs control group (3.2 days), time to cough relief was shorter in hydroxychloroquine group, and pneumonia improved in 25/31 pts (80.6%) in hydroxychloroquine group vs 17/31 pts</td>
<td>Oral hydroxychloroquine sulfate dosage used or being investigated in clinical trials: 400 mg once or twice daily for 5-10 days or 400 mg twice daily on day 1 then 200 mg twice daily on days 2-5 10, 18, 66</td>
<td>NIH COVID-19 Treatment Guidelines Panel recommends against use of hydroxychloroquine (with or without azithromycin) for the treatment of COVID-19 in hospitalized pts and recommends against use of hydroxychloroquine (with or without azithromycin) for the treatment of COVID-19 in nonhospitalized pts, except in a clinical trial. 39</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Oral hydroxychloroquine sulfate with azithromycin (France): 200 mg 3 times daily for 10 days with or without azithromycin (500 mg on day 1, then 250 mg once daily on days 2-5) 7, 34, 47</td>
<td>IDSA recommends against use of hydroxychloroquine (with or without azithromycin) for the treatment of COVID-19 in hospitalized pts. 38</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NIH COVID-19 Treatment Guidelines Panel recommends against the use of any drugs, including hydroxychloroquine, for preexposure prophylaxis (PrEP) for prevention of SARS-CoV-2 infection, except in a clinical trial. 35 The panel states that, to date, no agent is known to be effective for preventing SARS-CoV-2 infection when given before an exposure. 35</td>
</tr>
</tbody>
</table>

** Updated 2/25/21

\[\text{Hydroxychloroquine (Plaquenil\textsuperscript{*})}\]
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hydroxychloroquine randomized, parallel-group, open-label study in hospitalized adults with mild to moderate COVID-19 in China (ChiCTR2000029868):</td>
<td></td>
<td>NIH COVID-19 Treatment Guidelines Panel recommends against the use of hydroxychloroquine for postexposure prophylaxis (PEP) for prevention of SARS-CoV-2 infection and also recommends against the use of other drugs for PEP, except in a clinical trial. The panel states that, to date, no agent is known to be effective for preventing SARS-CoV-2 infection when given after an exposure. In addition, results of several randomized, controlled trials evaluating hydroxychloroquine for PEP (see Trials or Clinical Experience) indicated the drug was not effective and increased the risk of adverse events compared with placebo. Because 4-aminoquinolines (hydroxychloroquine, chloroquine) and azithromycin are independently associated with QT prolongation and because concomitant use of the drugs may further increase the risk of QT prolongation, caution is advised if considering use of hydroxychloroquine (with or without azithromycin) in pts with COVID-19, especially in outpatients who may not receive close monitoring and in those at risk for QT prolongation or receiving other drugs associated with arrhythmias. NIH panel states that 4-aminoquinolines (hydroxychloroquine, chloroquine) should be used concomitantly with drugs that pose a moderate to high risk for QT prolongation (e.g., antiarrhythmics, antipsychotics, antifungals, fluoroquinolones, macrolides [including azithromycin]) only if necessary. In addition, because of the long half-lives of both hydroxychloroquine (up to 40 days) and azithromycin (up to 72 hours), caution is warranted even when these drugs are used sequentially. The panel states that use of doxycycline (instead of azithromycin) should be considered for empiric therapy of atypical pneumonia in COVID-19 pts receiving hydroxychloroquine (or chloroquine).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(54.8%) in control group. Total of 4 pts progressed to severe illness (all in the control group). Note: This study did not include pts with severe disease and pts received other anti-infectives in addition to hydroxychloroquine. At study entry, 9 pts without fever and 9 pts without cough were included in hydroxychloroquine group and 14 pts without fever and 16 pts without cough were included in control group; unclear how these pts were addressed in TCTR calculations. Although initial registered study protocol specified 2 different hydroxychloroquine treatment groups and a placebo group (each with 100 pts) and primary end points of time to negative nucleic acid and T-cell recovery, data provided only for certain clinical symptoms in 62 pts without severe disease and PCR results not reported.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>By day 28, 73% of pts (53 treated with hydroxychloroquine with standard of care and 56 treated with standard of care alone) had converted to negative for SARS-CoV-2. The probability of negative conversion by day 28 in those treated with hydroxychloroquine was similar to that in those treated with standard of care alone; the median time to negative seroconversion (6 and 7 days) also was similar in both groups. Adverse effects reported in 30% of those treated with hydroxychloroquine and 9% of those treated with standard of care alone. Note: Results indicate that use of hydroxychloroquine in pts with mild to moderate COVID-19 did not provide additional benefits compared with use of standard of care alone.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td>Hydroxychloroquine with azithromycin open-label, nonrandomized study in France (Gautret et al): Preliminary data from an ongoing study in hospitalized pts with confirmed COVID-19 was used to assess efficacy of hydroxychloroquine used alone or with azithromycin; untreated pts were used as a negative control. The primary end point was negative PCR results in nasopharyngeal samples at day 6. Data from 14 pts treated with hydroxychloroquine sulfate (200 mg 3 times daily for 10 days), 6 pts treated with hydroxychloroquine and azithromycin (500 mg on day 1, then 250 mg daily on days 2-5), and 16 pts in the control group were analyzed. At day 6, 8/14 (57%) in the hydroxychloroquine group, 6/6 (100%) in the hydroxychloroquine and azithromycin group, and 2/16 (12.5%) in the control group had negative PCR results. At day 8, a positive PCR was reported in a pt treated with both drugs who had tested negative at day 6. <strong>Note:</strong> This was a small nonrandomized study that didn’t appear to be designed to compare hydroxychloroquine vs hydroxychloroquine and azithromycin (pts received antibiotics to prevent bacterial superinfection based on clinical judgment). Data on disease severity were unclear (some asymptomatic pts were included when study initiated) and information on disease progression and clinical outcomes was not presented.</td>
<td>Hydroxychloroquine with azithromycin open-label, uncontrolled study in France (Molina et al): 11 adults hospitalized with COVID-19 received hydroxychloroquine (600 mg daily for 10 days) and azithromycin (500 mg on day 1, then 250 mg daily on days 2-5). At time of treatment initiation, 8/11 pts had significant comorbidities associated with poor outcomes and 10/11 had fever and received O2. Within 5 days, 1 pt died and 2 transferred to ICU; the regimen was discontinued in 1 pt after 4 days because of prolonged QT interval. Nasopharyngeal samples were still PCR positive at days 5 and 6 in 8/10 pts tested. <strong>Note:</strong> In this small uncontrolled study, hydroxychloroquine and azithromycin regimen did not result in rapid viral clearance or provide clinical benefit.</td>
<td>The benefits and risks of hydroxychloroquine (with or without azithromycin) should be carefully assessed; diagnostic testing and monitoring are recommended to minimize risk of adverse effects, including drug-induced cardiac effects. FDA issued a safety alert regarding adverse cardiac effects (e.g., prolonged QT interval, ventricular tachycardia, ventricular fibrillation) reported with use of chloroquine or hydroxychloroquine (either alone or in conjunction with azithromycin or other drugs known to prolong QT interval) in hospital and outpatient settings; FDA cautions against use of chloroquine or hydroxychloroquine for treatment or prevention of COVID-19 outside of a clinical trial or hospital setting and urges healthcare professionals and pts to report adverse effects involving these drugs to FDA MedWatch. Emergency use authorization (EUA) for hydroxychloroquine (now revoked): Effective June 15, 2020, FDA has revoked the EUA for hydroxychloroquine and chloroquine previously issued on March 28, 2020 that permitted distribution of the drugs from the strategic national stockpile (SNS) for use in adults and adolescents weighing 50 kg or more hospitalized with COVID-19 for whom a clinical trial was not available or participation not feasible. Based on a review of new information and reevaluation of information available at the time the EUA was issued, FDA concluded that the original criteria for issuance of the EUA for these drugs are no longer met. Based on the totality of scientific evidence available, FDA concluded that it is unlikely that hydroxychloroquine and chloroquine may be effective in treating COVID-19 and, in light of ongoing reports of serious cardiac adverse events and several newly reported cases of methemoglobinemia in COVID-19 patients, the known and potential benefits of hydroxychloroquine and chloroquine do not outweigh the potential risks.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage(^a)</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>-------------</td>
<td>----------</td>
</tr>
<tr>
<td>Hydroxychloroquine with azithromycin</td>
<td>uncontrolled, retrospective, observational study in France (Gautret et al):</td>
<td>80 adults with confirmed COVID-19 (including 6 pts included in a previous study by the same group) were treated with hydroxychloroquine sulfate (200 mg 3 times daily for 10 days) and azithromycin (500 mg on day 1, then 250 mg daily on days 2-5). Majority (92%) were considered low risk for clinical deterioration (low national early warning score for COVID-19 based on age, respiratory rate, O(_2) saturation, temperature, BP, pulse, level of consciousness); only 15% had fever; 4 pts were asymptomatic carriers; mean time from onset of symptoms to treatment initiation was 4.9 days. Clinical outcome, contagiousness as assessed by nasopharyngeal PCR assay and culture, and length of stay in infectious disease (ID) unit were evaluated in pts who were treated for at least 3 days and followed for at least 6 days. Favorable outcome was reported for 81.3%; 15% required O(_2); 3 pts transferred to ICU; 1 pt died; mean time to discharge from ID unit was 4.1 days. At day 8, PCR results were negative in 93% of those tested; at day 5, viral cultures were negative in 97.5% of those tested. (^{34}) Note: Almost all pts were considered low risk for clinical deterioration (including 4 pts described as asymptomatic carriers) and it is unclear how many would have had spontaneous conversion to negative nasopharyngeal samples during same time frame. Although 80 pts were enrolled, PCR results available for fewer pts beginning on day 3 and only 60 pts represented in day 6 data. This was an uncontrolled study and data presented cannot be used to determine whether a regimen of hydroxychloroquine with azithromycin provides benefits in terms of disease progression or decreased infectiousness, especially for pts with more severe disease.</td>
<td></td>
<td>known and potential risks associated with the use authorized by the EUA. (^{57})</td>
<td>The basis for the FDA decision to revoke the EUA for hydroxychloroquine and chloroquine is summarized below:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1) Suggested hydroxychloroquine and chloroquine dosage regimens as detailed in the EUA fact sheets for healthcare providers are unlikely to produce an antiviral effect. (^{57})</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2) Earlier observations of decreased viral shedding with hydroxychloroquine or chloroquine treatment have not been consistently replicated and recent data from a randomized controlled trial assessing probability of negative conversion showed no difference between hydroxychloroquine and standard of care alone. (^{57})</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3) Current US treatment guidelines do not recommend the use of chloroquine or hydroxychloroquine in hospitalized patients with COVID-19 outside of a clinical trial and the NIH guidelines now recommend against such use outside of a clinical trial. (^{57})</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4) Recent data from a large, randomized, controlled trial showed no evidence of benefit in mortality or other outcomes such as hospital length of stay or need for mechanical ventilation for hydroxychloroquine treatment in hospitalized patients with COVID-19. (^{57})</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Consult the FDA letter regarding the revocation of the EUA for hydroxychloroquine and chloroquine and the FDA memorandum explaining the basis for the revocation for additional information. (^{57})</td>
</tr>
</tbody>
</table>

Hydroxychloroquine with azithromycin uncontrolled, retrospective, observational analysis in France (Million et al): Data for 1061 pts with PCR-documented SARS-CoV-2 RNA who were treated with a regimen of hydroxychloroquine sulfate (200 mg 3 times daily for 10 days) and azithromycin...
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>(500 mg on day 1, then 250 mg daily on days 2-5) were analyzed for clinical outcomes and persistence of viral shedding. Pts were included in the analysis if they received the combined regimen for at least 3 days and were clinically assessable at day 9. There were 56 asymptomatic and 1005 symptomatic pts; the majority (95%) had relatively mild disease and were considered low risk for clinical deterioration; median age was 43.6 years (range: 14-95 years) and mean time between onset of symptoms and initiation of treatment was 6.4 days. Within 10 days of treatment, good clinical outcome reported in 973 pts (91.7%) and poor clinical outcome reported in 46 pts (4.3%). Persistent nasal carriage of SARS-CoV-2 reported at completion of treatment in 47 pts (4.4%); 8 pts died.47</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Hydroxychloroquine (with or without azithromycin) in a retrospective analysis of patients hospitalized with COVID-19 in US Veterans Health Administration medical centers (Magagnoli et al):** Data for 368 males (median age >65 years) treated with hydroxychloroquine in addition to standard supportive management were analyzed for death rate and need for mechanical ventilation. Death rate was 27.8% (27/97) in those treated with hydroxychloroquine, 22.1% (25/113) in those treated with hydroxychloroquine and azithromycin, and 11.4% (18/158) in those not treated with hydroxychloroquine; rate of ventilation was 13.3, 6.9, and 14.1%, respectively. Use of hydroxychloroquine alone (but not use of hydroxychloroquine and azithromycin) was associated with increased overall mortality compared with no hydroxychloroquine; use of hydroxychloroquine with or without azithromycin did not reduce the risk of mechanical ventilation. 40 **Note:** The pt population included only elderly males 59-75 years of age, many with significant comorbidities. This analysis did not look at efficacy measures. 40

Two different retrospective studies analyzed outcome data for hospitalized pts with confirmed COVID-19 in New York to assess the effects of treatment with hydroxychloroquine with or without
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage$^a$</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>azithromycin</td>
<td></td>
<td></td>
<td>(Rosenberg et al, Geleris et al): Results of these studies suggest that use of hydroxychloroquine with or without azithromycin is not associated with decreased in-hospital mortality.$^{45,46}$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosenberg et al</td>
<td></td>
<td></td>
<td>analyzed data for 1438 hospitalized pts (735 received hydroxychloroquine with azithromycin, 271 received hydroxychloroquine alone, 211 received azithromycin alone, 221 received neither drug) and assessed in-hospital mortality (primary outcome). Overall, in-hospital mortality was 20.3%; in-hospital mortality was 25.7, 19.9, 10, or 12.7% in those treated with hydroxychloroquine with azithromycin, hydroxychloroquine alone, azithromycin alone, or neither drug, respectively.$^{45}$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geleris et al</td>
<td></td>
<td></td>
<td>analyzed data for 1376 hospitalized pts (811 received hydroxychloroquine [486 of these also received azithromycin] and 565 did not receive hydroxychloroquine [127 of these received azithromycin]) and assessed the primary end point of time from study baseline to intubation or death. Overall, 346 pts (25.1%) progressed to a primary end point of intubation and/or death and the composite endpoint of intubation or death was not affected by hydroxychloroquine treatment (intubation or death reported in 32.3% of pts treated with hydroxychloroquine and 14.9% of pts not treated with the drug).$^{46}$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Large, randomized, controlled, open-label, platform trial evaluating efficacy of various treatments in hospitalized pts with COVID-19 (NCT04381936; RECOVERY): This study is enrolling pts with suspected or confirmed COVID-19 from 176 hospitals in the UK. The protocol-specified primary outcome is all-cause mortality at day 28; secondary outcomes include duration of hospitalization and composite of initiation of invasive mechanical ventilation (including ECMO) or death among those not receiving invasive mechanical ventilation at time of randomization. In the hydroxychloroquine sulfate arm (now terminated), 1561 adults were randomized to...
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
</table>
| receive hydroxychloroquine sulfate (two 800-mg doses given 6 hours apart followed by two 400-mg doses given 12 and 24 hours after the initial dose on day 1, then 400 mg every 12 hours thereafter for 9 days or until hospital discharge, whichever came first) plus standard of care and 3155 were randomized to standard of care alone. Data analyses for this intention-to-treat (ITT) population indicated that hydroxychloroquine did not reduce mortality and did not provide other benefits in pts hospitalized with COVID-19. The 28-day mortality rate was 27% in those treated with hydroxychloroquine plus standard care vs 25% in those treated with standard care alone (death rate ratio 1.09); results were consistent across all subgroups defined at the time of randomization (age, sex, race, time since illness onset, level of respiratory support, predicted 28-day risk of death). In addition, pts in the hydroxychloroquine group had a longer duration of hospitalization than those in the standard care alone group (median time to discharge 16 vs 13 days) and a lower probability of discharge alive within 28 days. Among those not receiving invasive mechanical ventilation at baseline, the number of pts who progressed to invasive mechanical ventilation or death was higher in the hydroxychloroquine group than the standard care alone group (risk ratio 1.14).55

Large, multinational, open-label, randomized, adaptive trial launched by the World Health Organization (WHO) to evaluate effects of 4 different treatments compared with local standard of care in adults hospitalized with COVID-19 and not previously treated with any of the study drugs (SOLIDARITY): The protocol-specified primary outcome is in-hospital mortality; protocol-specified secondary outcomes are initiation of ventilation and duration of hospitalization.54, 67 From March 22 to June 19, 2020, 954 pts were randomized to receive hydroxychloroquine sulfate (two 800-mg doses given 6 hours apart followed by a 400-mg dose given 12 hours after the initial dose on day 1, then 400 mg twice daily for 10 days) with local standard of care and...
909 pts were randomized to hydroxychloroquine control (i.e., local standard of care only). Clinical characteristics at baseline were well balanced between groups. Data analysis for the intention-to-treat (ITT) population (947 pts in hydroxychloroquine group and 906 pts in standard of care only group) indicated that hydroxychloroquine did not reduce in-hospital mortality (either overall or in any subgroup defined by age or ventilation status at study entry) and did not reduce the need for initiation of ventilation or the duration of hospitalization. The log-rank death rate ratio for hydroxychloroquine in the ITT population was 1.19; 104/947 pts treated with hydroxychloroquine (10.2%) and 84/906 pts treated with standard of care (8.9%) died. Ventilation was initiated after randomization in 75 pts receiving hydroxychloroquine and 66 pts receiving standard of care.  

Multicenter, randomized, blinded, placebo-controlled trial evaluating hydroxychloroquine in adults hospitalized with COVID-19 (Self et al): A total of 479 adults with laboratory-confirmed SARS-CoV-2 infection were randomized 1:1 to receive hydroxychloroquine sulfate (400 mg twice daily on day 1, then 200 mg twice daily on days 2-5) or placebo. Baseline characteristics were similar between both groups; median age was 57 years and median duration of symptoms prior to randomization was 5 days. The primary outcome was clinical status at 14 days after randomization and clinical status was assessed using a 7-category ordinal scale (COVID outcomes scale); secondary outcomes included all-cause all-location mortality at 14 and 28 days after randomization, time to recovery, composite of death or need for ECMO, and support-free days through 28 days (e.g., no need for hospitalization, oxygen, intensive care, ventilator, vasopressors). At day 14, there was no difference in clinical status between the hydroxychloroquine group (242 pts) and placebo group (237 pts); median score (interquartile range) on the COVID outcomes scale was 6 (4-7) in both groups (score of 6 was defined as not hospitalized and unable to perform normal activities). There also was no difference in

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage*</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>clinical status at day 14 between the hydroxychloroquine and placebo groups in any of the prespecified subgroups (e.g., based on age, sex, race/ethnicity, baseline illness severity, duration of symptoms). In addition, there were no differences in any of the secondary outcomes between the treatment groups. Data for pts with confirmed vital status at day 28 indicated that 10.4% of those in the hydroxychloroquine group and 10.6% of those in the placebo group had died.(^6)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Retrospective, comparative cohort study evaluating clinical outcomes in hospitalized COVID-19 pts treated with hydroxychloroquine vs hydroxychloroquine with azithromycin vs azithromycin alone (Arshad et al):** Data for 2541 consecutive pts with laboratory-confirmed COVID-19 who were admitted to hospitals within the Henry Ford Health System in Michigan and received hydroxychloroquine and/or azithromycin or did not receive these drugs were analyzed. Median age of patients was 64 years; the majority had BMI of 30 or greater and many had various other comorbidities; 68% received corticosteroid treatment and 4.5% received tocilizumab; mSOFA scores were not available for 25% of pts and data were not available regarding duration of symptoms prior to hospitalization; and the median length of hospitalization was 6 days. The primary end point was inpatient mortality; median follow-up was 28.5 days. Results indicated that crude mortality rates were 18.1% in the entire group, 13.5% in the hydroxychloroquine group, 20.1% in the hydroxychloroquine with azithromycin group, 22.4% in the azithromycin group, and 26.4% in those not treated with hydroxychloroquine and/or azithromycin. The primary causes of mortality were respiratory failure (88%), cardiac arrest (4%), and cardiopulmonary arrest and multi-organ failure (8%). **Note: Only selected pts with minimal cardiac risk factors received hydroxychloroquine with azithromycin and all pts treated with hydroxychloroquine were monitored closely with telemetry and serial QTc evaluations.**\(^5\)**
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Open-label, randomized study in hospitalized pts with mild to moderate COVID-19 (Cavalcanti et al; Brazil; NCT04322123): Adults hospitalized with COVID-19 were randomized 1:1:1 to receive standard care (control group), hydroxychloroquine (400 mg twice daily for 7 days) with standard care, or hydroxychloroquine (same dosage) plus azithromycin (500 mg once daily for 7 days) with standard care. Pts not requiring supplemental oxygen or only requiring supplemental oxygen at a rate of 4 L/min or less at baseline were enrolled; pts with a history of severe ventricular tachycardia or with QTc of 480 msec or greater at baseline were excluded. The median time from onset of symptoms to randomization was 7 days. The primary outcome was clinical status at day 15 evaluated using a 7-point ordinal scale. Data for the 504 pts in the modified intention-to-treat population with laboratory-confirmed COVID-19 (173 pts in the control group, 159 pts in the hydroxychloroquine group, 172 pts in the hydroxychloroquine and azithromycin group) indicated there was no significant difference in clinical status at day 15 in those treated with hydroxychloroquine with or without azithromycin compared with the control group. There also were no significant differences in secondary outcomes (e.g., need for mechanical ventilation, duration of hospitalization, in-hospital death) among the groups.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Open-label, randomized study in outpatients with mild COVID-19 (Mitja et al; Spain): Total of 293 adults with laboratory-confirmed COVID-19 who did not require hospitalization and had mild symptoms (i.e., fever, acute cough, shortness of breath, sudden olfactory or gustatory loss, influenza-like illness) for less than 5 days before study enrollment were randomized 1:1 to receive hydroxychloroquine (800 mg on day 1, then 400 mg once daily for 6 days) or usual care only. The primary outcome was reduction of viral RNA load in nasopharyngeal swabs at days 3 and 7 after treatment initiation. Median age of pts was 41.6 years, 53% reported chronic health conditions, and 87% were healthcare workers. The median time from symptom onset</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
to randomization was 3 days, and the mean viral load at baseline was 7.9 log_{10} copies/mL. **Results indicated that a 7-day hydroxychloroquine regimen did not provide any clinical benefits compared with usual care alone in these outpatients with mild COVID-19.** There was no significant reduction in viral load at day 3 or 7 in those treated with hydroxychloroquine vs those treated with usual care only and there was no decrease in median time to resolution of COVID-19 symptoms (10 and 12 days, respectively) and no decrease in risk of hospitalization (7 and 6%, respectively).^{59}

**Double-blind, randomized, placebo-controlled study in outpatients with confirmed or probable early COVID-19 (Skipper et al; US and Canada; NCT04308668):** A total of 423 symptomatic adults with laboratory-confirmed COVID-19 or with symptoms compatible with COVID-19 and a high-risk exposure to a contact with laboratory-confirmed COVID-19 were randomized 1:1 to receive hydroxychloroquine (initial dose of 800 mg, 600 mg given 6-8 hours later, then 600 mg once daily for the next 4 days) or placebo. Enrolled pts had been symptomatic for no more than 4 days and did not require hospitalization at the time of enrollment. The primary efficacy end point specified in the initial study protocol was subsequently changed to overall symptom severity over 14 days; symptoms and severity were self-reported by the pts at days 3, 5, 10, and 14 using a survey with a 10-point visual analog scale. Median age of pts was 40 years, 68% reported no chronic medical conditions, 57% were healthcare workers, 25% had been exposed to COVID-19 through household contacts, and 56% of pts had enrolled within 1 day of symptom onset. **Results indicated that a 5-day hydroxychloroquine regimen did not provide any substantial improvement in symptom severity in these outpatients with confirmed or probable COVID-19.** At day 5, 54% of pts in the hydroxychloroquine group and 56% in the placebo group reported symptoms. At day 14, 24% of those treated with hydroxychloroquine had ongoing symptoms compared with 30% of those treated with placebo.
Overall, the decrease in prevalence of symptoms and the reduction in symptom severity score over 14 days were not significantly different between the two groups (symptom severity in the 10-point scale decreased 2.6 points in those treated with hydroxychloroquine and 2.3 points in those treated with placebo). In addition, there was no difference between the groups in the incidence of hospitalization or death.  

Large, multinational, retrospective study analyzed outcome data for hospitalized pts with confirmed COVID-19 to assess the effects of hydroxychloroquine or chloroquine used with or without a macrolide (Mehra et al; now retracted): Original publication included data obtained worldwide for 96,032 pts hospitalized with COVID-19 between Dec 20, 2019 and Apr 14, 2020, including 14,888 pts who received chloroquine or hydroxychloroquine with or without a macrolide (azithromycin or clarithromycin) initiated within 48 hours of diagnosis (treatment group) and 81,144 pts who did not receive these drugs (control group). Based on those data, in-hospital mortality rate in the control group was 9.3% compared with 18% in those treated with hydroxychloroquine alone (n=3016), 23.8% in those treated with hydroxychloroquine and a macrolide (n=6221), 16.4% in those treated with chloroquine alone (n=1868), and 22.2% in those treated with chloroquine and a macrolide (n=3783). 50 Note: This published study has now been retracted by the publisher at the request of 3 of the original authors. 52 Concerns were raised with respect to the veracity of the data and analyses conducted by a global healthcare data collaborative. 51,52

Hydroxychloroquine for postexposure prophylaxis of COVID-19 randomized, placebo-controlled trial in the US and Canada (NCT04308668): Asymptomatic adults with occupational or household exposure to an individual with COVID-19 were randomly assigned 1:1 to receive postexposure prophylaxis with a 5-day regimen of hydroxychloroquine sulfate (initial 800-mg dose followed by a 600-mg dose given 6-8
hours after first dose on day 1, then 600 mg once daily for 4 additional days) or placebo (folate tablets). A total of 821 asymptomatic adults were enrolled within 4 days after COVID-19 exposure (414 randomized to hydroxychloroquine and 407 randomized to placebo); 66% were healthcare workers. Overall, 88% of participants reported high-risk exposures (occurred at a distance of <6 feet for >10 minutes while not wearing a face mask or eye shield) and the others reported moderate-risk exposures (occurred at a distance of <6 feet for >10 minutes while wearing a face mask but no eye shield). Note: Participants were recruited primarily through social media outreach and traditional media platforms and were enrolled using an internet-based survey. The exposure event and subsequent onset of new symptoms and illness compatible with COVID-19 after enrollment were self-reported using email surveys on days 1, 5, 10, and 14 and at 4-6 weeks. Results of these surveys and information obtained using additional forms of follow-up indicated that confirmed or probable COVID-19 (based on self-reported symptoms or PCR testing) developed in 13% of participants overall (107/821) and did not differ significantly between those who received hydroxychloroquine prophylaxis (11.8%) and those who received placebo (14.3%).

Note: The various limitations of the trial design should be considered when interpreting the results. Exposure to someone with confirmed COVID-19, time from the exposure event to initiation of prophylaxis, and all outcome data (including possible COVID-19 symptoms and PCR test results) were self-reported by study participants. COVID-19 was confirmed with PCR testing in only a small percentage (<3%) of participants who self-reported COVID-19 symptoms. Survey results indicated that full adherence to the 5-day prophylaxis regimen was reported by only 75% of patients randomized to hydroxychloroquine and 83% of those randomized to placebo. In addition, a total of 52 participants did not complete any surveys after study enrollment.

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>-------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td></td>
<td></td>
<td>Double-blind, placebo-controlled, randomized trial in the US to evaluate hydroxychloroquine for preexposure prophylaxis (PrEP) for prevention of COVID-19 (Abella et al; NCT04329923): Healthcare personnel working ≥20 hours per week in hospital-based units (nurses, physicians, certified nursing assistants, emergency technicians, respiratory therapists) who had no known history of SARS-CoV-2 infection and no symptoms suggestive of COVID-19 within 2 weeks prior to trial enrollment were randomized 1:1 to receive hydroxychloroquine (600 mg daily) or placebo for preexposure prophylaxis of COVID-19. Nasopharyngeal swab tests for SARS-CoV-2 and serologic tests for anti-nucleocapside IgG, anti-spike protein receptor-binding domain (RBD) IgM, and anti-RBD IgG were performed at the time of randomization (baseline) and at 4 and 8 weeks; participants also were surveyed weekly for adherence and adverse events. The primary outcome was rate of conversion to SARS-CoV-2-positive status based on nasopharyngeal swab testing at 8 weeks. A total of 125 participants were evaluable for the primary outcome (64 in the hydroxychloroquine arm and 61 in the placebo arm); 22 of the evaluable participants (17.6%) discontinued study treatment early. Results indicate that preexposure prophylaxis with hydroxychloroquine did not provide clinical benefits in hospital-based healthcare personnel. The rate of COVID-19 positivity was similar in the hydroxychloroquine group (6.3%) and placebo group (6.6%); cases of infection occurred throughout the 8-week study period. All 8 individuals who became infected (4 in each group) were either asymptomatic or had mild disease with full recovery; none required hospitalization. After reviewing data at the time of a second planned interim analysis, the data safety and monitoring board recommended that the trial be terminated early. Grade 3 or 4 adverse events were not reported in any participants; the incidence of adverse events was significantly higher in the hydroxychloroquine group than the placebo group (45 vs 26%). Note: Limitations of this trial include the possibility that it was insufficiently powered because of low</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosagea</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>enrollment, data are not available to quantify the frequency of participant exposures to the virus or specific timing of such exposures, and most participants were young and healthy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Efficacy of hydroxychloroquine for preexposure prophylaxis (PrEP) for prevention of COVID-19</strong> was also evaluated in another double-blind, placebo-controlled, randomized trial in the US and Canada (Rajasingham et al; NCT04328467): This study enrolled 1483 healthcare personnel ≥18 years of age at high risk because of ongoing exposure to patients with SARS-CoV-2 (i.e., personnel working in emergency departments, intensive care units, or COVID-19 hospital wards; those performing aerosol-generating procedures; first responders) and randomized them to PrEP with hydroxychloroquine (two 400-mg doses given 6-8 hours apart, then 400 mg once or twice weekly for 12 weeks) or similar regimens of placebo (folic acid). The primary outcome was laboratory-confirmed COVID-19 or COVID-19-compatible illness. <strong>Results indicated that a once- or twice-weekly regimen of hydroxychloroquine did not reduce laboratory-confirmed COVID-19 or COVID-19-compatible illness in healthcare personnel at high risk of infection.</strong> Overall, COVID-19 (laboratory-confirmed or symptomatic compatible illness) occurred in 39 (7.9%) of those in the placebo group compared with 29 (5.9%) of those in the once-weekly hydroxychloroquine group and 29 (5.9%) of those in the twice-weekly hydroxychloroquine group. This corresponded to an incidence of 0.38 events/person-year with placebo compared with 0.27 events/person-year with once-weekly and 0.28 events/person-year with twice-weekly hydroxychloroquine.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Double-blind, placebo-controlled, randomized trial in the US to evaluate hydroxychloroquine for postexposure prophylaxis (PEP) for prevention of COVID-19 following contact with an infected individual</strong> (Barnabas et al; NCT04328961): Trial participants were adults with known exposure to an individual with SARS-CoV-2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Efficacy of Hydroxychloroquine for Postexposure Prophylaxis (PEP) for Prevention of COVID-19

Efficacy of hydroxychloroquine for postexposure prophylaxis (PEP) for prevention of COVID-19 following contact with an infected individual was also evaluated in another double-blind, placebo-controlled, randomized trial in the US and Canada (Boulware et al; NCT04308668): Trial participants were adults with household or occupational exposure to an individual with laboratory-confirmed COVID-19 at a distance of <6 feet for >10 minutes while not wearing a face mask or eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days of exposure, participants were randomly assigned to receive PEP with hydroxychloroquine (800-mg dose, then 600 mg 6-8 hours later, then 600 mg daily for 4 days) or placebo (folic acid). The primary outcome was laboratory-confirmed SARS-CoV-2 infection or COVID-19-related symptoms through day 14. Results indicated that hydroxychloroquine was not effective for PEP in high- or moderate-risk household or occupational contacts of an individual.
with confirmed COVID-19. A total of 821 participants (87.6% with high-risk exposures) were included in the efficacy analysis. COVID-19 (either PCR-confirmed or symptomatically compatible) developed in 107 participants (13%) during the 14 days of follow-up. The incidence of new illness compatible with COVID-19 was 11.8% in the hydroxychloroquine group and 14.3% in the placebo group.

Retrospective cohort study in the US to evaluate possible SARS-CoV-2 preventive benefits of hydroxychloroquine therapy used in pts with rheumatic conditions (Gentry et al): Possible benefit of long-term hydroxychloroquine therapy used for management of rheumatic conditions for prevention of SARS-CoV-2 infection in such pts was investigated retrospectively using data obtained from the US Veterans Affairs Medical Centers (VAMCs) database. Adults in the database with ICD-10 diagnostic code entries for rheumatoid arthritis, systemic lupus erythematosus, and associated rheumatologic conditions were identified and each such pt receiving hydroxychloroquine was matched to 2 such pts not receiving hydroxychloroquine (controls). The primary end point was the proportion of pts with PCR-confirmed SARS-CoV-2 infection between March 1 and June 30, 2020 among those receiving long-term hydroxychloroquine therapy versus the propensity-matched patients not receiving hydroxychloroquine. Data analyses indicated that long-term hydroxychloroquine therapy in patients receiving the drug for rheumatic conditions was not associated with a preventive effect against SARS-CoV-2 infection. The incidence of SARS-CoV-2 infection was similar in pts receiving hydroxychloroquine (0.3%; 31 of 10,703 pts) and those not receiving the drug (0.4%; 78 of 21,406 pts). In those who developed active SARS-CoV-2 infection, there were no significant differences in secondary outcomes between the hydroxychloroquine group and control group.

Various clinical trials evaluating hydroxychloroquine for treatment or prevention of COVID-19 are registered at clinicaltrials.gov.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage**</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuraminidase inhibitors (e.g., oseltamivir)</td>
<td>8:18.28</td>
<td>Antivirals active against influenza viruses</td>
<td>Oseltamivir has been included as a component of various antiviral regimens used for the treatment of COVID-19. While oseltamivir is noted to have been widely used for confirmed or suspected COVID-19 cases in hospitals in China in the early stages of the pandemic, there has been no evidence that oseltamivir is effective in the treatment of COVID-19. In a retrospective case series of 99 adults with COVID-19 at a single center in Wuhan from 1/1/20 to 2/20/20, 76% of pts received antiviral treatment, including oseltamivir (75 mg orally every 12 hours). At the time of evaluation, 58% of patients remained hospitalized, 31% had been discharged, and 11% had died. In a retrospective case series of 79 adults with COVID-19 who were negative for influenza A and B, early use of oseltamivir had no effect on COVID-19 and did not effectively slow the progression of the disease. In a retrospective cohort study of 1190 adults with COVID-19 at a single center in Wuhan from 12/29/19 to 2/28/20, 61.6% of pts received antiviral therapy (e.g., oseltamivir, ganciclovir, lopinavir/ritonavir, interferon, umifenovir). A survival analysis indicated that administration of oseltamivir appeared to have reduced the risk of death in pts with severe disease and seemed to have been associated with less deterioration (i.e., progression from nonsevere to severe disease or severe disease to death). Note: Limitations of this study include missing laboratory data because of retrospective data extraction, lack of information on possible mixed viral infections, and inability to analyze possible reasons for mortality benefit. Oseltamivir may be included in some COVID-19 clinical trials registered at clinicaltrials.gov.</td>
<td>Dosage of oseltamivir in the case series of 99 COVID-19 patients was 75 mg orally every 12 hours.</td>
<td>Although oseltamivir was suggested as a potential treatment and included in various antiviral regimens used during the early stages of the COVID-19 pandemic, the drug does not appear to have in vitro activity against SARS-CoV-2 and there are no data to support the use of oseltamivir or other neuraminidase inhibitors in the treatment of COVID-19. NIH COVID-19 Treatment Guidelines Panel states that, when SARS-CoV-2 and influenza are cocirculating, testing for both viruses is recommended in all hospitalized pts with acute respiratory illness and also recommended in outpatients with acute respiratory illness if results will change clinical management of the pt. Testing is the only way to distinguish between influenza and SARS-CoV-2 and identify coinfection. Treatment of influenza is the same in all pts regardless of SARS-CoV-2 coinfection. If SARS-CoV-2 and influenza are cocirculating, the panel recommends that hospitalized pts suspected of having one or both viral infections receive oseltamivir for empiric influenza treatment as soon as possible without waiting for influenza testing results; empiric influenza treatment can be de-escalated based on results of testing and intubation status. Significant drug interactions not expected with oseltamivir and remdesivir. CDC states that, when SARS-CoV-2 and influenza are cocirculating, priority groups for influenza antiviral treatment include pts who are hospitalized with respiratory illness; outpatients with severe, complicated, or progressive respiratory illness; and outpatients at higher risk for influenza complications presenting with any symptoms of acute respiratory illness (with or without fever). CDC recommends oseltamivir for treatment of hospitalized pts with suspected or confirmed influenza and states that oseltamivir, zanamivir, or peramivir may be used for the treatment of influenza in outpatients, taking into account the severity and progression of illness and the presence of complications.</td>
</tr>
</tbody>
</table>

**Updated 1/14/21**
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remdesivir (Veklury*)</td>
<td>8:18.32 Antiviral</td>
<td>Nucleotide analog prodrug; RNA polymerase inhibitor26</td>
<td>Randomized, double-blind, placebo-controlled trial in hospitalized adults with severe COVID-19 in China (NCT04257656; Wang et al): Pts were randomized 2:1 to receive remdesivir (200 mg IV on day 1, then 100 mg IV once daily on days 2-10) or placebo initiated within 12 days of symptom onset. Primary outcome was time to clinical improvement within 28 days after randomization or hospital discharge, whichever came first. ITT population included 158 pts treated with remdesivir and 78 pts treated with placebo; 32% of pts also received interferon α-2b, 28% also received LPV/RTV, and 66% also received corticosteroids during hospitalization. Median time to clinical improvement was not significantly different in remdesivir group (21 days) vs placebo group (23 days); 28-day mortality rate was similar in both groups (14 vs 13%). When remdesivir was initiated within 10 days of symptom onset, median time to clinical improvement was numerically shorter (but not statistically significant) compared with placebo group (18 vs 23 days). Duration of invasive mechanical ventilation was numerically shorter (but not statistically significant) in remdesivir group; only a small percentage of pts (0.4%) were on invasive mechanical ventilation at time of enrollment. Remdesivir did not result in significant reduction in SARS-CoV-2 viral load in nasopharyngeal, oropharyngeal, and sputum samples. Remdesivir was discontinued in 18 pts (12%) because of adverse effects. <strong>Note:</strong> Enrollment was terminated before the pre-specified number of pts was attained (lack of available pts); trial was insufficiently powered to detect assumed differences in clinical outcome.21</td>
<td>Remdesivir dosage for FDA-labeled indication for treatment of COVID-19 in adults and pediatric patients ≥12 years of age weighing at least 40 kg (lyophilized powder formulation or solution concentrate formulation): Loading dose of 200 mg by IV infusion on day 1, followed by maintenance doses of 100 mg by IV infusion once daily from day 2. For pts not requiring invasive mechanical ventilation and/or ECMO, recommended total treatment duration is 5 days; if pt does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days (i.e., up to a total treatment duration of 10 days). For those requiring invasive mechanical ventilation and/or ECMO, recommended total treatment duration is 10 days.46</td>
<td>The only direct-acting antiviral (DAA) currently approved by FDA for treatment of COVID-19 in certain populations.</td>
</tr>
<tr>
<td>Updated 7/15/21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Received FDA approval on October 22, 2020 for treatment of COVID-19 in adults and pediatric patients ≥12 years of age weighing at least 40 kg who are hospitalized or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.46 FDA states that such alternative care sites may include temporary facilities intended to provide additional hospital surge capacity/capabilities for communities overwhelmed by patients with COVID-19 and at-home care provided by hospitals that have received CMS waiver approval as part of CMS’s Acute Hospice at Home (AHCaH) program. The drug may be used for the FDA-labeled indication to treat patients directly to an alternative care site and, if clinically indicated, to complete the course of treatment in patients transferred to an alternative care site.48</td>
</tr>
</tbody>
</table>

Pharmacokinetic data available from studies in healthy adults46

In vitro evidence of activity against SARS-CoV-2 in Vero E6 cells; 1.18 antiviral activity against SARS-CoV-2 in human airway epithelial (HAE) cells 56

In Rhesus macaques infected with SARS-CoV-2, treatment with a 6-day regimen of IV remdesivir initiated 12 hours after virus inoculation was associated with some benefits (lower disease severity scores, fewer pulmonary infiltrates, lower virus titers in bronchoalveolar lavage samples) compared with vehicle control 59

In vitro activity against SARS-CoV and MERS-CoV; active in animal models of SARS and MERS; prevented MERS in Rhesus macaques when given before infection and provided benefits when given after animal already infected 48

Note: Updated 7/15/21
ventilation at study entry; protocol was subsequently modified to include pts 12 years of age or older, add an extension phase, and include a cohort of pts receiving mechanical ventilation. Data for the initial 397 pts not requiring mechanical ventilation at study entry (200 received a 5-day regimen and 197 received a 10-day regimen) indicate similar clinical improvement with both treatment durations after adjusting for baseline clinical status. Pt demographics and clinical characteristics at baseline generally were similar in both groups, although the 10-day group included a higher percentage of pts in the most severe disease categories and a higher proportion of men (who are known to have worse COVID-19 outcomes than women); median duration of symptoms before first dose of remdesivir was similar in both groups (8 or 9 days). At day 14, 129/200 pts (65%) in the 5-day group and 106/197 pts (54%) in the 10-day group achieved clinical improvement (defined as an improvement of at least 2 points from baseline on a 7-point ordinal scale). After adjusting for baseline imbalances in disease severity, data indicate that clinical status at day 14, time to clinical improvement, recovery, and death (from any cause) were similar in both groups. Although eligibility criteria according to the initial study protocol excluded pts receiving invasive mechanical ventilation, 4 pts in the 5-day group and 9 pts in the 10-day group were receiving invasive mechanical ventilation or ECMO (need identified after initial screening and before treatment initiation or pts were accepted as protocol deviations). There also were more pts in the 10-day group (30%) who required high-flow oxygen support at baseline compared with the 5-day group (24%). Post-hoc analysis among pts receiving mechanical ventilation or ECMO at day 5 indicate that, by day 14, 40% of such individuals who had received the 5-day regimen had died compared with 17% of those who had received the 10-day regimen. Treatment with remdesivir beyond 5 days did not appear to improve outcomes among pts who were receiving noninvasive positive-pressure ventilation or high-flow oxygen, low-flow oxygen, or breathing ambient ventilation and/or ECMO, recommended total treatment duration is 5 days; if pt does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days (i.e., up to a total treatment duration of 10 days). For those requiring invasive mechanical ventilation and/or ECMO, recommended total treatment duration is 10 days.

NIH COVID-19 Treatment Guidelines

Panel-recommended duration of remdesivir treatment: The NIH panel recommends that hospitalized pts who require supplemental oxygen but do not require high-flow oxygen, noninvasive ventilation, mechanical ventilation, or ECMO, should receive remdesivir for a duration of 5 days or until hospital discharge, whichever comes first. If such pts progress to requiring high-flow oxygen, noninvasive ventilation, mechanical ventilation, or ECMO during such treatment, the panel recommends that the remdesivir course be completed. The panel states that there are insufficient data on the optimal duration of remdesivir treatment for pts who have not shown clinical improvement after a 5-day regimen; some experts would extend the total duration of remdesivir treatment to up to 10 days in these patients.

To FDA approval of remdesivir for use in adults and pediatric patients ≥12 years of age weighing at least 40 kg, the EUA was reissued on October 22, 2020 to allow continued authorization of the drug (lyophilized powder formulation only) for emergency use in pediatric patients weighing 3.5 to <40 kg and pediatric patients <12 years of age weighing at least 3.5 kg with suspected or laboratory-confirmed COVID-19.

The EUA for remdesivir requires that the drug be administered by a healthcare provider in an inpatient hospital setting (or alternative care site capable of providing acute care comparable to general inpatient hospital care) via IV infusion at dosages recommended in the EUA. Although distribution of remdesivir under the EUA was previously directed by the HHS Office of Preparedness and Response (ASPR) in collaboration with state health departments, the EUA now designates the manufacturer (Gilead) and its authorized distributor(s) as the parties responsible for distribution of the drug. For additional information about the remdesivir EUA, consult the EUA letter of authorization, EUA fact sheet for healthcare providers, and EUA fact sheet for parents and caregivers.

Healthcare providers should contact Gilead’s sole US distributor (Amneal) at 800-746-6273) to purchase remdesivir for age-appropriate use under the FDA-approved indication (lyophilized powder formulation or solution concentrate formulation) or the EUA (lyophilized powder formulation only).

Concerns regarding variations in remdesivir packaging: The
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

air. Note: Results for the initial 397 study pts with severe COVID-19 not requiring mechanical ventilation at study entry cannot be extrapolated to critically ill pts receiving mechanical ventilation. 21

Comparative analysis of data from phase 3 SIMPLE-Severe trial and real-world retrospective cohort of patients: The manufacturer announced results of an analysis that compared data for 312 hospitalized pts with severe COVID-19 who received remdesivir in this randomized, open-label trial with a retrospective cohort of 818 pts with similar baseline characteristics and disease severity who received standard of care treatment (without remdesivir) during the same time period. More than 90% of pts in both groups were enrolled at North American trial sites and the rest were enrolled at European or Asian trial sites. Clinical recovery (improvement in clinical status based on a 7-point ordinal scale) and mortality rate for these 2 groups were compared. By day 14, recovery was reported in 74.4% of pts treated with remdesivir and 59% of pts in the retrospective cohort treated with standard of care and the mortality rate was 7.6 and 12.5%, respectively. 24

Subgroup analyses of data from Phase 3 SIMPLE-Severe trial: The manufacturer announced results of subgroup analyses of 229 hospitalized pts with severe COVID-19 who received remdesivir in this randomized, open-label trial and were enrolled at US trial sites. Clinical improvement was defined as a 2-point or greater improvement on a 7-point ordinal scale. At day 14, the rate of clinical improvement was 94% in black pts (n=43), 76% in Hispanic white pts (n=17), 67% in Asian pts (n=18), 67% in non-Hispanic white pts (n=119), and 63% in pts who did not identify with any of these groups (n=32). An analysis of 397 pts who were enrolled globally indicated that black race, age less than 65 years, treatment outside of Italy, and requirement of only low-flow oxygen support or room air at baseline were factors significantly associated with clinical improvement of at least 2 points on day 14. Another subgroup analysis was performed to evaluate outcomes in manufacturer is alerting healthcare providers that there are variations in remdesivir packaging and labeling (e.g., use of the tradename Veklury®, expiration dates) depending on whether the drug was originally manufactured for use under the EUA or for commercial use. 49 FDA states that, if patient safety can be assured, they do not intend to object to remdesivir supplies that have labels specifying “for use under Emergency Use Authorization” being distributed for appropriate use under the FDA-labeled indication during the first six months after the drug received this approval. 49 Questions related to carton or vial labeling or expiration dates should be directed to Gilead at 866-633-4474 or www.askgileadmedical.com. 49

NIH COVID-19 Treatment Guidelines Panel issued the following recommendations for use of remdesivir for the management of COVID-19 based on disease severity:

1) Hospitalized with COVID-19 not requiring supplemental oxygen: The panel states that data are insufficient to recommend either for or against routine use of remdesivir. For pts at high risk of disease progression, use of remdesivir may be appropriate. 20

2) Hospitalized requiring supplemental oxygen but not requiring high-flow oxygen, noninvasive ventilation, invasive mechanical ventilation, or ECMO: The panel recommends remdesivir (e.g., for pts requiring minimal supplemental oxygen) or remdesivir plus dexamethasone (e.g., for pts requiring increasing amounts of supplemental oxygen) or dexamethasone alone (e.g., when combination therapy with remdesivir is unavailable or cannot be used).

3) Hospitalized requiring high-flow oxygen or noninvasive ventilation: The panel recommends dexamethasone alone or dexamethasone plus remdesivir. The panel recommends against use of remdesivir alone. In recently hospitalized pts (e.g., within 3
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>pts who received concomitant therapy with remdesivir and hydroxychloroquine vs those who received only remdesivir. At a median follow-up of 14 days, the rates and likelihood of recovery were lower in those treated with both drugs (57%) compared with those treated with remdesivir alone (69%). Although concomitant hydroxychloroquine was not associated with increased mortality at 14 days, the overall rate of adverse effects was higher and, after adjusting for baseline variables, the incidence of grade 3-4 adverse events was significantly higher in those treated with both drugs.24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>**Phase 3 randomized, open-label trial in hospitalized pts with moderate COVID-19 (NCT04222730; GS-US-540-5774; SIMPLE-Moderate) sponsored by the manufacturer (Gilead): Initial study protocol was designed to evaluate safety and antiviral activity of 5- and 10-day regimens of remdesivir (200 mg IV on day 1, followed by 100 mg IV once daily for total of 5 or 10 days) in conjunction with standard of care compared with standard care alone in adults with moderate COVID-19 (i.e., hospitalized with evidence of pulmonary infiltrates and SpO2 &gt;94% on room air); protocol was subsequently modified to change the primary end point to clinical status on day 11 based on a 7-point ordinal scale, include pts 12 years of age or older, and add an extension phase to include additional pts.**11, 30</td>
<td>Data for the initial group of adults who received a 5-day regimen of remdesivir with standard care (n=191), 10-day regimen of the drug with standard care (n=193), or standard care alone (n=200) have been published. At day 11, 70, 65, or 61% of pts in the 5-day, 10-day, or standard of care alone group, respectively, had clinical improvement based on at least a 2-point improvement from baseline on a 7-point ordinal scale. Pts in the 5-day remdesivir group had statistically significant higher odds of a better clinical status distribution on the 7-point scale on day 11 than those receiving standard care (odds ratio: 1.65) but the difference was of uncertain clinical importance; the difference in clinical status distribution between pts in the 10-day remdesivir group and the pts who received standard care was not statistically significant. The difference in clinical status distribution between those receiving standard care alone group, respectively, had clinical improvement based on at least a 2-point improvement from baseline on a 7-point ordinal scale. Pts in the 5-day remdesivir group had statistically significant higher odds of a better clinical status distribution on the 7-point scale on day 11 than those receiving standard care (odds ratio: 1.65) but the difference was of uncertain clinical importance; the difference in clinical status distribution between pts in the 10-day remdesivir group and the pts who received standard care was not statistically significant. The difference in clinical status distribution between those receiving standard care alone was not statistically significant.</td>
<td>4) <strong>Hospitlized requiring invasive mechanical ventilation or ECMO:</strong> The panel recommends dexamethasone. Dexa-methasone plus remdesivir may be considered for pts who were recently intubated. The panel <strong>recommends against</strong> use of remdesivir alone. For pts who were receiving remdesivir monotherapy and progressed to requiring invasive mechanical ventilation or ECMO, dexamethasone should be initiated and the remdesivir treatment course completed. For pts who are within 24 hours of admission to the ICU, the panel recommends dexamethasone (with or without remdesivir) plus tocilizumab.20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5) <strong>Discharged from hospital inpatient setting:</strong> If pt is in stable condition not requiring supplemental oxygen, the panel <strong>recommends against</strong> continuing remdesivir or remdesivir plus dexamethasone after hospital discharge. If pt is discharged requiring supplemental oxygen, the panel states that data are insufficient to recommend either for or against continuing use of remdesivir or remdesivir plus dexamethasone.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6) <strong>Discharged from emergency department despite new or increasing need for supplemental oxygen:</strong> The panel recommends dexamethasone for the duration of supplemental oxygen. The panel states that data are insufficient to recommend either for or against remdesivir in such pts.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Although safety and efficacy of combined use of remdesivir with dexamethasone or other corticosteroids have not been specifically studied in clinical
standard care group was not statistically significant. At day 11, 4 deaths were reported in the standard care alone group compared with none in the 5-day group and 2 in the 10-day group. There were no significant differences between the 5- or 10-day remdesivir groups and standard care group for any of the exploratory end points at day 11 (time to 2-point or greater improvement in clinical status, time to 1-point or greater improvement in clinical status, time to recovery, time to modified recovery, time to discontinuation of oxygen support). At day 14, the clinical status of pts in the 5-day and 10-day remdesivir groups was significantly different than that of the standard care group. Note: Effect of remdesivir on SARS-CoV-2 viral load was not assessed. Limitations of this study include the open-label design and use of an ordinal scale to evaluate outcomes that was not ideal for detecting differences in pts with moderate COVID-19.  

**Phase 3 adaptive, randomized, double-blind, placebo-controlled trial (NCT04280705; NIAID Adaptive COVID-19 Treatment Trial 1 [ACTT-1]) in hospitalized adults with COVID-19:** Pts were randomized 1:1 to receive remdesivir (200 mg IV on day 1, then 100 mg IV once daily on days 2-10 or until hospital discharge or death) or placebo. All pts received supportive care according to the standard of care for the trial site hospital. The primary outcome was time to recovery, defined as the first day within 28 days after enrollment when clinical status met criteria for category 1, 2, or 3 on an 8-category ordinal scale (i.e., discharged from hospital with or without limitations on activities or requirement for home oxygen, or hospitalized but not requiring supplemental oxygen and no longer requiring ongoing medical care). A total of 1062 pts were randomized with 541 assigned to remdesivir and 521 assigned to placebo (intention-to-treat population). Baseline demographics and clinical characteristics (e.g., age, disease severity, comorbidities at study enrollment, time to initiation of treatment after symptom onset) were similar in both groups. A total of 957 pts (90.1%) had severe disease

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
</table>
|         |            |           |                              |         | trials to date, the NIH panel states that there are theoretical reasons that such combined therapy may be beneficial in some pts with severe COVID-19. Concomitant use of remdesivir with dexamethasone is expected to result in minimal or no reduction in remdesivir exposure. If dexamethasone is not available, the panel recommends using alternative corticosteroids (e.g., hydrocortisone, methylprednisolone, prednisone). (See Corticosteroids [Systemic] in this Evidence Table.)  

**IDSA issued the following recommendations for use of remdesivir in hospitalized pts:**

1) **Hospitalized with SpO2 >94% on room air without need for supplemental oxygen:** IDSA suggests against routine use of remdesivir. Additional study needed to assess benefits and harms of remdesivir in pts with moderate COVID-19.  

2) **Hospitalized with severe COVID-19 (i.e., SpO2 ≤94% on room air) and requiring supplemental oxygen but not on mechanical ventilation or ECMO:** IDSA suggests use of a 5-day regimen of remdesivir.  

3) **Hospitalized with severe COVID-19 and on mechanical ventilation or ECMO:** IDSA suggests against routine use of remdesivir.  

**Pregnant women:** The NIH panel states that remdesivir should not be withheld from pregnant women if it is otherwise indicated. The manufacturer states that available data from published case reports and compassionate use of remdesivir are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.  

Concomitant use of remdesivir and chloroquine or hydroxychloroquine is not recommended; 26, 29, 33, 46 FDA warns that there is in vitro evidence that
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i.e., required mechanical ventilation, required supplemental oxygen, had (\text{SpO}_2 \leq 94%) on room air, or had tachypnea with respiratory rate (\geq 24) breaths/minute) at study enrollment, and the median time from symptom onset to randomization was 9 days (range: 6-12 days). Final trial data indicated <strong>shorter median time to recovery</strong> in the remdesivir group (10 days) vs the placebo group (15 days); <strong>recovery rate ratio 1.29</strong>. Those who received remdesivir were more likely to have clinical improvement at day 15 than those who received placebo (odds ratio 1.5). Kaplan-Meier estimates of mortality by day 15 were 6.7% in the remdesivir group vs 11.9% in the placebo group (hazard ratio 0.55); by day 29, mortality was 11.4 and 15.2%, respectively (hazard ratio 0.73). Posthoc analysis of efficacy based on disease severity at enrollment suggested that benefits of remdesivir were most apparent in hospitalized pts receiving low-flow oxygen (recovery rate ratio 1.45); the recovery rate ratio in the subgroup of pts on mechanical ventilation or ECMO at enrollment was 0.98. There was no observed benefit of remdesivir compared with placebo in the subgroup with mild to moderate disease (defined as (\text{SpO}_2 &gt;94%) on room air or a respiratory rate &lt;24 beats/minute without supplemental oxygen) at enrollment; however, the number of pts in this subgroup was relatively small. Although there was no observed difference in time to recovery in subgroups requiring high-flow oxygen, noninvasive ventilation, mechanical ventilation, or ECMO at enrollment, the trial was not powered to detect differences in outcomes within subgroups and there is uncertainty about the effects of remdesivir on the course of COVID-19 in patients who are mechanically ventilated or on ECMO.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chloroquine antagonizes intracellular metabolic activation and antiviral activity of remdesivir.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remdesivir clinical drug interaction studies have not been performed to date. In vitro studies indicate remdesivir is a substrate for cytochrome P-450 (CYP) isoenzyme 3A4, organic anion transporting polypeptide (OATP) 1B1, and P-glycoprotein (P-gp), and is an inhibitor of CYP3A4, OATP1B1, OATP1B3, and multidrug and toxin extrusion transporter (MATE) 1. The clinical relevance of these in vitro assessments has not been established.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
mortality; protocol-specified secondary outcomes were initiation of ventilation and duration of hospitalization. ⁴⁻⁵ From March 22 to October 4, 2020, 2750 pts were randomized to receive remdesivir (200 mg on day 1, then 100 mg on days 2-10) with local standard of care and 2725 pts were randomized to remdesivir control (i.e., local standard of care only). Clinical characteristics at baseline were well balanced between groups. Data analysis for the intention-to-treat (ITT) population (2743 pts in remdesivir group and 2708 pts in standard of care group) indicated that remdesivir did not reduce in-hospital mortality (either overall or in any subgroup defined by age or ventilation status at study entry) and did not reduce the need for initiation of ventilation or the duration of hospitalization. The log-rank death rate ratio for remdesivir in the ITT population was 0.95; 301/2743 pts treated with remdesivir (12.5%) and 303/2708 pts treated with standard of care (12.7%) died. Ventilation was initiated after randomization in 295 pts in the remdesivir group and 284 pts in the standard of care group. ⁴⁴

**Data from the manufacturer’s compassionate use program (adults):** Preliminary data are available for a cohort of 53 adults from multiple sites in the US, Italy, Japan, and other countries who were hospitalized with severe COVID-19 and received treatment with remdesivir; 40 pts received the full 10-day regimen (200 mg IV on day 1, then 100 mg IV on days 2-10), 10 pts received 5-9 days and 3 pts received less than 5 days of treatment with the drug. At baseline, 30 pts (57%) were receiving mechanical ventilation and 4 (18%) were receiving extracorporeal membrane oxygenation (ECMO). Over a median follow-up of 18 days after first dose, 36 pts (68%) showed clinical improvement based on oxygen-support status and 8 pts (15%) worsened. There were 7 deaths (13%), including 6 pts receiving invasive ventilation. Adverse effects (e.g., increased hepatic enzymes, diarrhea, rash, renal impairment, hypotension) were reported in 32 pts (60%); 12 pts (23%) had serious adverse effects (e.g., multiple organ dysfunction syndrome,

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>-------------------</td>
<td>----------</td>
</tr>
<tr>
<td>remdesivir</td>
<td></td>
<td>septic shock, acute kidney injury, hypotension; 4 pts (8%) discontinued the drug because of adverse effects.</td>
<td>Note: Data presented for this small cohort of pts offers only limited information regarding efficacy and safety of remdesivir for treatment of COVID-19. There was no control group and, although supportive therapy could be provided at the discretion of the clinician, it is unclear whether pts at any of the various study sites also received other therapeutic agents being used for treatment of COVID-19. In addition, data were not presented regarding the effects of remdesivir on viral load.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Data from the manufacturer’s compassionate use program (pediatric pts): The manufacturer announced that preliminary data are available for 77 pediatric pts treated with remdesivir in the compassionate use program. Analysis of day-28 data indicated that 73% of these pediatric pts were discharged from the hospital, 12% remained hospitalized but on ambient air, and 4% had died. There were 39 critically ill pediatric pts who required invasive mechanical ventilation at baseline and 80% of these pts recovered; there were 38 pediatric pts who did not require invasive ventilation and 87% of these pts recovered. No new safety signals were identified for remdesivir in this population.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
|          |            |          | Data from the manufacturer’s compassionate use program (pregnant and postpartum women): The manufacturer announced that preliminary data are available for 86 pregnant and postpartum women treated with remdesivir in the compassionate use program. Analysis of data for these pts (median age 33 years) indicated that 96% of the pregnant women and 89% of the postpartum women achieved improvement in oxygen support levels. Those with more severe illness at baseline achieved similarly high rates of clinical recovery (93 or 89% in those who were pregnant or postpartum, respectively). Pregnant women not on invasive oxygen support at baseline had the shortest median time to recovery (5 days), and both pregnant and postpartum women on invasive ventilation at
baseline had similar median times to recovery (13 days). No new safety signals were identified for remdesivir in this population; the most common adverse events were due to underlying disease and most laboratory abnormalities were grades 1–2.  

Phase 2/3 single-arm, open-label trial in pediatric patients (NCT04431453; CARAVAN): The manufacturer (Gilead) initiated a trial to evaluate safety, tolerability, pharmacokinetics, and efficacy of remdesivir in pediatric pts (birth to <18 years of age) with laboratory-confirmed COVID-19.  

Phase 3 adaptive, randomized, double-blind trial compared a regimen of remdesivir alone vs a regimen of remdesivir with baricitinib in hospitalized adults (NCT04401579; ACTT-2): Pts were randomized 1:1 to receive remdesivir (200 mg IV on day 1, then 100 mg IV once daily for a total treatment duration of 10 days or until hospital discharge) with either baricitinib (4 mg once daily orally or through a nasogastric tube for 14 days or until hospital discharge) or 14-day regimen of oral placebo. The primary end point was time to recovery through day 29 (defined as discharged without limitations on activities, discharged with limitations on activities and/or requiring home oxygen, or still hospitalized but not requiring supplemental oxygen and no longer requiring ongoing medical care). Data for the 1033 pts in the intention-to-treat (ITT) population (515 in the remdesivir and baricitinib group and 518 in the remdesivir alone group) indicate that those who received the combined regimen were more likely to have better clinical outcomes than those who received remdesivir alone. Based on results of this trial and other data, FDA issued an emergency use authorization (EUA) for baricitinib to permit use of the drug in combination with remdesivir for treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric pts ≥2 years of age. (See Baricitinib in this Evidence Table.)

Phase 3 adaptive, randomized, double-blind trial to compare a regimen of...
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>remdesivir alone vs a regimen of remdesivir with interferon beta-1a (NCT04492475; ACTT-3): This iteration of NIAID’s Adaptive COVID-19 Treatment Trial (ACTT) is evaluating possible benefits of using interferon beta-1a in conjunction with remdesivir in hospitalized adults with laboratory-confirmed SARS-CoV-2 infection. Inclusion criteria include evidence of lung involvement (radiographic infiltrates, SpO₂ of 94% or lower on room air, or requiring supplemental oxygen or mechanical ventilation); exclusion criteria include need for ECMO, prior treatment with ≥3 doses of remdesivir, treatment with any interferon preparation within the previous 2 weeks, prior treatment with convalescent plasma or IGIV or various other drugs used for management of COVID-19. Pts will be randomized 1:1 to receive remdesivir (200 mg IV on day 1, then 100 mg IV once daily for the duration of hospitalization up to 10 days total) with either sub-Q interferon beta-1a (44 mcg once daily on days 1, 3, 5, and 7 during hospitalization for a total of 4 doses) or placebo.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Phase 3 randomized, double-blind, placebo-controlled trial to compare a regimen of remdesivir alone vs a regimen of remdesivir with tocilizumab (NCT04409262; REMDACTA): This trial was designed to evaluate efficacy and safety of a combination regimen of remdesivir and tocilizumab (an interleukin-6 [IL-6] inhibitor) in hospitalized pts ≥12 years of age with severe COVID-19 pneumonia. Pts were randomized 2:1 to receive a 10-day regimen of IV remdesivir with tocilizumab (single dose of 8 mg/kg [up to 800 mg] by IV infusion on day 1) or placebo. If clinical signs or symptoms worsened or did not improve, an additional dose of blinded treatment with tocilizumab or placebo could be administered 8-24 hours after the first dose. The primary efficacy end point was time from randomization to hospital discharge (or ready for discharge) up to day 28; secondary end points included time to mechanical ventilation or death up to day 28. Data for the modified intention-to-treat population (430 adults in the remdesivir... |
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2-Specific Monoclonal Antibodies</td>
<td>8:18.24 Monoclonal Antibodies</td>
<td>Monoclonal antibodies (mAbs) used in the treatment or prevention of infectious diseases are engineered versions of antibodies naturally produced by the immune system in response to invading viruses or other pathogens. mAbs that are specific for certain infectious agents or their toxins (e.g., respiratory syncytial virus, <em>Bacillus anthracis</em>, <em>Clostridioides difficile</em>) have been used for the treatment or prevention of infections caused by these agents. Animal studies evaluating neutralizing mAbs specific for other coronaviruses</td>
<td>Clinical trials are ongoing to evaluate efficacy and safety of various investigational SARS-CoV-2-specific mAbs for the treatment or prevention of COVID-19, including the following: <strong>Bamlanivimab (LY-CoV555)</strong> and <strong>Etesevimab (LY-CoV016)</strong>:</td>
<td>Because mAbs generally have long half-lives, it is likely that only a single dose of the SARS-CoV-2-specific mAbs may be required. <strong>Bamlanivimab (LY-CoV555)</strong> and <strong>Etesevimab (LY-CoV016)</strong>: Emergency use authorization (EUA) dosage and administration of bamlanivimab and etesevimab for treatment of mild to moderate COVID-19 in adults and pediatric pts ≥12 years of age weighing ≥40 kg with positive results of direct SARS-CoV-2 viral testing who are outpatients and are at high risk for progressing to severe COVID-19 and/or hospitalization: Single dose of 700 mg of bamlanivimab and 1.4 g of etesevimab administered together after dilution as a single IV infusion; administer in an appropriate setting as soon as possible after positive viral test for SARS-CoV-2 and within 10 days of symptom onset.</td>
<td>SARS-CoV-2-specific mAbs are not commercially available. Safety and efficacy of investigational SARS-CoV-2-specific mAbs for the treatment or prevention of COVID-19 have not been established. Although additional data from controlled clinical trials are needed regarding the safety and efficacy of SARS-CoV-2-specific mAbs in the treatment or prevention of COVID-19, data to date suggest that outpatients with COVID-19 may benefit from treatment with a SARS-CoV-2-specific mAb early in the course of the infection and it has been suggested that such mAbs may offer some advantages over other immunotherapies used for the treatment of COVID-19 (e.g., COVID-19 convalescent plasma, hIGIV) in terms of specificity and safety.</td>
</tr>
</tbody>
</table>
Drug(s) | AHFS Class | Rationale | Trials or Clinical Experience | Dosage* | Comments
--- | --- | --- | --- | --- | ---
(SARS-CoV-1, MERS-CoV) |  |  |  |  | 
have demonstrated benefits in such models. 1, 2, 4, 5, 6, 30
SARS-CoV-2-specific mAbs are designed to directly target the virus and may act as neutralizing antibodies (nAbs). Most SARS-CoV-2-specific mAbs being investigated target epitopes on the spike protein (S protein) of the virus and block the receptor-binding domain (RBD) of the S protein from interacting with human angiotensin-converting enzyme 2 (ACE2), thereby preventing the virus from entering cells and inhibiting viral replication. 1, 6, 25, 27, 30
SARS-CoV-2-specific mAbs potentially could limit or modify SARS-CoV-2 infection and may be effective for both treatment and prevention since such mAbs could provide immediate and longer-term (weeks or months) protection against the virus. 1, 3, 30
Various mAbs specific for SARS-CoV-2 are being investigated for the treatment and prevention of COVID-19, including the following:

**Bamlanivimab (LY-CoV555; LY3819253) and Etesevimab (LY-CoV016; LY3832479; JS016):** Recombinant neutralizing IgG mAbs that bind to different, but overlapping, epitopes on the S protein of SARS-CoV-2 and block the virus from binding to the human ACE2 receptor; 12, 13, 43, 65
preclinical studies
Study completed; results not yet published (NCT04441931). 33
Randomized, double-blind, placebo-controlled phase 2/3 study is evaluating efficacy and safety of bamlanivimab and etesevimab together for treatment of COVID-19 in adults and adolescents ≥12 years of age who are outpatients with mild to moderate disease (NCT04427501; BLAZE-1). 30 In the phase 2 portion of BLAZE-1, 112 adults received a single IV infusion of bamlanivimab and etesevimab (2.8 g of each drug; higher than EUA-authorized dosage), 309 adults received bamlanivimab alone (dose of 700 mg, 2.8 g, or 7 g), and 156 adults received placebo. Final data analysis indicated that there was a statistically significant difference in the phase 2 primary efficacy end point (i.e., change in SARS-CoV-2 viral load from baseline to day 11) in the bamlanivimab and etesevimab group compared with placebo; however, the change in viral load in each of the 3 bamlanivimab monotherapy dosage groups was not significantly different compared with placebo. At day 29, the proportion of phase 2 pts with hospitalizations or emergency department visits related to COVID-19 was 0.9% in the bamlanivimab and etesevimab group, 1-2% in the bamlanivimab monotherapy groups, and 5.8% in the placebo group. 1 In the phase 3 portion of BLAZE-1, 511 pts received a single IV infusion of bamlanivimab and etesevimab (700 mg of bamlanivimab and 1.4 g of etesevimab) and 258 pts received placebo. The majority of these pts (99.2%) met the criteria for high-risk adults; some pts were 12-17 years of age and met high-risk criteria as defined in the trial protocol. The phase 3 primary end point was the proportion of pts with COVID-19-related hospitalizations (defined in the EUA, a dose of 300 mg of casirivimab and 300 mg of imdevimab) or death by any cause by day 29. Data indicate an 87% decrease in such events in those treated with bamlanivimab and etesevimab (0.8% of pts) compared with those treated with placebo (6% of pts). There were no deaths in the bamlanivimab and etesevimab group and 4 deaths in the placebo group. 65
Casirivimab and Imdevimab (REGN10933 and REGN10987; REGN-COV®):
Emergency use authorization (EUA) dosage and administration of casirivimab and imdevimab for treatment of mild to moderate COVID-19 in adults and pediatric pts ≥12 years of age weighing ≥40 kg with positive results of direct SARS-CoV-2 viral testing who are outpatients and are at high risk for progressing to severe COVID-19, including hospitalization or death: Single dose of 600 mg of casirivimab and 600 mg of imdevimab given together and administered by IV infusion or, alternatively, by sub-Q injection. On June 3, 2021, FDA lowered the EUA-authorized dosage of casirivimab and imdevimab to 600 mg of each drug; a higher dosage is no longer authorized under the EUA. 49
Emergency use authorization (EUA) dosage and administration of casirivimab and imdevimab for post-exposure prophylaxis of COVID-19 in certain adults and pediatric pts ≥12 years of age weighing ≥40 kg who are at high risk for progressing to severe COVID-19, including hospitalization or death, and are exposed to an individual infected with SARS-CoV-2 under certain circumstances specified in the EUA: Single dose of 600 mg of casirivimab and 600 mg of imdevimab administered together either by sub-Q injection or IV infusion as soon as possible after exposure. In certain individuals at high risk of ongoing exposure (lasting >4 weeks) or with ongoing exposure (≥4 weeks for the duration of ongoing exposure). 49
Doses of casirivimab and imdevimab must be prepared according to
Bamlanivimab (LY-CoV555):
Effective April 16, 2021, FDA revoked the EUA for use of bamlanivimab alone (monotherapy) for the treatment of mild to moderate COVID-19. 81 Because of a sustained increase in SARS-CoV-2 viral variants in the US that are resistant to bamlanivimab alone and because testing technologies are not available to enable healthcare providers to test individual COVID-19 patients for SARS-CoV-2 viral variants prior to initiation of mAb treatment, FDA concluded that, based on the totality of scientific evidence available, the known and potential benefits of bamlanivimab alone no longer outweighed the known and potential risks of monotherapy with the drug. **Note:** Healthcare facilities that have existing supplies of bamlanivimab alone, distributed prior to revocation of the EUA for the use of the drug as monotherapy, should contact the authorized US distributor (AmersiSourceBergen) to determine if they have existing supplies of bamlanivimab that can be used for emergency use under the EUA for bamlanivimab and etesevimab. 81, 82
Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016):
FDA issued an Emergency Use Authorization (EUA) for bamlanivimab and etesevimab on February 9, 2021 that permits use of these drugs administered together for the treatment of mild to moderate COVID-19 in adults and pediatric pts ≥12 years of age weighing ≥40 kg with positive results of direct SARS-CoV-2 viral testing who are outpatients and are at high risk for progressing to severe COVID-19 and/or hospitalization. FDA states that, based on a review of data from an ongoing randomized, double-blind, placebo-controlled phase 2/3 trial in outpatients with mild to moderate COVID-19 (BLAZE-1; NCT04427501), it is reasonable to believe that bamlanivimab and etesevimab administered together may be effective for the treatment of mild to moderate COVID-19.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casirivimab and Imdevimab (REGN10933 and REGN10987; REGN-COV®):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sotrovimab (VIR-7831; GSK4182136): Recombinant neutralizing IgG1 mAbs that bind to non-overlapping epitopes on the S protein RBD of SARS-CoV-2 and block the virus from binding to the human ACE2 receptor; preclinical studies demonstrated neutralizing activity in vitro and protective effects against SARS-CoV-2 infection and viral replication in animal models. 27,28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZD7442: Contains two mAbs (AZD8895 and AZD1061) that specifically target SARS-CoV-2 at two non-overlapping sites; has an enhanced half-life and reduced Fc receptor binding. 20, 50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-GUARD (STI-1499) and COVI-AMG (STI-2020): Randomized, double-blind, placebo-controlled phase 3 trial initiated by the manufacturer (Eli Lilly) in collaboration with NIAID is evaluating efficacy and safety of bamlanivimab used alone or with etesevimab for prevention of SARS-CoV-2 infection in adult residents and staff of skilled nursing or assisted living facilities in the US (NCT04497987; BLAZE-2). 13 Study participants were screened for enrollment within 7 days after a case of COVID-19 was confirmed at the facility and, if eligible, were randomized to receive prophylaxis with bamlanivimab (4.2 g as a single IV infusion) or placebo. A total of 1175 adults with no history of COVID-19 who were negative for SARS-CoV-2 infection at baseline were enrolled from August 2 to November 20, 2020. The primary efficacy outcome was the incidence of COVID-19 (defined as detection of SARS-CoV-2 by RT-PCR and mild or worse disease severity within 21 days of detection) within 8 weeks after randomization. Data for 966 participants (666 staff and 300 residents) in part 1 of this study indicate that the incidence of COVID-19 at 8 weeks of follow-up was significantly reduced in those who received bamlanivimab prophylaxis (8.5%) compared with placebo (15.2%). Note: This study was conducted prior to revocation of the EUA for use of bamlanivimab alone (as monotherapy) for treatment of COVID-19 that was based on surveillance data indicating a sustained increase in SARS-CoV-2 viral variants in the US resistant to bamlanivimab alone. 62 (See Comments column.) Multicenter, adaptive, randomized, placebo-controlled, phase 3 trial evaluating safety and efficacy of various therapeutic regimens for hospitalized pts with COVID-19 sponsored by NIAID (NCT04501978; TICO; ACTIV-3): Trial included a treatment arm to evaluate bamlanivimab with standard of care vs placebo with standard of care in hospitalized adults. 40, 41 NIAID announced that the bamlanivimab treatment arm was terminated following a recommendation from the independent data and safety monitoring board (DSMB) based on low likelihood of clinical benefit in hospitalized pts. 41 Data for the 314 enrolled pts specific instructions provided in the EUA fact sheet for healthcare providers. Preparation instructions vary depending on which formulation of the drugs is used (single-dose vials containing co-formulated solution of casirivimab and imdevimab; vials of casirivimab and etesevimab that must be combined and are supplied in separate cartons or in dose packs) and whether the dose will be given by IV infusion or sub-Q injection. Casirivimab and imdevimab must be diluted prior to IV infusion, but is used undiluted when administered by sub-Q injection. 63 Errors regarding medication errors related to different formulations of casirivimab and imdevimab and variations in packaging of the drugs: The manufacturer alerted healthcare providers that casirivimab and imdevimab is now available in single-dose vials containing a co-formulated solution of both drugs in addition to the previously available individual vials containing casirivimab and imdevimab solutions that must be combined and administered together and are supplied in individual cartons or packaged together in dose packs. Casirivimab and imdevimab may each be supplied as two different vial sizes (1332 mg/11.1 mL or 300 mg/2.5 mL). Instructions for preparing the dose of casirivimab and imdevimab (e.g., number of vials) specified in the EUA fact sheet for healthcare providers must be followed to ensure the correct dose. Although some cartons and vials of the drugs may be labeled “solution for intravenous administration” or “for intravenous infusion after dilution,” the drugs may be administered together by IV infusion or, alternatively, by sub-Q injection as specified in the EUA. Cartons and vials of co-formulated casirivimab and imdevimab solution are labeled REGEN-COV®. Although dose packs may be labeled REGEN-COV®, individual cartons and vials of moderate COVID-19 in adults and pediatric patients ≥12 years of age weighing ≥40 kg with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 and/or hospitalization and, when used under the conditions of the EUA, the known and potential benefits of bamlanivimab and etesevimab administered together for treatment of COVID-19 in such pts outweigh the known and potential risks. 64 Casirivimab and Imdevimab (REGN10933 and REGN10987; REGN-COV®): FDA issued an Emergency Use Authorization (EUA) for casirivimab and imdevimab on November 21, 2020 that permits use of these drugs administered together for the treatment of mild to moderate COVID-19 in adults and pediatric pts ≥12 years of age weighing ≥40 kg with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 and/or hospitalization. The EUA was reissued in its entirety on June 3, 2021 to authorize a change in casirivimab and imdevimab dosage and a new formulation (casirivimab and imdevimab co-formulated in a 1:1 ratio) and to authorize administration by sub-Q injection as an alternative to IV infusion when the IV route is not feasible and would lead to delay in treatment. (See Dosage column.) FDA states that, based on a review of phase 3 data from an ongoing randomized, double-blind, placebo-controlled, phase 1/2/3 trial of casirivimab and imdevimab in outpatients with mild to moderate COVID-19 (NCT04425629; COV-2067), it is reasonable to believe that casirivimab and imdevimab administered together (600 mg of each drug) may be effective for the treatment of mild to moderate COVID-19 in adults and pediatric patients ≥12 years of age weighing ≥40 kg with positive results of direct SARS-CoV-2 viral testing who are at high risk for</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: The current version of this document can be found on the ASHP COVID-19 Resource Center.*
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarilumab, Siltuximab, and Tocilizumab (See Table.)</td>
<td></td>
<td></td>
<td>Included in the prespecified interim futility assessment have been published. Enrolled pts were hospitalized with documented SARS-CoV-2 infection (duration of symptoms ≤12 days, no end-organ failure at baseline) and randomized 1:1 to receive bamlanivimab (163 pts) or placebo (151 pts). Pts also received remdesivir (95% of pts), corticosteroids (49% of pts), and supplemental oxygen when indicated. The futility assessment evaluated pulmonary function on day 5 based on a 7-category ordinal scale and indicated that a single IV infusion of bamlanivimab did not result in better clinical outcomes at day 5 compared with placebo. The odds ratio of being in a more favorable category in the bamlanivimab group compared with the placebo group was 0.85 (95% CI, 0.56 to 1.29; P = 0.45). Among 167 pts who were followed for at least 28 days or died within 28 days, 82 or 79% in the bamlanivimab or placebo group, respectively, had sustained recovery (rate ratio 1.06).The percentage of patients with the primary safety outcome (a composite of death, serious adverse events, or clinical grade 3 or 4 adverse events through day 5) was similar in the bamlanivimab and placebo group (19% and 14%, respectively).&lt;sup&gt;50&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sotrovimab (VIR-7831; GSK4182136):</td>
<td></td>
<td>Emergency use authorization (EUA) dosage and administration of sotrovimab for treatment of mild to moderate COVID-19 in adults and pediatric pts ≥12 years of age weighing ≥40 kg with positive results of direct SARS-CoV-2 viral testing who are outpatients and are at high risk for progressing to severe COVID-19, including hospitalization or death: Single dose of 500 mg of sotrovimab after dilution as a single IV infusion; administer in a more appropriate setting as soon as possible after positive viral test for SARS-CoV-2 and within 10 days of symptom onset. &lt;sup&gt;84&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>FDA expanded the EUA for casirivimab and imdevimab on July 30, 2021 to authorize use for postexposure prophylaxis of COVID-19 in certain adults and pediatric pts ≥12 years of age weighing ≥40 kg. FDA states that it is reasonable to believe that casirivimab and imdevimab may be effective for postexposure prophylaxis in susceptible, exposed individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, and, when used under the conditions described in the EUA, the known and potential benefits of casirivimab and imdevimab outweigh the known and potential risks and there are no adequate, approved, and available alternatives to the emergency use of casirivimab and imdevimab for postexposure prophylaxis of COVID-19. &lt;sup&gt;48&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ly-CoV1404 (LY3853113): Recombinant neutralizing IgG1 mAb that targets the S protein RBD of SARS-CoV-2; binds to an epitope distinct from mutation sites identified in various known SARS-CoV-2 viral variants; in vitro evidence that neutralizing activity is retained against these known viral variants. &lt;sup&gt;50&lt;/sup&gt;</td>
<td></td>
<td>Note that various recombinant humanized monoclonal antibodies that target key immunologic and inflammatory mediators (e.g., complement, granulocyte-macrophage colony-stimulating factor [GM-CSF], interleukin-6 [IL-6]) but do not target the SARS-CoV-2 virus are being investigated for the treatment of COVID-19. &lt;sup&gt;7,8&lt;/sup&gt; (See Sarilumab, Siltuximab, and Tocilizumab in this Evidence Table.)</td>
<td></td>
<td></td>
<td>Sotrovimab (VIR-7831; GSK4182136):</td>
</tr>
</tbody>
</table>
onset ≤ 7 days prior to randomization. Results of this interim analysis indicated that casirivimab and imdevimab reduced viral load and there was a positive trend in reduction of medical visits; benefits were greatest in those who had not mounted their own effective immune response.\(^a\)

The manufacturer subsequently announced results for an additional 524 outpatients enrolled in the phase 1/2 portion of this trial (not peer reviewed) and stated that analysis of data for these pts confirmed that a combined regimen of casirivimab and imdevimab significantly reduces viral load, is associated with reduced COVID-19-related medical visits, and is most beneficial in pts who are at risk for poor outcomes due to higher viral load and/or no detectable antibodies at baseline; data also indicated there were no significant differences in virologic or clinical efficacy between the 2 dosage regimens of casirivimab and imdevimab.\(^b\) Based on phase 1/2 results, the phase 3 protocol of this placebo-controlled trial in outpatients was amended to compare a dosage regimen of 1.2 g of casirivimab and imdevimab (600 mg of each mAb) or 2.4 g of casirivimab and imdevimab (1.2 g of each mAb) with placebo. Pts enrolled in the phase 3 portion met the criteria for high risk for progression to severe COVID-19 and treatment was initiated within 3 days of positive RT-PCR results for SARS-CoV-2. The phase 3 primary end point was the proportion of pts with ≥ 1 COVID-19-related hospitalization or all-cause death through day 29. Data for pts in the modified full analysis set (mFAS) indicated that a single dose of 600 mg of casirivimab and 600 mg of imdevimab resulted in a 70% reduction in COVID-19-related hospitalization or all-cause death compared with placebo; such events occurred in 7 out of 736 (1%) of pts treated with casirivimab and imdevimab and in 24 out of 724 (3.2%) of pts who received placebo. A single dose of 1.2 g of casirivimab and 1.2 g of imdevimab resulted in a similar reduction in COVID-19-related hospitalization or all-cause death compared with placebo (71%); such events occurred in 18 out of 1355 (1.3%) of patients treated with this higher dosage and in 62 out of 1341 (4.6%) of pts who received placebo.\(^c\)

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FDA currently states that the following medical conditions and factors that may place adults and pediatric pts ≥ 12 years of age weighing ≥ 40 kg at higher risk for progression to severe COVID-19 should be considered when determining appropriate use of currently authorized SARS-CoV-2-specific mAbs: 49, 65, 86</td>
</tr>
</tbody>
</table>

1) Older age (e.g., ≥ 65 years of age).
2) Obesity or being overweight (e.g., BMI ≥ 25 kg/m\(^2\) or, if 12-17 years of age, BMI ≥ 85th percentile for their age and gender based on CDC growth charts).
3) Pregnancy.
4) Immunosuppressive disease or immunosuppressive treatment.
5) Chronic kidney disease, diabetes mellitus, sickle cell disease.
6) Cardiovascular disease (including congenital heart disease) or hypertension.
7) Chronic lung disease (e.g., COPD, moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension).
8) Neurodevelopmental disorders (e.g., cerebral palsy) or other conditions that confer medical complexity (e.g., genetic or metabolic syndromes and severe congenital anomalies).
9) Medical-related technological dependence (e.g., tracheostomy, gastrostomy, or positive-pressure ventilation not related to COVID-19).

FDA also states that use of currently authorized SARS-CoV-2-specific mAbs is not limited only to the medical conditions or factors listed above and that other medical conditions and factors (e.g., race or ethnicity) may also place individual pts at high risk for progressing to severe COVID-19. Healthcare providers should consider the benefit-risk for the individual pt when making
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
</table>
|         |            | Randomized, placebo-controlled, phase 1/2/3 trial sponsored by the manufacturer (Regeneron) to evaluate safety, tolerability, and efficacy of a single IV dose of casirivimab and imdevimab for treatment of COVID-19 in hospitalized adults *(NCT04426695)*. 22 Initial study protocol included 4 different cohorts of pts (i.e., on low-flow oxygen, not requiring oxygen, on high-flow oxygen without mechanical ventilation, on mechanical ventilation) to be randomized to receive casirivimab and imdevimab (administered together) or placebo. 22 The manufacturer announced that further enrollment of hospitalized pts requiring high-flow oxygen or mechanical ventilation was terminated following a recommendation from the independent data monitoring committee (IDMC) based on a potential safety signal and unfavorable risk/benefit profile in such pts. Enrollment of hospitalized pts not requiring oxygen or on low-flow oxygen is continuing as recommended by the IDMC. 22 The manufacturer announced preliminary data analyses (not peer reviewed) for pts hospitalized with laboratory-confirmed COVID-19 who were on low-flow oxygen (defined as maintaining O2 saturation of >93% via nasal cannula, simple facemask, or similar device) and were randomized to receive 2.4 g of casirivimab and imdevimab (1.2 g of each mAb; low dose), 8 g of casirivimab and imdevimab (4 g of each mAb; high dose), or placebo in addition to standard of care (67% received remdesivir and 74% received systemic corticosteroids). Results of the preliminary analysis (i.e., futility analysis) indicated that the mAb regimen had sufficient efficacy to warrant continuing the trial. Data for the 217 pts serum-negative for endogenous antibodies against SARS-CoV-2 at baseline indicated that casirivimab and imdevimab treatment reduced the time-weighted average daily viral load through day 7 by 0.54 log10 copies/mL and through day 11 by 0.63 log10 copies/mL (nominal p = 0.002 for combined doses). Data for the 270 pts seropositive at baseline indicated that clinical and virologic benefit of the mAb treatment was limited in these pts (time-weighted average viral load through day 7 reduced by 0.2 log10) treatment decisions regarding use of FDA-authorized SARS-CoV-2-specific mAbs. Additional information on medical conditions and factors associated with increased risk for progression to severe COVID-19 is available at https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html.

The EUAs for FDA-authorized SARS-CoV-2-specific mAbs state that these drugs are not authorized for use in pts who are hospitalized due to COVID-19, require oxygen therapy due to COVID-19, or are on chronic oxygen therapy due to an underlying non-COVID-19-related comorbidity and require an increase in baseline oxygen flow rate due to COVID-19. SARS-CoV-2-specific mAbs may be associated with worse clinical outcomes when administered to hospitalized COVID-19 pts requiring high flow oxygen or mechanical ventilation. 48, 64, 65, 81, 84 If a patient is hospitalized for reasons other than COVID-19 (e.g., an elective orthopedic procedure) and reports mild to moderate symptoms of COVID-19, confirmed with positive results of a direct SARS-CoV-2 viral test, FDA states that treatment with a SARS-CoV-2-specific mAb available under an EUA may be appropriate if the patient is at high risk for progressing to severe COVID-19, including COVID-19-related hospitalization or death, and terms and conditions of the EUA are met. 56, 67, 86 The EUAs for FDA-authorized SARS-CoV-2-specific mAbs require that the dosage of these drugs recommended in their respective EUAs be administered by a healthcare provider in an appropriate setting where there is immediate access to medications to treat a severe infusion reaction such as anaphylaxis and ability to activate the emergency medical system (EMS) as necessary. The EUAs also require that healthcare facilities and healthcare providers administering FDA-authorized SARS-CoV-2-
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>casirivimab and imdevimab</td>
<td></td>
<td></td>
<td>Efficacy of the low- and high-dose regimens of casirivimab and imdevimab was similar.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Large, randomized, controlled, open-label, platform trial evaluating efficacy of various treatments in hospitalized pts with COVID-19 (NCT04381936; RECOVERY). This study is enrolling pts with suspected or confirmed COVID-19 from 176 hospitals in the UK. The protocol-specified primary outcome is all-cause mortality at day 28; secondary outcomes include duration of hospitalization and, in those not receiving invasive mechanical ventilation at time of randomization, the composite of initiation of invasive mechanical ventilation (including ECMO) or death.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In the casirivimab and imdevimab arm of the trial, a total of 4839 adults and adolescents ≥12 years of age were randomized to receive a single IV dose of casirivimab and imdevimab (4 g of each drug) with usual care and 4936 were randomized to receive usual care alone. Usual care included remdesivir in about 25% of pts and tocilizumab in about 14% of pts. At the time of randomization, 94% of pts were receiving corticosteroids, 54% were seropositive for SARS-CoV-2 antibodies, 32% were seronegative, and 14% had unknown serostatus. Preliminary data analyses of trial results (not peer reviewed) indicated that casirivimab and imdevimab can reduce mortality in pts hospitalized with COVID-19 who have not mounted a natural antibody response. Among those known to be seronegative at baseline, a single IV dose of casirivimab and imdevimab (4 g of each drug) with usual care was associated with a significant reduction in the primary outcome of all-cause mortality at 28 days compared with usual care alone; 24% of such pts (396 of 1633) in the casirivimab and imdevimab group compared with 30% of such pts (451 of 1520) in the usual care alone group. In addition, subgroup analyses of pts seronegative and not on mechanical ventilation at baseline indicated that the rate of progression to the composite secondary outcome of invasive mechanical ventilation or death was lower in the casirivimab and imdevimab group (30%) compared with the usual care alone group (37%).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Specific mAbs comply with certain mandatory record keeping and reporting requirements (including adverse event reporting to FDA MedWatch).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The EUAs for FDA-authorized SARS-CoV-2-specific mAbs require that manufacturers establish a process for monitoring genomic databases for emergence of global viral variants of SARS-CoV-2 and, if requested by FDA, assess activity of the drugs against any global SARS-CoV-2 variants of interest.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reduced in vitro susceptibility or resistance to SARS-CoV-2-specific mAbs reported in SARS-CoV-2 variants circulating in the US: The EUA fact sheets for healthcare providers for each currently authorized SARS-CoV-2-specific mAb includes information on specific variants and resistance.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>On June 25, 2021, distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with existing supplies of bamlanivimab) in the US was paused until further notice. This decision was based on CDC surveillance data indicating that the combined frequency of the SARS-CoV-2 B.1.351 variant (labeled Beta by WHO; first identified in South Africa) and the P.1 variant (labeled Gamma by WHO; first identified in Brazil) throughout the US exceeds 11% and is trending upward and in vitro data suggesting that bamlanivimab and etesevimab together are unlikely to be active against these variants. For additional information, see the Office of the Assistant Secretary for Preparedness and Response (ASPR) website at <a href="https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-Etesevimab">https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-Etesevimab</a>.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage*</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>------------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Casirivimb and Imdevimab: For additional information about the EUA, consult the bamlanivimab and etesevimab EUA letter of authorization, 64 EUA fact sheet for healthcare providers, 65 and EUA fact sheet for patients, parents and caregivers. 66</td>
<td>SARS-CoV-2-specific mAbs</td>
<td>For use under their respective EUAs is being directed by ASPR in collaboration with state and territorial health departments and the manufacturers. Healthcare providers should contact the authorized US distributor (AmersourceBergen) to obtain bamlanivimab and etesevimab or casirivimab and imdevimab; 46, 51, 70 contact the manufacturer of sotrovimab (GlaxoSmithKline) at 866-475-2684 for information on how to obtain the drug. 86 Information on specific locations in the US administering SARS-CoV-2-specific mAbs may be available at the HHS protect public data hub (<a href="https://protect-public.hhs.gov/pages/therapeutics-distribution">https://protect-public.hhs.gov/pages/therapeutics-distribution</a>) or National Infusion Center Association (NICA) website (<a href="https://covid.infusioncenter.org">https://covid.infusioncenter.org</a>). 68, 67, 68 Bamlanivimab and Etesevimab: For additional information about the EUA, consult the bamlanivimab and etesevimab EUA letter of authorization, 64 EUA fact sheet for healthcare providers, 65 and EUA fact sheet for patients, parents and caregivers. 66 Casirivimab and Imdevimab: For additional information about the EUA, consult the casirivimab and imdevimab EUA letter of authorization, 48 EUA fact sheet for healthcare providers, 49 and EUA fact sheet for patients, parents and caregivers. 50 Sotrovimab: For additional information about the EUA, consult the sotrovimab EUA letter of authorization, 67 EUA fact sheet for healthcare providers, 68 and EUA fact sheet for patients, parents and caregivers. 85 NIH COVID-19 Treatment Guidelines Panel states that, based on data available to date, use of SARS-CoV-2-specific mAb is recommended for treatment of outpatients with mild to moderate COVID-19 who are at high risk of clinical progression as defined by the EUA criteria. Because such therapy has greatest potential for clinical benefit if</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation of FDA-authorized SARS-CoV-2-specific mAbs for use under their respective EUAs is being directed by ASPR in collaboration with state and territorial health departments and the manufacturers. Healthcare providers should contact the authorized US distributor (AmersourceBergen) to obtain bamlanivimab and etesevimab or casirivimab and imdevimab; 46, 51, 70 contact the manufacturer of sotrovimab (GlaxoSmithKline) at 866-475-2684 for information on how to obtain the drug. 86 Information on specific locations in the US administering SARS-CoV-2-specific mAbs may be available at the HHS protect public data hub (<a href="https://protect-public.hhs.gov/pages/therapeutics-distribution">https://protect-public.hhs.gov/pages/therapeutics-distribution</a>) or National Infusion Center Association (NICA) website (<a href="https://covid.infusioncenter.org">https://covid.infusioncenter.org</a>). 68, 67, 68 Bamlanivimab and Etesevimab: For additional information about the EUA, consult the bamlanivimab and etesevimab EUA letter of authorization, 64 EUA fact sheet for healthcare providers, 65 and EUA fact sheet for patients, parents and caregivers. 66 Casirivimab and Imdevimab: For additional information about the EUA, consult the casirivimab and imdevimab EUA letter of authorization, 48 EUA fact sheet for healthcare providers, 49 and EUA fact sheet for patients, parents and caregivers. 50 Sotrovimab: For additional information about the EUA, consult the sotrovimab EUA letter of authorization, 67 EUA fact sheet for healthcare providers, 68 and EUA fact sheet for patients, parents and caregivers. 85 NIH COVID-19 Treatment Guidelines Panel states that, based on data available to date, use of SARS-CoV-2-specific mAb is recommended for treatment of outpatients with mild to moderate COVID-19 who are at high risk of clinical progression as defined by the EUA criteria. Because such therapy has greatest potential for clinical benefit if</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Among all randomized pts (i.e., seronegative, seropositive, or unknown antibody status at baseline), there was no significant difference in the primary outcome; 20% (944 of 4839) in the casirivimab and imdevimab group and 21% (1026 of 4946) in the usual care alone group. Data for the overall study population also indicated no difference in rate of progression to the composite secondary outcome of invasive mechanical ventilation or death in the casirivimab and imdevimab group (24%) compared with the usual care alone group (25%). 56 Randomized, double-blind, placebo-controlled, phase 3 trial sponsored by the manufacturer (Regeneron) is evaluating safety, tolerability, and efficacy of a single sub-Q dose of casirivimab and imdevimab for prevention of SARS-CoV-2 infection in healthy, asymptomatic, household contacts of individuals infected with SARS-CoV-2 (NCT04452318). Initial study protocol only included adults; protocol was modified to include adults and adolescents ≥12 years of age weighing ≥40 kg. 56 Data are available for 1505 participants who had no evidence of SARS-CoV-2 infection (RT-qPCR-negative) and no evidence of prior infection (seronegative) at baseline and were randomized 1:1 to receive prophylaxis with a single sub-Q dose of casirivimab and imdevimab (600 mg of each drug; dose divided among 4 different sub-Q injection sites) or placebo within 96 hours after laboratory diagnosis of SARS-CoV-2 infection in the household index case. Primary efficacy endpoint was the proportion of participants who developed symptomatic SARS-CoV-2 infection within 28 days. Data analysis (not peer reviewed) indicated that prophylaxis with a single sub-Q dose of casirivimab and imdevimab reduced the risk of symptomatic SARS-CoV-2 infection in household contacts by 81.4%. Within 28 days after randomization, 1.5% of household contacts in the casirivimab and imdevimab group and 7.8% in the placebo group developed symptomatic SARS-CoV-2 infection. Among those who become infected, median time to resolution of symptoms was 2 weeks shorter in the casirivimab and imdevimab group compared with the placebo group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage</td>
<td>Comments</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-----------</td>
<td>------------------------------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1.2 and 3.2 weeks, respectively) and duration of time with high viral load (&gt;104 copies/mL) also was shorter (0.4 and 1.3 weeks, respectively). Sotrovimab (VIR-7831; GSK4182136):</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Randomized, double-blind, placebo-controlled, phase 2/3 trial is ongoing to assess safety, tolerability, and efficacy of a single IV dose of sotrovimab for treatment of mild or moderate COVID-19 in adults who are outpatients at high risk of disease progression (NCT04545060; COMET-ICE). Pts were randomized 1:1 to receive a single IV infusion of 500 mg of sotrovimab or placebo. The primary end point is the proportion of patients with progression of COVID-19 (defined as hospitalization for ≥24 hours for acute management of any illness or death from any cause) through day 29. Interim analysis for 583 adults in the ITT population (291 received sotrovimab and 292 received placebo) indicated an 85% reduction in the primary end point in those treated with sotrovimab. A total of 3 pts (1%) in the sotrovimab group and 21 pts (7%) in the placebo group had progression of COVID-19 as defined in the protocol; there were no deaths in the sotrovimab group and one death in the placebo group.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Randomized, double-blind, placebo-controlled phase 2 study evaluating various mAb regimens for treatment in adult outpatients with mild to moderate COVID-19 (NCT04634409; BLAZE-4): One treatment arm is evaluating a regimen of sotrovimab with bamlanivimab (SARS-CoV-2-specific mAbs that bind to different regions of the S protein of SARS-CoV-2). The primary outcome measure is the percentage of pts with SARS-CoV-2 viral load &gt;5.27 on day 7. The manufacturers (Lilly, VIR Biotechnology, and GlaxoSmithKline) announced that preliminary data (not peer reviewed) indicate that a single-dose regimen of IV sotrovimab (500 mg) co-administered with IV bamlanivimab (700 mg) met the primary end point. The combined regimen resulted in a 70% relative reduction in persistently high viral load (&gt;5.27; CT &lt;27.5) at day 7 compared with placebo. In addition, the combined regimen resulted in a statistically significant 77% reduction in the primary end point. The combined regimen resulted in a statistically significant 85% reduction in the primary end point in those treated with sotrovimab.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Given during the earliest stages of the disease, these experts state that SARS-CoV-2-specific mAb treatment should be given as soon as possible after COVID-19 diagnosis is confirmed by positive SARS-CoV-2 antigen or nucleic acid amplification test (NAAT) and within 10 days after symptom onset. The panel recommends against use of SARS-CoV-2-specific mAbs in pts hospitalized because of COVID-19, except in a clinical trial; however, such treatment should be considered in those with mild to moderate COVID-19 who are hospitalized for reasons other than COVID-19 but who otherwise meet the EUA criteria.

IDSA suggests use of SARS-CoV-2-specific mAb rather than no SARS-CoV-2-specific mAb treatment in outpatients with mild to moderate COVID-19 at high risk for progression to severe disease since expected benefits likely outweigh any potential harms. These experts recommend selecting the most appropriate SARS-CoV-2-specific mAb regimen based on in vitro susceptibility data available for locally circulating SARS-CoV-2 variants.

Pregnant women: NIH panel states that FDA-authorized SARS-CoV-2-specific mAbs should not be withheld from a pregnant woman who has a condition that poses a high risk of progression to severe COVID-19 if the clinician thinks that the potential benefits outweigh potential risks.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage(a)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>significant reduction in the key virologic secondary end point (i.e., mean change in viral load from baseline to days 3, 5, and 7) compared with placebo. By day 29, there were no COVID-19-related hospitalizations or fatalities in either the bamlanivimab and VIR-7831 group or the placebo group. (75)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>AZD7442:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Double-blind, placebo-controlled, phase 1 trial initiated by the manufacturer (AstraZeneca) to evaluate safety, tolerability, and pharmacokinetics of IV and IM doses of AZD-7442 in healthy adults (NCT04507256). (19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Randomized, double-blind, placebo-controlled, phase 3 trial initiated by the manufacturer (AstraZeneca) to evaluate safety and efficacy of a single IM dose of AZD7442 for treatment of mild to moderate COVID-19 in outpatient adults (NCT04723394; TACKLE). (71)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adaptive platform, randomized, placebo-controlled, phase 2/3 trial evaluating various drugs for the treatment of COVID-19 in outpatients includes a treatment arm to evaluate AZD7442 in such pts (NCT04518410; ACTIV-2). (47)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Randomized, double-blind, placebo-controlled, phase 3 trials initiated by the manufacturer (AstraZeneca) to evaluate safety and efficacy of a single IM dose of AZD7442 for preexposure prophylaxis (NCT04625725; PROVENT) or postexposure prophylaxis (NCT04625972; STORM CHASER) of SARS-CoV-2 infection in adults. (54, 55)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>COVI-AMG (STI-2020):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Manufacturer (Sorrento Therapeutics) initiated a randomized, double-blind, placebo-controlled, phase 1/phase 2 study to evaluate safety and efficacy of single 40-, 100-, and 200-mg IV doses of COVI-AMG for treatment of COVID-19 in adult outpatients (NCT04738175). (79)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
|              |            |           | Manufacturer (Sorrento Therapeutics) initiated a randomized, double-blind, placebo-
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Umifenovir (Arbidol®)</td>
<td>8:18.92 Antiviral</td>
<td>Broad-spectrum antiviral with in vitro activity against various viruses, including coronaviruses 4 Although data limited, in vitro activity against SARS-CoV-1 5 and SARS-CoV-2 5 reported Licensed in China, Russia, Ukraine, and possibly other countries for prophylaxis and treatment of influenza 4</td>
<td>Limited data do not suggest benefit in pts with COVID-19. Meta-analysis of 10 retrospective and 2 prospective, randomized controlled studies conducted in China (total of 1052 adults with laboratory-confirmed COVID-19; high heterogeneity) suggested that treatment with umifenovir was not associated with benefit in pts with COVID-19, as assessed by time to negative RT-PCR conversion, rate of negative RT-PCR on day 7, rate of fever or cough alleviation on day 7, hospital length of stay, or a composite endpoint of admission to intensive care unit, need for mechanical ventilation, or death, in studies that measured these endpoints. An increased rate of negative RT-PCR on day 14 was noted. 13 Retrospective cohort study in 50 adults with COVID-19 in China suggests better viral suppression with umifenovir vs LPV/RTV. All pts received conventional therapy, including interferon α-2b. At 7 days after hospital admission, SARS-CoV-2 was undetectable in 50% of pts treated with umifenovir vs 23.5% treated with LPV-RTV; at 14 days, viral load undetectable in all pts treated with umifenovir vs 44.1% treated with LPV/RTV. Duration of positive SARS-CoV-2 RNA positive test was shorter with umifenovir vs LPV-RTV 8 Retrospective cohort study in 33 adults with COVID-19 in China suggests more favorable outcome with LPV/RTV plus</td>
<td>Dosage recommended for treatment of COVID-19 in China: Adults, 200 mg orally 3 times daily for up to 10 days 5,7 Dosage used in COVID-19 clinical trials: 200 mg orally 3 times daily for duration of 7-10 days or longer 2,3,6,8 Dosage recommended for treatment of COVID-19 in Russia: 200 mg orally every 6 hours for 5 days 11</td>
<td>Not commercially available in the US Has been included in COVID-19 treatment guidelines used in some other countries (e.g., China, Russia) 7,11,12 Efficacy for the treatment of COVID-19 not established</td>
</tr>
</tbody>
</table>
umifenovir vs LPV/RTV alone: Primary end point was negative conversion in nasopharyngeal samples and progression or improvement of pneumonia. At 7 days, SARS-CoV-2 undetectable in nasopharyngeal specimens in 12/16 pts (75%) treated with LPV/RTV plus umifenovir vs 6/17 pts (35%) treated with LPV/RTV alone; at 14 days, undetectable in 15/16 pts (94%) treated with both drugs vs 8/17 pts (53%) treated with LPV/RTV alone. At 7 days, chest CT scans were improving in 11/16 pts (69%) treated with both drugs vs 5/17 pts (29%) treated with LPV/RTV alone.  

**Retrospective cohort study** in 81 hospitalized, non-ICU adults with COVID-19 in China found no difference in clearance of SARS-CoV-2 virus between pts receiving umifenovir vs those who did not. At 7 days, SARS-CoV-2 undetectable in pharyngeal specimens in 33/45 pts (73.3%) treated with umifenovir vs 28/36 pts (77.8%) who did not receive umifenovir. No difference in median time from onset of symptoms to negative SARS-CoV-2 test (18 vs 16 days).  

**Open-label, prospective, randomized, multicenter study** in 236 adults with COVID-19 in China (ChiCTR200030254): When favipiravir was compared with umifenovir, clinical recovery rate was greater in those treated with favipiravir than in those treated with umifenovir. (See Favipiravir in this Evidence Table.)  

**Randomized, single-center, partially blind-ed trial in China** (NCT04258885) evaluated efficacy of umifenovir in conjunction with standard care vs LPV/RTV in conjunction with standard care vs standard care without an antiviral in hospitalized adults with mild/moderate COVID-19. Data for the 86 enrolled pts suggest no difference in mean time for positive-to-negative conversion of SARS-CoV-2 nucleic acid in respiratory specimens and no difference in clinical outcomes between pts treated with umifenovir or LPV/RTV compared with no antiviral therapy.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anakinra (Kineret®)</td>
<td>92:36 Disease-modifying Anti-rheumatic Drug</td>
<td>Recombinant human interleukin-1 (IL-1) receptor antagonist 1</td>
<td>There are case study data but no known published prospective clinical trial evidence supporting efficacy or safety of anakinra for treatment of COVID-19 2, 3, 4, 5</td>
<td>Various dosage regimens are being studied 1, 8</td>
<td>Some studies under way in Europe are evaluating 100 mg given subcutaneously once to 4 times daily for 7 to 28 days or until hospital discharge 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL-1 levels are elevated in patients with COVID-19; anakinra may potentially combat cytokine release syndrome (CRS) symptoms in severely ill COVID-19 patients 2, 3, 4, 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anakinra has been used off-label for severe chimeric antigen receptor T cell (CAR T-cell)-mediated cytokine release syndrome (CRS) and macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis. IL-1 levels are elevated in patients with these conditions. Case reports and series describe a favorable response to anakinra in these syndromes, including survival benefit in sepsis and reversing cytokine storm in adults with MAS after tocilizumab failure. 7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France: A cohort study (Ana-COVID) included a prospective cohort of 52 adults with severe COVID-19 treated with anakinra plus standard of care and a historical comparison group of 44 patients who received standard and supportive care at Groupe Hospitalier Paris Saint-Joseph. Inclusion criteria included severe COVID-19-associated bilateral pneumonia on chest x-ray or lung CT scan, laboratory-confirmed SARS-CoV-2 or typical lung infiltrates on a lung CT scan, and an oxygen saturation of ≤93% under oxygen ≥6 L/min or deterioration (saturation ≤93% under oxygen 3 L/min with loss of 3% oxygen saturation in ambient air over previous 24 hours). Anakinra was given subcutaneously in a dosage of 100 mg twice daily on days 1–3, then 100 mg once daily from day 4–10 8, 9</td>
<td>A retrospective cohort study in Italy compared high-dose anakinra by IV infusion (5 mg/kg twice daily) and low-dose anakinra (100 mg twice daily) given subcutaneously 10</td>
<td>(Note: Anakinra is approved only for subcutaneous administration in the U.S.) 1, 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France: A small case series (9 patients) of open-label anakinra treatment in hospitalized (non-ICU) adults with moderate to severe COVID-19 pneumonia has been published with encouraging results 8</td>
<td>A French case series and a French cohort study, anakinra was given subcutaneously in a dosage of 100 mg twice daily (i.e., every 12 hours) on days 1–3, then 100 mg once daily from day 4–10 8, 9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy: Retrospective cohort study (part of NCT04318366) with high- or low-dose anakinra in adults with COVID-19, moderate to severe acute respiratory distress syndrome (ARDS), and hyperinflammation (defined as elevated serum C-reactive protein [CRP] and/or ferritin levels) managed with non-invasive ventilation outside of the ICU at a Milan hospital. Patients received standard therapy (hydroxychloroquine and lopinavir/ritonavir) and either high-dose anakinra (5 mg/kg twice daily by IV infusion for a</td>
<td>Various dosage regimens are being studied 1, 8</td>
<td>Some studies under way in Europe are evaluating 100 mg given subcutaneously once to 4 times daily for 7 to 28 days or until hospital discharge 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8, 9 dose anakinra by IV infusion (5 mg/kg twice daily) and low-dose anakinra (100 mg twice daily) given subcutaneously 10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL-1 levels are elevated in patients with COVID-19; anakinra may potentially combat cytokine release syndrome (CRS) symptoms in severely ill COVID-19 patients 2, 3, 4, 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anakinra has been used off-label for severe chimeric antigen receptor T cell (CAR T-cell)-mediated cytokine release syndrome (CRS) and macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis. IL-1 levels are elevated in patients with these conditions. Case reports and series describe a favorable response to anakinra in these syndromes, including survival benefit in sepsis and reversing cytokine storm in adults with MAS after tocilizumab failure. 7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France: A cohort study (Ana-COVID) included a prospective cohort of 52 adults with severe COVID-19 treated with anakinra plus standard of care and a historical comparison group of 44 patients who received standard and supportive care at Groupe Hospitalier Paris Saint-Joseph. Inclusion criteria included severe COVID-19-associated bilateral pneumonia on chest x-ray or lung CT scan, laboratory-confirmed SARS-CoV-2 or typical lung infiltrates on a lung CT scan, and an oxygen saturation of ≤93% under oxygen ≥6 L/min or deterioration (saturation ≤93% under oxygen 3 L/min with loss of 3% oxygen saturation in ambient air over previous 24 hours). Anakinra was given subcutaneously in a dosage of 100 mg twice daily on days 1–3, then 100 mg once daily from day 4–10 8, 9</td>
<td>A French case series and a French cohort study, anakinra was given subcutaneously in a dosage of 100 mg twice daily (i.e., every 12 hours) on days 1–3, then 100 mg once daily from day 4–10 8, 9</td>
<td>(Note: Anakinra is approved only for subcutaneous administration in the U.S.) 1, 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France: A small case series (9 patients) of open-label anakinra treatment in hospitalized (non-ICU) adults with moderate to severe COVID-19 pneumonia has been published with encouraging results 8</td>
<td>A French case series and a French cohort study, anakinra was given subcutaneously in a dosage of 100 mg twice daily (i.e., every 12 hours) on days 1–3, then 100 mg once daily from day 4–10 8, 9</td>
<td>(Note: Anakinra is approved only for subcutaneous administration in the U.S.) 1, 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy: Retrospective cohort study (part of NCT04318366) with high- or low-dose anakinra in adults with COVID-19, moderate to severe acute respiratory distress syndrome (ARDS), and hyperinflammation (defined as elevated serum C-reactive protein [CRP] and/or ferritin levels) managed with non-invasive ventilation outside of the ICU at a Milan hospital. Patients received standard therapy (hydroxychloroquine and lopinavir/ritonavir) and either high-dose anakinra (5 mg/kg twice daily by IV infusion for a</td>
<td>Various dosage regimens are being studied 1, 8</td>
<td>Some studies under way in Europe are evaluating 100 mg given subcutaneously once to 4 times daily for 7 to 28 days or until hospital discharge 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8, 9 dose anakinra by IV infusion (5 mg/kg twice daily) and low-dose anakinra (100 mg twice daily) given subcutaneously 10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL-1 levels are elevated in patients with COVID-19; anakinra may potentially combat cytokine release syndrome (CRS) symptoms in severely ill COVID-19 patients 2, 3, 4, 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anakinra has been used off-label for severe chimeric antigen receptor T cell (CAR T-cell)-mediated cytokine release syndrome (CRS) and macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis. IL-1 levels are elevated in patients with these conditions. Case reports and series describe a favorable response to anakinra in these syndromes, including survival benefit in sepsis and reversing cytokine storm in adults with MAS after tocilizumab failure. 7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France: A cohort study (Ana-COVID) included a prospective cohort of 52 adults with severe COVID-19 treated with anakinra plus standard of care and a historical comparison group of 44 patients who received standard and supportive care at Groupe Hospitalier Paris Saint-Joseph. Inclusion criteria included severe COVID-19-associated bilateral pneumonia on chest x-ray or lung CT scan, laboratory-confirmed SARS-CoV-2 or typical lung infiltrates on a lung CT scan, and an oxygen saturation of ≤93% under oxygen ≥6 L/min or deterioration (saturation ≤93% under oxygen 3 L/min with loss of 3% oxygen saturation in ambient air over previous 24 hours). Anakinra was given subcutaneously in a dosage of 100 mg twice daily on days 1–3, then 100 mg once daily from day 4–10 8, 9</td>
<td>A French case series and a French cohort study, anakinra was given subcutaneously in a dosage of 100 mg twice daily (i.e., every 12 hours) on days 1–3, then 100 mg once daily from day 4–10 8, 9</td>
<td>(Note: Anakinra is approved only for subcutaneous administration in the U.S.) 1, 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France: A small case series (9 patients) of open-label anakinra treatment in hospitalized (non-ICU) adults with moderate to severe COVID-19 pneumonia has been published with encouraging results 8</td>
<td>A French case series and a French cohort study, anakinra was given subcutaneously in a dosage of 100 mg twice daily (i.e., every 12 hours) on days 1–3, then 100 mg once daily from day 4–10 8, 9</td>
<td>(Note: Anakinra is approved only for subcutaneous administration in the U.S.) 1, 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy: Retrospective cohort study (part of NCT04318366) with high- or low-dose anakinra in adults with COVID-19, moderate to severe acute respiratory distress syndrome (ARDS), and hyperinflammation (defined as elevated serum C-reactive protein [CRP] and/or ferritin levels) managed with non-invasive ventilation outside of the ICU at a Milan hospital. Patients received standard therapy (hydroxychloroquine and lopinavir/ritonavir) and either high-dose anakinra (5 mg/kg twice daily by IV infusion for a</td>
<td>Various dosage regimens are being studied 1, 8</td>
<td>Some studies under way in Europe are evaluating 100 mg given subcutaneously once to 4 times daily for 7 to 28 days or until hospital discharge 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8, 9 dose anakinra by IV infusion (5 mg/kg twice daily) and low-dose anakinra (100 mg twice daily) given subcutaneously 10</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
median of 9 days followed by daily low-dose subcutaneous administration [100 mg twice daily] for 3 additional days to prevent relapse) or low-dose anakinra (100 mg twice daily subcutaneously) and were compared with a historical cohort of patients who did not receive anakinra. At 21 days, high-dose anakinra was associated with reduced CRP levels and progressive improvement in respiratory function in 21 of 29 (72%) of patients; 5 patients (17%) were placed on mechanical ventilation and 3 patients (10%) died. High-dose IV anakinra appeared to be relatively well tolerated. Anakinra was discontinued in the low-dose subcutaneous anakinra group after 7 days because of a lack of improvement in CRP levels and clinical status. In the standard treatment alone group (retrospective cohort), 8 out of 16 patients (50%) showed respiratory improvement at 21 days; 1 patient (6%) was placed on mechanical ventilation and 7 patients (44%) died.

Various clinical trials evaluating anakinra alone or in conjunction with other drugs for treatment of COVID-19 are registered at clinicaltrials.gov.

### Ascorbic acid

**Updated 3/11/21**

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascorbic acid</td>
<td>88:12 Vitamin C</td>
<td>Antioxidant and cofactor for numerous physiologic reactions; may support host defenses against infection and protect host cells against infection-induced oxidative stress.Presence of infection may decrease vitamin C concentrations.</td>
<td>IV ascorbic acid: Open-label, randomized, nonblinded, controlled trial in 60 hospitalized adults with laboratory-confirmed or suspected severe COVID-19 (with manifestations of ARDS or myocarditis and SpO₂ &lt;93%): Treatment with ascorbic acid (1.5 g IV every 6 hours for 5 days) plus standard care (daily regimen of lopinavir/ritonavir plus single hydroxychloroquine dose upon hospitalization) failed to improve outcomes compared with standard care alone. Body temperature and SpO₂ at discharge, length of ICU stay, and mortality rate were not significantly different between the treatment groups. Median hospital stay was longer in the ascorbic acid group compared with the control group (8.5 vs 6.5 days). Patients receiving ascorbic acid had lower mean IV ascorbic acid: Various dosages of IV ascorbic acid used in COVID-19 studies. In one study, ascorbic acid 1.5 g IV every 6 hours for 5 days failed to improve outcomes. Various dosages of IV ascorbic acid used in sepsis studies; 50 mg/kg every 6 hours for 4 days used in CITRIS-ALI study; 50 mg/kg (maximum 3 g) every 12 hours for 48 hours used in ATESS study; 1.5 g every 6 hours used in VITAMINS, HYVCTSSS, ACTS, and ORANGES studies, but treatment duration varied by study. Efficacy for the treatment of COVID-19 not established. NIH COVID-19 Treatment Guidelines Panel states that there are insufficient data to recommend either for or against use of ascorbic acid for the treatment of COVID-19 in critically ill patients. The panel states that there are no completed controlled trials of ascorbic acid in patients with COVID-19, and the available observational data are sparse and inconclusive. Studies of ascorbic acid in patients with sepsis or ARDS have shown variable efficacy and few safety concerns. NIH COVID-19 Treatment Guidelines Panel also states that there are insufficient data to recommend either for...</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage*</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Oral ascorbic acid:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04342728 (COVID A to Z): Oral ascorbic acid dosage of 8 g daily, given in 2 or 3 divided doses, did not reduce duration of symptoms in outpatients.</td>
<td>Oral ascorbic acid:</td>
<td></td>
<td></td>
<td>or against use of ascorbic acid for the treatment of COVID-19 in noncritically ill patients. The panel states that the role of ascorbic acid in this setting is unknown since patients who are not critically ill with COVID-19 are less likely to experience oxidative stress or severe inflammation.</td>
<td></td>
</tr>
<tr>
<td>NCT04395768 (outpatients): Ascorbic acid 1 g orally 3 times daily for 7 days following initial 200-mg/kg IV dose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Laboratory test interference:</strong> May interfere with laboratory tests based on oxidation-reduction reactions (e.g., blood and urine glucose testing, nitrite and bilirubin concentrations, leukocyte counts). High circulating vitamin C concentrations may affect accuracy of point-of-care glucometers. Manufacturer states to delay oxidation-reduction reaction-based tests until 24 hours after infusion, if possible.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium content: May be substantial with high-dose IV therapy (e.g., each mL of ascorbic acid 500-mg/mL injection provides 65 mg of sodium).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxalate nephrolithiasis: Potential for prolonged, high-dose IV therapy to increase risk of oxalate nephrolithiasis or nephropathy.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

body temperature on admission and on day 3 and higher mean SpO2 on day 3. 18

Phase 3 randomized, blinded, placebo-controlled trial (NCT03680274; LOVIT) evaluating effect of high-dose IV ascorbic acid on mortality and persistent organ dysfunction in septic ICU patients (including COVID-19 patients); other clinical trials of high-dose IV ascorbic acid for treatment of COVID-19 (including NCT04401150 [LOVIT-COVID]) are registered at clinicaltrials.gov. 1

Oral ascorbic acid:

Randomized, open-label study (NCT04342728; COVID A to Z) in an outpatient setting in 214 adults with confirmed SARS-CoV-2 infection: A 10-day oral regimen of ascorbic acid (8 g daily given in 2 or 3 divided doses with meals), zinc gluconate (50 mg at bedtime), or both supplements in combination failed to reduce the time required to achieve a 50% reduction in symptom severity compared with usual care alone. The mean number of days from peak symptom score to 50% resolution of symptoms (including fever/chills, cough, shortness of breath, and fatigue, each rated on a 4-point scale) was 5.5 days with ascorbic acid, 5.9 days with zinc, 5.5 days with ascorbic acid and zinc, or 6.7 days with usual care alone. Target enrollment was 520 patients; the study was stopped early for futility. 17

Other clinical trials of outpatient oral ascorbic acid treatment are registered at clinicaltrials.gov. 1

Included at lower dosages as an active or placebo-equivalent comparator (control) in other COVID-19 prevention or treatment studies. 1

Included as a component of some combination regimens being studied for prevention or treatment of COVID-19. 1

Other infections:

Sepsis: Meta-analysis of several small studies suggested beneficial effects from IV ascorbic acid. 14 However, primary end
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin</td>
<td>8:12.12 Macrolides</td>
<td>Antibacterial with some in vitro activity against some viruses (e.g., influenza A, H1N1, ZIka)</td>
<td>Points not improved in CITRIS-ALI study (NCT02106975) in patients with sepsis and ARDS, HYVCTTSS study (NCT03258684) in patients with sepsis or septic shock, or VITAMINS study (NCT03333278), ACTS study (NCT03389555), or ATTESS study in patients with septic shock; one primary end point (resolution of shock [i.e., discontinuance of vasopressor support]) was improved but other primary end point (change in SOFA score) was not improved in ORANGES study (NCT03422159) in patients with sepsis or septic shock; variable findings reported with respect to certain primary or secondary outcomes.</td>
<td>Adjunctive therapy in certain respiratory viral infections: Although contradictory results reported, some evidence of beneficial immunomodulatory or anti-inflammatory effects when used in pts with some viral infections (e.g., influenza). However, in a retrospective cohort study in critically ill pts with laboratory-confirmed MERS, there was no statistically significant difference in 90-day mortality rates or clearance of MERS-CoV RNA between those who received macrolide therapy and those who did not.</td>
<td>Adjunctive treatment in certain viral infections: 500 mg once daily has been used. COVID-19: 500 mg on day 1, then 250 mg once daily on days 2-5 or 500 mg once daily for 7 days has been used in conjunction with a 5-, 7-, or 10-day regimen of hydroxychloroquine. Only limited information available regarding the frequency and microbiology of bacterial pulmonary coinfections or superinfections in pts with COVID-19. Empiric coverage for bacterial pathogens has been used, but is not required in all pts with confirmed COVID-19-related pneumonia. If bacterial pneumonia or sepsis is strongly suspected or confirmed, empiric antibacterial treatment should be administered. Although data are limited, bacterial pathogens in COVID-19 pts with community-acquired pneumonia (CAP) are likely the same as those seen in other pts with CAP. Therefore, if antibacterial coverage for CAP is indicated in COVID-19 pts, the usually recommended regimens for empiric treatment of CAP should be used. Antimicrobial stewardship policies should be used to guide appropriate use of antibacterials in COVID-19 pts; such drugs should be discontinued if bacterial infection is not confirmed.</td>
</tr>
</tbody>
</table>

Updated 3/11/21

NonCommercial 4.0 International

Page 57
Drug(s) | AHFS Class | Rationale | Trials or Clinical Experience | Dosage* | Comments
--- | --- | --- | --- | --- | ---

infections (e.g., influenza) 10, 13  
Has been used as adjunctive therapy to provide antibacterial coverage and potential immunomodulatory and anti-inflammatory effects in the management of certain respiratory conditions (e.g., bronchiectasis, bronchiolitis, cystic fibrosis, COPD exacerbations, ARDS) 6, 8, 17

**Clinical experience in pts with COVID-19:** Has been used for antibacterial coverage in hospitalized pts with COVID-19 15

**Use in conjunction with hydroxychloroquine in pts with COVID-19:** Azithromycin (500 mg on day 1, then 250 mg daily on days 2-5) has been used in addition to a 10-day regimen of hydroxychloroquine (600 mg daily) in an open-label nonrandomized study in France (6 pts), 7 open-label uncontrolled study in France (11 pts), 18 uncontrolled observational study in France (80 pts), 19 and larger uncontrolled observational study in France (1061 pts). 21 Data presented to date are insufficient to evaluate possible clinical benefits of azithromycin in pts with COVID-19. (See Hydroxychloroquine in this Evidence Table.)

**Use in conjunction with hydroxychloroquine in hospitalized pts with COVID-19:** Data from 2 retrospective studies that analyzed outcome data for hospitalized pts in New York treated with hydroxychloroquine with or without azithromycin indicate that use of the 4-aminoquinoline antimalarial with or without azithromycin is not associated with decreased in-hospital mortality. 30, 31 (See Hydroxychloroquine in this Evidence Table.)

**Open-label, randomized, multicenter trial in adults hospitalized with severe COVID-19 in Brazil (NCT04321278; COALITION II):** Patients were randomized 1:1 to receive oral azithromycin (500 mg once daily for 10 days) plus standard of care (n=214) or standard of care (control group; n=183). All pts received oral hydroxychloroquine (400 mg twice daily for 10 days) as part of standard of care; concomitant use of corticosteroids, other immunomodulators, antibiotics (no macrolides), and antivirals was allowed. Inclusion criteria required at least one severity criterion (use of oxygen supplementation at more than 4 L/minute, high-flow nasal cannula, noninvasive positive-pressure ventilation, or mechanical ventilation). Exclusion criteria included history of severe ventricular cardiac arrhythmia or QT ≥480 msec in any ECG performed before randomization. The primary outcome

Data from various randomized, controlled clinical trials and retrospective studies have not shown evidence of clinical benefit when azithromycin was used alone or in conjunction with hydroxychloroquine for the treatment of COVID-19 in hospitalized pts; 21, 22, 30, 31, 34, 37, 38  
there are data indicating that combined use of azithromycin and chloroquine or hydroxychloroquine may be associated with an increased risk of adverse cardiac effects 21, 22, 33 (See Hydroxychloroquine in this Evidence Table.)

NIH COVID-19 Treatment Guidelines Panel recommends against use of a combined regimen of hydroxychloroquine (or chloroquine) and azithromycin for the treatment of COVID-19 in hospitalized pts and recommends against use of a combined regimen of hydroxychloroquine (or chloroquine) and azithromycin for the treatment of COVID-19 in nonhospitalized pts, except in the context of a clinical trial. 21

IDSA recommends against use of a combined regimen of hydroxychloroquine (or chloroquine) and azithromycin for the treatment of COVID-19 in hospitalized pts. 22

Because azithromycin and 4-aminoquinolines (hydroxychloroquine, chloroquine) are independently associated with QT prolongation, caution is advised if considering use of azithromycin with one of these drugs in pts with COVID-19, especially in outpatients who may not receive close monitoring and in those at risk for QT prolongation or receiving other drugs associated with arrhythmias. 20, 22, 25, 28, 33

NIH panel states that macrolides (including azithromycin) should be used concomitantly with hydroxychloroquine (or chloroquine) only if necessary. In addition, because of the long half-lives of both azithromycin (up to 72 hours) and hydroxychloroquine (up to 40 days), caution is warranted even when the
was clinical status at day 15 based on a 6-level ordinal scale that ranged from not hospitalized (1) to death (6); the key secondary outcome was mortality at day 29. Results for the modified intention-to-treat (mITT) population (i.e., those with confirmed COVID-19) indicated that addition of azithromycin to standard of care was not superior to standard of care alone. At day 15, there was no difference in the proportional odds of being in higher categories on the 6-point ordinal scale between the azithromycin group and control group. At day 29, 42% of pts in the azithromycin group and 40% of those in the control group had died. There also was no difference between the groups in the proportion of pts with QTc interval prolongation (20% in azithromycin group and 21% in control group). 34

Azithromycin in randomized, controlled, open-label, adaptive, platform trial (NCT04381936; RECOVERY): This study is enrolling pts with suspected or confirmed COVID-19 from 176 hospitals in the UK. In the azithromycin arm (now terminated), 2582 pts were randomized to receive azithromycin (500 mg by mouth, NG tube, or IV once daily for 10 days or until discharge, whichever came first) plus standard of care and 5181 pts were randomized to standard of care alone. The primary outcome was all-cause mortality at day 28. Results of this study indicated that azithromycin is not an effective treatment for pts hospitalized with COVID-19. There was no difference in the 28-day mortality rate between the azithromycin plus standard of care group and the standard of care alone group (22% in both groups). In addition, the time to hospital discharge was similar (median 10 days in the azithromycin group and 11 days in the standard of care alone group) and, in those not requiring mechanical ventilation at baseline, azithromycin did not decrease the risk of progression to mechanical ventilation or death (25% in azithromycin group vs 26% in standard of care alone group). Results were consistent across all prespecified pt subgroups (age; sex; ethnicity; and symptom duration, level of respiratory support, and

---

### Drug(s) | AHFS Class | Rationale | Trials or Clinical Experience | Dosage* | Comments
--- | --- | --- | --- | --- | ---

---

drugs are used sequentially. The panel states that use of doxycycline (instead of azithromycin) should be considered for empiric therapy of atypical pneumonia in COVID-19 pts receiving hydroxychloroquine (or chloroquine). 21

The benefits and risks of a combined regimen of azithromycin and hydroxychloroquine (or chloroquine) should be carefully assessed; if the regimen is used, diagnostic testing and monitoring are recommended to minimize risk of adverse effects, including drug-induced cardiac effects. 20, 21, 25-28, 33

(See Hydroxychloroquine in this Evidence Table.)
Azithromycin in randomized, controlled, open-label, adaptive, platform trial in the UK (PRINCIPLE): Adult outpatients with PCR-confirmed or suspected COVID-19 and ongoing symptoms for ≤14 days who were considered at increased risk of adverse outcomes (i.e., ≥65 years of age or ≥50 years of age with at least one comorbidity) were randomly assigned to various interventions with usual care or usual care alone. Patients randomized to the azithromycin intervention arm received oral azithromycin (500 mg once daily for 3 days) with usual care, and results were compared with those for pts randomized to usual care alone. The two coprimary end points were time to first self-reported recovery and COVID-19-related hospital admission or death (both end points measured within 28 days after randomization). Results of this study indicated that use of azithromycin in symptomatic outpatients with known or suspected COVID-19 did not provide benefits in terms of reducing time to recovery or risk of hospitalization. A Bayesian primary analysis for 500 pts treated with azithromycin and usual care and 823 pts treated with usual care alone indicated that 80% of those who received azithromycin and 77% of those who received usual care alone reported feeling recovered within 28 days (median time to first reported recovery was 7 and 8 days, respectively); 3% of pts in each group were hospitalized within 28 days; there were no deaths in either group. Enrollment in the azithromycin arm of the study was terminated when analyses indicated the prespecified criterion for futility was met.

Various clinical trials evaluating azithromycin alone or in conjunction with other drugs for treatment of COVID-19 are registered at clinicaltrials.gov.
Baricitinib (Olumiant®)  
**Updated 8/19/21**

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Baricitinib     | 92:36       | Janus kinase (JAK) 1 and 2 inhibitor; disrupts regulators of endocytosis (AP2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase [GAK]), which may help reduce viral entry and inflammation; also may interfere with intracellular virus particle assembly | There is some clinical trial evidence that baricitinib may be beneficial in the treatment of patients with COVID-19  
15, 13, 18, 19, 24, 26  
In a small (12 patients) open-label study in Italy (NCT04358614), use of baricitinib (4 mg orally once daily for 2 weeks) in combination with lopinavir/ritonavir was evaluated in patients with moderate COVID-19 pneumonia.  
13, 14 Baricitinib was well tolerated with no serious adverse events reported.  
14 At week 1 and week 2, patients who received baricitinib had significant improvement in respiratory function parameters and none of the patients required ICU support.  
13  
Phase 3 adaptive, randomized, double-blind trial compared a regimen of remdesivir alone vs a regimen of remdesivir with baricitinib in hospitalized adults (NCT04401579; ACTT-2): Inclusion criteria included laboratory-confirmed SARS-CoV-2 infection with at least one of the following: radiographic infiltrates by imaging, SpO2 <94% on room air, or requiring supplemental oxygen, mechanical ventilation, or ECMO. Patients were randomized 1:1 to receive remdesivir (200 mg IV on day 1, then 100 mg IV once daily for a total treatment duration of 10 days or until hospital discharge) with either baricitinib (4 mg orally or through a nasogastric tube once daily for 14 days or until hospital discharge) or placebo.  
17, 19, 24 The primary end point was time to recovery through day 29 (defined as discharged without limitations on activities, discharged with limitations on activities and/or requiring home oxygen, or still hospitalized but not requiring supplemental oxygen and no longer requiring ongoing medical care). Data for 1033 patients in the intent-to-treat population (515 in the remdesivir and baricitinib group and 518 in the remdesivir alone group) indicate that those who received the combined regimen were more likely to have better clinical outcomes than those who received remdesivir alone. Use of the combined regimen of remdesivir and baricitinib met the primary end point of reduced time to recovery compared with use of remdesivir | Therapeutic dosages of baricitinib (2 or 4 mg orally once daily) are sufficient to inhibit AAK1  
1, 2, 5  
Optimal dosage and duration for treatment of COVID-19 not known (see Trials or Clinical Experience)  
Emergency use authorization (EUA) baricitinib dosage for treatment of COVID-19 in hospitalized adults and pediatric patients 29 years of age: 4 mg orally once daily for 14 days or until hospital discharge, whichever comes first. For pediatric patients 2 to <9 years of age, 2 mg orally once daily for 14 days or until hospital discharge, whichever comes first. Not authorized for pediatric patients <2 years of age. Dosage adjustment is necessary for laboratory abnormalities, including renal and hepatic impairment. Consult the baricitinib EUA fact sheet for healthcare providers for additional dosage adjustment information.  
19  
NIH COVID-19 Treatment Guidelines Panel states that there are limited data on concurrent use of baricitinib and potent OAT3 inhibitors and that such combined use is generally not recommended.  
11 If baricitinib and potent OAT3 inhibitors are used in combination, the EUA and NIH Panel recommend adjustment of baricitinib dosage.  
11, 19  
Emergency use authorization (EUA) for baricitinib: FDA issued an EUA on November 19, 2020 that permitted use of baricitinib in combination with remdesivir for treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients ≥2 years of age requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). On July 28, 2021, FDA reissued the EUA for baricitinib to permit use of baricitinib without remdesivir. FDA states that, based on review of data from a randomized, double-blind, placebo-controlled trial comparing baricitinib in combination with remdesivir to remdesivir alone (NCT04401579; ACTT-2), data from a randomized, double-blind, placebo-controlled clinical trial comparing baricitinib with placebo in hospitalized adults with confirmed SARS-CoV-2 infection (NCT04421027; COV-BARRIER), baricitinib data that were reviewed for the FDA-approved indication of rheumatoid arthritis, and data from populations studied for other indications (including pediatric patients), it is reasonable to believe that baricitinib may be effective for the treatment of suspected or laboratory-confirmed COVID-19 in the patient population specified in the baricitinib EUA and, when used under the conditions described in the EUA, the known and potential benefits of baricitinib when used to treat COVID-19 in such patients outweigh the known and potential risks.  
18 Consult the baricitinib EUA letter of authorization,  
18 EUA fact sheet for healthcare providers,  
18 and EUA fact sheet for patients, parents and caregivers  
20 for additional information.  
Based on preliminary results (not yet peer-reviewed) from the COV-BARRIER trial, NIH COVID-19 Treatment Guidelines Panel has updated its recommendations on use of baricitinib for the treatment of COVID-19 in adults:  
11, 26 |

**Updated 8/19/21**

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Baricitinib     | 92:36       | Janus kinase (JAK) 1 and 2 inhibitor; disrupts regulators of endocytosis (AP2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase [GAK]), which may help reduce viral entry and inflammation; also may interfere with intracellular virus particle assembly | There is some clinical trial evidence that baricitinib may be beneficial in the treatment of patients with COVID-19  
15, 13, 18, 19, 24, 26  
In a small (12 patients) open-label study in Italy (NCT04358614), use of baricitinib (4 mg orally once daily for 2 weeks) in combination with lopinavir/ritonavir was evaluated in patients with moderate COVID-19 pneumonia.  
13, 14 Baricitinib was well tolerated with no serious adverse events reported.  
14 At week 1 and week 2, patients who received baricitinib had significant improvement in respiratory function parameters and none of the patients required ICU support.  
13  
Phase 3 adaptive, randomized, double-blind trial compared a regimen of remdesivir alone vs a regimen of remdesivir with baricitinib in hospitalized adults (NCT04401579; ACTT-2): Inclusion criteria included laboratory-confirmed SARS-CoV-2 infection with at least one of the following: radiographic infiltrates by imaging, SpO2 <94% on room air, or requiring supplemental oxygen, mechanical ventilation, or ECMO. Patients were randomized 1:1 to receive remdesivir (200 mg IV on day 1, then 100 mg IV once daily for a total treatment duration of 10 days or until hospital discharge) with either baricitinib (4 mg orally or through a nasogastric tube once daily for 14 days or until hospital discharge) or placebo.  
17, 19, 24 The primary end point was time to recovery through day 29 (defined as discharged without limitations on activities, discharged with limitations on activities and/or requiring home oxygen, or still hospitalized but not requiring supplemental oxygen and no longer requiring ongoing medical care). Data for 1033 patients in the intent-to-treat population (515 in the remdesivir and baricitinib group and 518 in the remdesivir alone group) indicate that those who received the combined regimen were more likely to have better clinical outcomes than those who received remdesivir alone. Use of the combined regimen of remdesivir and baricitinib met the primary end point of reduced time to recovery compared with use of remdesivir | Therapeutic dosages of baricitinib (2 or 4 mg orally once daily) are sufficient to inhibit AAK1  
1, 2, 5  
Optimal dosage and duration for treatment of COVID-19 not known (see Trials or Clinical Experience)  
Emergency use authorization (EUA) baricitinib dosage for treatment of COVID-19 in hospitalized adults and pediatric patients 29 years of age: 4 mg orally once daily for 14 days or until hospital discharge, whichever comes first. For pediatric patients 2 to <9 years of age, 2 mg orally once daily for 14 days or until hospital discharge, whichever comes first. Not authorized for pediatric patients <2 years of age. Dosage adjustment is necessary for laboratory abnormalities, including renal and hepatic impairment. Consult the baricitinib EUA fact sheet for healthcare providers for additional dosage adjustment information.  
19  
NIH COVID-19 Treatment Guidelines Panel states that there are limited data on concurrent use of baricitinib and potent OAT3 inhibitors and that such combined use is generally not recommended.  
11 If baricitinib and potent OAT3 inhibitors are used in combination, the EUA and NIH Panel recommend adjustment of baricitinib dosage.  
11, 19  
Emergency use authorization (EUA) for baricitinib: FDA issued an EUA on November 19, 2020 that permitted use of baricitinib in combination with remdesivir for treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients ≥2 years of age requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). On July 28, 2021, FDA reissued the EUA for baricitinib to permit use of baricitinib without remdesivir. FDA states that, based on review of data from a randomized, double-blind, placebo-controlled trial comparing baricitinib in combination with remdesivir to remdesivir alone (NCT04401579; ACTT-2), data from a randomized, double-blind, placebo-controlled clinical trial comparing baricitinib with placebo in hospitalized adults with confirmed SARS-CoV-2 infection (NCT04421027; COV-BARRIER), baricitinib data that were reviewed for the FDA-approved indication of rheumatoid arthritis, and data from populations studied for other indications (including pediatric patients), it is reasonable to believe that baricitinib may be effective for the treatment of suspected or laboratory-confirmed COVID-19 in the patient population specified in the baricitinib EUA and, when used under the conditions described in the EUA, the known and potential benefits of baricitinib when used to treat COVID-19 in such patients outweigh the known and potential risks.  
18 Consult the baricitinib EUA letter of authorization,  
18 EUA fact sheet for healthcare providers,  
18 and EUA fact sheet for patients, parents and caregivers  
20 for additional information.  
Based on preliminary results (not yet peer-reviewed) from the COV-BARRIER trial, NIH COVID-19 Treatment Guidelines Panel has updated its recommendations on use of baricitinib for the treatment of COVID-19 in adults:  
11, 26 |
alone (median time to recovery was 7 days in those receiving the combined regimen vs 8 days in those receiving remdesivir). Patients treated with combined remdesivir and baricitinib were also more likely to have a better clinical status at day 15 compared with those receiving remdesivir alone. The proportion of patients who progressed to ventilation (noninvasive or invasive) by day 29 was lower in patients receiving combined remdesivir and baricitinib. In addition, the 28-day mortality rate was 5.1% in those treated with the combined regimen and 7.8% in those treated with remdesivir alone. Based on results of this trial and other data, FDA issued an emergency use authorization (EUA) for baricitinib that permits use of the drug in combination with remdesivir. An important limitation of this trial was the inability to evaluate the effect of baricitinib in combination with corticosteroids.

Multinational, randomized, double-blind, placebo-controlled, phase 3 trial (COV-BARRIER; NCT04421027) sponsored by the manufacturer (Lilly): Preliminary (non-peer-reviewed) data are available for 1525 hospitalized adults with COVID-19 who had at least one elevated marker of inflammation but did not require mechanical ventilation upon study entry. Patients were randomized 1:1 to receive baricitinib 4 mg orally daily or placebo in addition to the local standard of care (e.g., corticosteroids in 79% [91% of these received dexamethasone] and remdesivir in 19% of patients) for up to 14 days or until hospital discharge. The primary end point was the proportion of patients who progressed to high-flow oxygen, noninvasive ventilation, invasive mechanical ventilation, or death by day 28. All-cause mortality within 28 days was a key secondary end point. Overall, 27.8% of patients receiving baricitinib versus 30.5% of those receiving placebo progressed. The 28-day all-cause mortality was 8.1% for baricitinib and 13.1% for placebo, corresponding to a 38.2% reduction in mortality. Reduction in mortality was seen for all prespecified subgroups of baseline severity and was most pronounced for patients on high-flow oxygen/non-invasive ventilation at baseline. The frequency of

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1) Recently hospitalized patients (e.g., within 3 days) on high-flow oxygen or noninvasive ventilation who have evidence of clinical progression or increased markers of inflammation: The NIH panel recommends using either baricitinib or tocilizumab in combination with dexamethasone alone or dexamethasone plus remdesivir.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2) Hospitalized patients with hypoxemia who require supplemental oxygen therapy: The NIH panel states that there currently is insufficient evidence to identify which patients would benefit from the addition of baricitinib or tocilizumab to dexamethasone (with or without remdesivir). For patients exhibiting signs of systemic inflammation and rapidly increasing oxygen needs while on dexamethasone, but who do not yet require noninvasive ventilation or high-flow oxygen, some panel members would add either baricitinib or tocilizumab. (See Tocilizumab in this Evidience Table.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3) The NIH panel recommends against the use of baricitinib in combination with tocilizumab for the treatment of COVID-19, except in a clinical trial. Because both baricitinib and tocilizumab are potent immunosuppressants, there is potentially an additive risk of infection.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NIH COVID-19 Treatment Guidelines Panel states that there is insufficient evidence to recommend either for or against use of baricitinib for the treatment of COVID-19 in children (see Dosage).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NIH COVID-19 Treatment Guidelines Panel states that use of baricitinib is not recommended in patients with hepatic or renal impairment (GFR &lt;60 mL/min/1.73 m²) (see Dosage).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Minimal interaction with CYP enzymes and drug transporters and low protein binding of baricitinib allow for combined use with antiviral agents and</td>
</tr>
</tbody>
</table>
Colchicine

Updated 6/17/21

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colchicine</td>
<td>92:16 An-</td>
<td>Exerts broad anti-inflammatory and immunomodulatory effects through multiple mechanisms, including inhibition of NOD-like receptor protein 3 (NLRP3) inflammasome assembly and disruption of cytoskeletal functions through inhibition of microtubule polymerization.</td>
<td>Limited anecdotal experience and clinical trial data reported to date in COVID-19; results pending from multiple clinical trials. On March 5, 2021, researchers announced that enrollment into the colchicine arm of the RECOVERY trial had been halted on the advice of the data monitoring committee (DMC) when a preliminary analysis revealed no difference in mortality between hospitalized patients receiving colchicine for treatment of COVID-19 and those receiving usual care alone; full data are not available yet, but the researchers stated that the DMC found no convincing evidence that further recruitment would provide conclusive proof of worthwhile mortality benefit overall or in any prespecified subgroup.</td>
<td>Dosage in NCT04322682: Colchicine loading dosage: 1.5 mg followed in 1 hour by 0.5 mg (reduced to a single 1-mg dose in those receiving azithromycin); maintenance dosage: 0.5 mg twice daily (reduced to 0.5 mg once daily in those weighing &lt;60 kg) until hospital discharge or maximum of 21 days.</td>
<td>Safety and efficacy for treatment of COVID-19 not established. The potential for toxic doses of colchicine to affect alveolar type II pneumocytes (which may inhibit surfactant release and contribute to ARDS) and increase the risk of multiple-organ failure and disseminated intravascular coagulation (DIC) has been raised as a possible concern with the use of colchicine in COVID-19 patients.</td>
</tr>
</tbody>
</table>

NIH COVID-19 Treatment Guidelines Panel states that there are insufficient data to recommend either for or against use of colchicine for the treatment of nonhospitalized patients with COVID-19. The COLCORONA trial did not reach its primary efficacy end point of reducing hospitalization or death, although a slight reduction in hospitalizations was observed in the subset of patients with PCR-confirmed disease.


Pregnancy: Limited data are available on use of colchicine during pregnancy; data are lacking on use in pregnant women with acute COVID-19. Fetal risk cannot be ruled out.

Limited data are available on use of colchicine during pregnancy; data are lacking on use in pregnant women with acute COVID-19. Fetal risk cannot be ruled out.

Colchicine has also been hypothesized based on the observed slight reduction in hospitalizations was observed in the subset of patients with PCR-confirmed disease. However, dosage adjustment recommended when used with strong CYP3A4 inhibitors.
drug’s mechanisms of action and promising results of ongoing research on colchicine in various cardiac conditions.\(^3\)-\(^{10}\),\(^{19}\)

SARS-CoV-1 envelope (E) protein, a viroporin involved in replication and virulence, activates the NLRP3 inflammasome in vitro in Vero E6 cells by forming calcium-permeable ion channels, leading to increased IL-1β production.\(^2\),\(^{12}\),\(^{13}\)

In one observational study (not peer-reviewed), mortality rate in patients with COVID-19 pneumonia was numerically lower in those receiving colchicine compared with those not receiving the drug, but the effect of the drug was not statistically significant; 80% of patients in the study received corticosteroids.\(^23\) The studies had substantial limitations, and larger well-designed studies are needed to further evaluate efficacy.\(^{20-23}\)

**Open-label, randomized, 16-hospital clinical trial (NCT04326790, GRECCO-19)** in hospitalized adults with RT-PCR-confirmed COVID-19: 55 patients received colchicine plus standard treatment and 50 received standard treatment alone; colchicine was administered orally as a loading dose of 1.5 mg followed in 1 hour by 0.5 mg (reduced to a single 1-mg dose in those receiving azithromycin) followed by a maintenance dosage of 0.5 mg twice daily (reduced to 0.5 mg once daily in those weighing <60 kg) until hospital discharge or for a maximum of 21 days. Most patients also received chloroquine or hydroxychloroquine (98%) and azithromycin (92%).

**Clinical deterioration** (2-grade increase on a 7-grade ordinal scale) was observed in a greater proportion of control patients than colchicine-treated patients (7 patients [14%] vs 1 patient [1.8%]); cumulative 10-day event-free survival was higher with colchicine than with control (97 vs 83%). Baseline score on the 7-grade scale was 3 or 4 in 97% of study patients. No difference observed between the groups in baseline or peak high-sensitivity cardiac troponin or peak C-reactive protein concentration. Small number of clinical events limited the statistical robustness of the results.\(^{17}\)

**Interim analysis** (not peer reviewed) of a single-center, randomized, double-blind, placebo-controlled trial in hospitalized adults with moderate to severe, RT-PCR-confirmed COVID-19 with pneumonia (not requiring ICU admission): Analysis of first 38 patients randomized 1:1 to colchicine or placebo indicated shorter duration of oxygen supplementation (3 vs 7 days) and shorter hospital stay (6 vs 8.5 days) in colchicine group vs placebo group. One

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage(^a)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colchicine</td>
<td>class 2A</td>
<td>Rationale: drug's mechanisms of action and promising results of ongoing research on colchicine in various cardiac conditions.(^3)-(^{10}),(^{19})</td>
<td>in one observational study (not peer-reviewed), mortality rate in patients with COVID-19 pneumonia was numerically lower in those receiving colchicine compared with those not receiving the drug, but the effect of the drug was not statistically significant; 80% of patients in the study received corticosteroids.(^23) The studies had substantial limitations, and larger well-designed studies are needed to further evaluate efficacy.(^{20-23})</td>
<td>Use of colchicine in patients with renal or hepatic impairment receiving P-gp inhibitors or potent CYP3A4 inhibitors is contraindicated.(^7)</td>
<td>Pediatric use: Colchicine use in children is limited mainly to treatment of familial Mediterranean fever; data are lacking on use for treatment of acute COVID-19 or multisystem inflammatory syndrome in children (MIS-C).(^{28})</td>
</tr>
</tbody>
</table>
patient in each group required ICU admission. Median duration of symptoms prior to treatment was 9 days (colchicine group) or 7 days (placebo group). Colchicine dosage was 0.5 mg 3 times daily for 5 days, then 0.5 mg twice daily for 5 days (initial dose was 1 mg if body weight ≥80 kg); dosage was reduced for renal impairment. Standard concomitant treatment included 7-day azithromycin regimen, up to 10-day hydroxychloroquine regimen, and heparin with or without methylprednisolone (depending on oxygenation status). 18

Nonhospitalized Patients:

Uncontrolled case series: 9 patients in community setting with COVID-19 received colchicine (1 mg orally every 12 hours on day 1, then 1 mg daily until third day of temperature <37.5°C); colchicine was initiated at a median of 8 days (range: 6-13 days) after symptom onset and after 3-5 days of spiking fever despite acetaminophen or antibiotic treatment. Defervescence occurred within 72 hours in all patients. One patient was hospitalized because of persistent dyspnea and discharged after 4 days of oxygen therapy. Basis for diagnosis of COVID-19 not stated. 16

Phase 3, randomized, double-blind, adaptive, multinational placebo-controlled study (NCT04322682; COLCORONA): A total of 4488 adult outpatients (including 4159 patients with PCR-confirmed COVID-19) with at least 1 high-risk criterion were randomized within 24 hours of COVID-19 diagnosis to receive colchicine (0.5 mg twice daily for 3 days, then 0.5 mg once daily for 27 days) or placebo. The mean time from symptom onset to enrollment was 5.3 days. The primary end point was the composite of death or hospitalization due to COVID-19 within 30 days after randomization. Investigators (not the data safety monitoring board) decided to halt enrollment for logistical reasons prior to reaching the target of 6000 patients. In the intention-to-treat population, colchicine did not result in a statistically significant reduction in the composite end point of death or hospitalization due to COVID-19.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticosteroids (systemic)</td>
<td>68:04 Adrenals</td>
<td>Potent anti-inflammatory and antibioretic properties; use of corticosteroids may prevent an extended cytokine response and may accelerate resolution of pulmonary and systemic inflammation in pneumonia.</td>
<td>Compared with placebo (4.7 vs 5.8%, respectively) or in the individual end points of death, hospitalization due to COVID-19, or need for mechanical ventilation. In those with PCR-confirmed COVID-19, a statistically significant difference was observed between the colchicine and placebo groups in the composite end point of death or hospitalization (4.6 vs 6%, respectively) and in the rate of hospitalization, but not in the individual end points of death or need for mechanical ventilation. Pulmonary embolism occurred in 11 patients receiving colchicine compared with 2 placebo recipients.</td>
<td>The NIH COVID-19 Treatment Guidelines Panel recommends an IV or oral dexamethasone dosage of 6 mg daily for up to 10 days or until hospital discharge, whichever comes first, in COVID-19 patients requiring mechanical ventilation and in patients who require supplemental oxygen but who are not mechanically ventilated. Although the clinical benefits of other corticosteroids (e.g., hydrocortisone, methylprednisolone, prednisone) are not clear, the panel recommends using total daily dosages of these drugs equivalent to dexamethasone 6 mg (IV or oral) as follows: Hydrocortisone 160 mg, Methylprednisolone 32 mg, or Prednisone 40 mg. Based on half-life and duration of action, frequency of administration varies among these corticosteroids. Dexamethasone is long-acting and administered once daily. Methylprednisolone and Prednisone are intermediate-acting and administered once daily or in 2 divided doses daily. Hydrocortisone is short-acting and administered in 2-4 divided doses daily.</td>
<td>Data on the use of corticosteroids in COVID-19 are limited. The benefits and risks of corticosteroid therapy should be carefully weighed before use in patients with COVID-19. Non-severe or non-critical patients: Corticosteroids generally should not be used in the treatment of early or mild disease since the drugs can inhibit immune response, reduce pathogen clearance, and increase viral shedding. The NIH COVID-19 Treatment Guidelines Panel recommends against the use of dexamethasone or other corticosteroids in nonhospitalized patients with mild to moderate COVID-19 or in hospitalized patients with COVID-19 who do not require supplemental oxygen.</td>
</tr>
</tbody>
</table>

Updated 08-19-2021. The current version of this document can be found on the ASHP COVID-19 Resource Center.
4321 patients were randomized to receive standard care alone. Preliminary data analysis indicates that overall 28-day mortality was reduced in patients receiving dexamethasone compared with those receiving standard care alone with the greatest benefit observed in patients requiring mechanical ventilation at enrollment. Overall, 22.9% of patients receiving dexamethasone and 25.7% of those receiving standard care died within 28 days of study enrollment. In patients receiving dexamethasone, the incidence of death was lower than that in the standard care group among those receiving invasive mechanical ventilation (29.3 vs 41.4%) and among those receiving supplemental oxygen without invasive mechanical ventilation (23.3 vs 26.2%). However, no survival benefit was observed with dexamethasone and there was a possibility of harm in patients who did not require respiratory support at enrollment; the incidence of death in such patients receiving dexamethasone compared with standard care was 17.8 vs 14%, respectively.

Dexamethasone was associated with a reduction in 28-day mortality among patients with symptoms for >7 days compared with those having more recent symptom onset. Dexamethasone treatment also was associated with a shorter duration of hospitalization and a greater probability of discharge within 28 days with the greatest effect observed among patients receiving invasive mechanical ventilation at baseline.

Note: Data regarding potential adverse effects, efficacy in combination with other treatments (e.g., remdesivir), and efficacy in other patient populations (e.g., pediatric patients and pregnant women) not available to date. 24

Dexamethasone randomized, controlled, open-label, multicenter study (NCT04327401; CoDEX): This trial was conducted to determine whether IV dexamethasone increases the number of ventilator-free days among patients with COVID-19-associated ARDS. The study enrolled adults with COVID-19 and moderate or severe ARDS who were receiving mechanical ventilation from 41 ICUs in Brazil. In the dexamethasone treatment arm, 151 patients

Regimens used in early cases of COVID-19 in China were typically methylprednisolone 40-80 mg IV daily for a course of 3-6 days. Some experts suggest that equivalent dosages of dexamethasone (i.e., 7-15 mg daily, typically 10 mg daily) may have an advantage of producing less fluid retention, since dexamethasone has less mineralocorticoid activity. 8 This dosage of dexamethasone is consistent with those used in the DEXA-ARDS trial. 8, 52 However, lower dosages of dexamethasone (i.e., 6 mg once daily for 10 days) were used in the RECOVERY trial. 13, 51

Higher dosages of IV Dexamethasone (i.e., 20 mg once daily for 5 days followed by 10 mg once daily for an additional 5 days or until ICU discharge, whichever came first) were used in the CoDEX trial in patients with COVID-19 and moderate or severe ARDS. 59

Continuous IV infusion of Hydrocortisone 200 mg/day for 7 days, followed by 100 mg/day for 4 days, and then 50 mg/day for 3 days (total of 14 days) was used in the CAPE COVID study. If a patient’s respiratory and general status sufficiently improved by day 4, a shorter treatment regimen of Hydrocortisone was used at a dosage of 200 mg/day for 4 days followed by 100 mg/day for 2 days and then 50 mg/day for 2 days (total of 8 days). 40

A fixed dosage of IV Hydrocortisone (50 or 100 mg every 6 hours for 7 days) or a shock-dependent regimen of IV hydrocortisone (50 mg every 6 hours for up to 28 days in the presence of clinically evident shock) was used in the REMAP-CAP study. 41

The WHO Guideline Development Group suggests not using systemic corticosteroids in the treatment of patients with non-severe COVID-19, regardless of hospitalization status. However, if the clinical condition of such non-severe patients worsens (e.g., increased respiratory rate, signs of respiratory distress, or hypoxemia), systemic corticosteroids are recommended for treatment. The WHO Guideline Development Group recommends against discontinuing systemic corticosteroids in patients with non-severe COVID-19 who are receiving systemic corticosteroids for chronic conditions (e.g., COPD, autoimmune diseases). 53

Severely or critically ill patients: The Surviving Sepsis Campaign COVID-19 subcommittee (a joint initiative of the Society of Critical Care Medicine and the European Society of Intensive Care Medicine) supports a strong recommendation to use a short course of systemic corticosteroids over not using corticosteroids in severe 28-day mortality or in those who require supplemental oxygen but are not on mechanical ventilation or in those who require supplemental oxygen but are not on mechanical ventilation. 24 (See Remdesivir in this Evidence Table for recommendations from the NIH guidelines panel regarding use of dexamethasone with or without remdesivir in COVID-19.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Hydrocortisone |  |  | were randomized to receive dexamethasone (20 mg IV once daily for 5 days followed by 10 mg IV once daily for another 5 days or until ICU discharge) plus standard care; 148 patients were randomized to receive standard care alone. The primary study end point was ventilator-free days (defined as number of days alive and free from mechanical ventilation) during the first 28 days. Preliminary data analysis indicates that use of IV dexamethasone plus standard care was associated with a higher mean number of ventilator-free days (6.6 days) compared with those receiving standard care alone (4 days). Although there was no significant difference in treatment mortality at 28 days between the treatment groups, the trial was terminated early after results of the RECOVERY trial became available and, therefore, likely underpowered to determine secondary outcomes such as mortality. Dexamethasone was not associated with an increased risk of adverse effects in this study population of critically ill COVID-19 patients.  

Hydrocortisone randomized, double-blind sequential trial (NCT02517489; CAPE COVID): This trial was conducted to evaluate the effect of low-dose hydrocortisone compared with placebo on treatment failure in critically ill patients with COVID-19-related acute respiratory failure. The study enrolled adults with COVID-19-associated acute respiratory failure from 9 ICUs in France. In the hydrocortisone treatment arm, 76 patients received a continuous IV infusion of hydrocortisone at an initial dosage of 200 mg/day for 7 days followed by 100 mg/day for 4 days, and then 50 mg/day for 3 days (total of 14 days; some patients received a shorter regimen); 79 patients received placebo. The primary study end point was treatment failure (defined as death or persistent dependency on mechanical ventilation or high-flow oxygen therapy) on day 21. Treatment failure on day 21 occurred in 42.1% of patients in the hydrocortisone group compared with 50.7% of patients in the placebo group. The difference between the treatment groups was not statistically significant; however, the study was discontinued early after finding the effects of dexamethasone or hydrocortisone were similar to placebo. The NIH COVID-19 Treatment Guidelines Panel recommends use of dexamethasone or hydrocortisone in patients receiving mechanical ventilation or high-flow oxygen therapy. For patients who were recently hospitalized with COVID-19 who are receiving invasive mechanical ventilation or ECMO and who are within 24 hours of ICU admission with respiratory decompensation (See Tocilizumab in this Evidence Table for recommendations from the NIH guidelines panel regarding use of dexamethasone with tocilizumab in COVID-19 patients.) |

The NIH guidelines panel states that prolonged use of systemic corticosteroids in patients with COVID-19 may increase the risk of reactivation of latent infections (e.g., hepatitis B virus [HBV], herpesvirus, strongyloidiasis, tuberculosis). The risk of reactivation of latent infections following a 10-day course of dexamethasone (6 mg once daily) is not well established. When initiating dexamethasone in patients with COVID-19, appropriate screening and treatment to reduce the risk of Strongyloides hyperinfection in those at high risk of strongyloidiasis (e.g., patients from tropical, subtropical, or warm, temperate regions or those engaged in agricultural activities) or fulminant reactivations of HBV should be considered.  

The NIH guidelines panel also states that it is not known at this time whether... |
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosageᵃ</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>results of the RECOVERY trial were announced and, therefore, likely underpowered to determine a statistically and clinically important difference in the primary outcome. ²⁴ ⁴⁰</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone multicenter, ongoing, international open-label trial using a randomized, embedded multifactorial adaptive platform (NCT02735707; REMAP-CAP): This trial randomized patients to multiple interventions within multiple domains. In the COVID-19 corticosteroid domain, adults from 8 countries with suspected or confirmed COVID-19 following admission to an ICU for respiratory or cardiovascular organ support were randomized to receive a fixed 7-day regimen of IV hydrocortisone (50 or 100 mg every 6 hours), a shock-dependent regimen of IV hydrocortisone (50 mg every 6 hours when shock was clinically evident), or no hydrocortisone or other corticosteroid. The primary study end point was organ support-free days (defined as days alive and free of ICU-based respiratory or cardiovascular support) within 21 days. The 7-day fixed regimen and the shock-dependent regimen of hydrocortisone were associated with a 93 and 80% probability of benefit in terms of organ support-free days compared with no hydrocortisone. However, the trial was discontinued early after results of the RECOVERY trial were announced and no treatment strategy met the prespecified criteria for statistical superiority, precluding definitive conclusions. In addition, serious adverse effects were reported in 2.6% of patients in the study (4 patients receiving the fixed-dosage regimen and 5 patients receiving the shock-dependent regimen compared with 1 patient receiving no hydrocortisone). ²⁴ ⁴¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prospective meta-analysis of studies using systemic corticosteroids (i.e., dexamethasone, hydrocortisone, or methylprednisolone) from the WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group: This meta-analysis pooled data from 7 randomized clinical trials in 12 countries that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19. The primary outcome was other corticosteroids will have a similar benefit as dexamethasone. However, if dexamethasone is not available, the panel recommends using alternative corticosteroids (e.g., hydrocortisone, methylprednisolone, prednisone). ²⁴</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IDSA suggests the use of dexamethasone over no dexamethasone therapy in hospitalized patients with severe, but noncritical, COVID-19 (i.e., defined as patients with SpO₂ &lt;94% on room air including those who require supplemental oxygen). IDSA recommends the use of dexamethasone over no dexamethasone in hospitalized, critically ill patients with COVID-19 (i.e., defined as patients who are receiving mechanical ventilation or ECMO including those with end organ dysfunction as seen in cases of septic shock or ARDS). These experts suggest the use of dexamethasone 6 mg orally or IV daily for 10 days or until hospital discharge, whichever comes first, or substitution of equivalent daily dosages of other corticosteroids (e.g., methylprednisolone 32 mg, prednisone 40 mg) if dexamethasone is unavailable. However, IDSA suggests against using corticosteroids in hospitalized patients with nonsevere COVID-19 without hypoxemia (i.e., defined as patients with SpO₂ &gt;94% on room air and not requiring supplemental oxygen). ²⁵</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The WHO Guideline Development Group strongly recommends the use of systemic corticosteroids (e.g., dexamethasone 6 mg orally or IV daily or hydrocortisone 50 mg IV every 8 hours for 7-10 days) over no systemic corticosteroid therapy for the treatment of patients with severe and/or critical COVID-19, regardless of hospitalization status. This treatment recommendation includes critically ill patients with COVID-19 who could not be hospitalized or receive oxygen supplementation because of resource limitations. This treatment recommendation is less clear for populations under-represented in recent clinical trials (e.g., children, patients</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
all-cause mortality up to 30 days after randomization to treatment. Administration of systemic corticosteroids was associated with lower all-cause mortality at 28 days compared with usual care or placebo (222 deaths among 678 patients who received corticosteroids and 425 deaths among 1025 patients who received usual care or placebo). The effect of corticosteroids on reduced mortality was observed in critically ill patients who were and were not receiving mechanical ventilation at randomization and also in patients from the RECOVERY trial who required supplemental oxygen with or without noninvasive ventilation but who were not receiving invasive mechanical ventilation at the time of randomization. The odds ratios for the association between corticosteroids and mortality were similar for dexamethasone and hydrocortisone. The optimal dosage and duration of corticosteroid treatment could not be determined from this analysis; however, there was no evidence suggesting that a higher dosage of corticosteroids was associated with greater benefit than a lower dosage. The authors also concluded that there was no suggestion of an increased risk of serious adverse effects associated with corticosteroid use.

Methylprednisolone randomized, parallel, double-blind, placebo-controlled, phase IIb trial (NCT04343729; Metcovid): This trial was conducted to evaluate the effect of a short course of IV methylprednisolone compared with placebo in hospitalized adults with suspected COVID-19 infection from a single center in Brazil. Patients were enrolled prior to laboratory confirmation of COVID-19 to avoid treatment delays. The presence of COVID-19 was later confirmed based on RT-PCR testing in 81.3% of these patients. At time of enrollment, 34% of patients in each treatment group required invasive mechanical ventilation. Supplemental oxygen was required in 51% of patients receiving methylprednisolone and in 45% of those receiving placebo. In the methylprednisolone treatment arm, 194 patients received IV methylprednisolone at a dosage of 0.5 mg/kg twice daily for 5 days; 199 patients received placebo.

with tuberculosis, immunocompromised individuals); however, the risk of not using systemic corticosteroids and depriving such patients of potentially life-saving therapy should be considered. The WHO treatment recommendation does not apply to the following uses of corticosteroids: transdermal or inhaled administration, high-dose or long-term dosage regimens, or prophylaxis.

The WHO Guideline Development Group also recommends the concomitant use of systemic corticosteroids with an interleukin (IL-6) inhibitor (e.g., sarilumab, tocilizumab) for patients with severe or critical COVID-19 infection. (See Sarilumab and Tocilizumab in this Evidence Table.)

Cytokine storm: There is no well-established or evidence-based treatment for cytokine storm in patients with COVID-19. However, some experts suggest that use of more potent immunosuppression with corticosteroids may be beneficial in such patients. These experts suggest higher dosages of corticosteroids (e.g., IV methylprednisolone 60-125 mg every 6 hours for up to 3 days) followed by tapering of the dose when inflammatory markers (e.g., C-reactive protein levels) begin to decrease.

Septic shock: The effect of corticosteroids in COVID-19 patients with sepsis or septic shock may be different than the effects seen in those with ARDS. The Surviving Sepsis Campaign and NIH suggest the use of low-dose corticosteroid therapy (e.g., hydrocortisone 200 mg daily as an IV infusion or intermittent doses) over no corticosteroid therapy in adults with COVID-19 and refractory shock.

Randomized controlled studies evaluating use of corticosteroids (e.g., hydrocortisone, dexamethasone, methylprednisolone, prednisolone) in septic shock suggest a small, but uncertain mortality reduction. Clinicians considering
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>methylprednisolone</td>
<td></td>
<td></td>
<td>A modified intent-to-treat analysis was conducted; the primary study end point was 28-day mortality. Overall, the 28-day mortality rate was 37.1 or 38.2% in patients who received methylprednisolone or placebo, respectively, showing no significant difference in overall mortality between the treatment groups. However, a subgroup analysis found a lower mortality rate in patients &gt;60 years of age who received methylprednisolone compared with placebo (46.6 vs 61.9%, respectively). Patients &gt;60 years of age reportedly had a higher degree of systemic inflammatory disease as manifested by increased median levels of C-reactive protein (CRP) compared with patients ≤60 years of age. In patients ≤60 years of age, there was a higher incidence of fatal outcomes in the methylprednisolone group. The authors concluded that caution is needed when using corticosteroids in patients with less severe COVID-19 since a trend toward more harm was noted in the younger age group. <strong>Note:</strong> Limitations of this study include the following: single-center study with a moderate sample size, longer median time from symptom onset to treatment administration compared with other corticosteroid studies, shorter treatment duration and higher equivalent corticosteroid dosage compared with the RECOVERY trial, and higher baseline mortality of the patient population possibly limiting the generalizability of the results to populations with lower baseline mortality. 24-44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>methylprednisolone multicenter, observational, longitudinal study (NCT04323592):</td>
<td></td>
<td></td>
<td>This trial was conducted to evaluate the association between use of prolonged, low-dose methylprednisolone treatment and ICU admission, intubation, or all-cause death within 28 days (composite primary end point) in patients with severe COVID-19 pneumonia admitted to 14 respiratory high-dependency units in Italy. A total of 173 patients were enrolled in the study with 83 patients receiving methylprednisolone plus standard care and 90 patients receiving standard care alone. In the methylprednisolone treatment arm, patients received a loading dose of IV methylprednisolone 80 mg at study entry</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
followed by IV infusion of the drug at a dosage of 80 mg daily at a rate of 10 mL/hr for at least 8 days until achievement of either a PaO$_2$/FiO$_2$ (P/F) ratio >350 mm Hg or CRP levels <20 mg/L. Subsequently, twice-daily administration of either oral methylprednisolone 16 mg or IV methylprednisolone 20 mg was given until achievement of a P/F ratio >400 mm Hg or CRP levels reached <20% of the normal range. The composite primary end point was reached by 22.9 or 44.4% of patients in the group receiving methylprednisolone or standard care alone, respectively. Therefore, use of methylprednisolone was associated with a reduction in the risk of ICU admission, invasive mechanical ventilation, or death within 28 days (adjusted hazard ratio: 0.41). Specifically, 18.1 or 30% of patients required ICU admission and 16.9 or 28.9% of patients required invasive mechanical ventilation in those receiving methylprednisolone or standard care alone, respectively. In addition, use of methylprednisolone was associated with a 28-day lower risk of all-cause mortality than use of standard care alone (7.2 vs 23.3%, respectively) with an adjusted hazard ratio of 0.29. Overall, there was no difference in adverse effects between treatment groups with the exception of increased reports of hyperglycemia and mild agitation in the methylprednisolone-treated patients; no adverse effects resulted in drug discontinuation. The authors concluded that early, low-dose, prolonged therapy with methylprednisolone resulted in decreased ICU burden, reduced need for invasive mechanical ventilation, and lower mortality along with improvement in systemic inflammation and oxygenation markers in hospitalized patients with severe COVID-19 pneumonia at high risk of progression to acute respiratory failure. 48

Retrospective, case-control study using systemic corticosteroids (i.e., methylprednisolone, prednisone): This trial was conducted to evaluate the efficacy of early, low-dose, short-term therapy with systemic methylprednisolone or prednisone in hospitalized adults from a single center in China with non-severe COVID-19 pneumonia.

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
</table>

If such individuals develop symptoms such as fever and a dry continuous cough, they should immediately double their daily oral corticosteroid dosage and continue with this regimen until the fever subsides. 15 These guidelines also apply to patients who are receiving prolonged therapy (>3 months) with corticosteroids for underlying inflammatory conditions, including asthma, allergy, and rheumatoid arthritis. 19 In such patients whose condition worsens or in those experiencing vomiting or diarrhea, treatment with parenteral corticosteroids may be necessary. 19, 26 Administration of physiologic stress doses of corticosteroids (e.g., IV hydrocortisone 50-100 mg 3 times daily) and not pharmacologic doses should be considered in all cases to avoid potentially fatal adrenal failure. 19, 20 Additional study is needed to determine the optimum corticosteroid stress dosage regimen in patients with COVID-19. 26, 27 There is some evidence suggesting that continuous IV infusion of hydrocortisone (following an initial IV bolus dose) may provide more stable circulating cortisol concentrations in patients with adrenal insufficiency and reduce the potentially harmful effects of peak and trough concentrations of cortisol on the immune system. 26-27

**Pregnancy:** For pregnant women with COVID-19, the NIH COVID-19 Treatment Guidelines Panel states that a short course of corticosteroids that cross the placenta (i.e., betamethasone, dexamethasone) is routinely used for fetal benefit (e.g., to hasten fetal lung maturity). Given the potential benefit of decreased maternal mortality and the low risk of fetal adverse effects for this short course of corticosteroid therapy, the panel recommends the use of dexamethasone in pregnant women with COVID-19 who are receiving mechanical ventilation or in those who require supplemental oxygen but are not on mechanical ventilation. 24

The WHO Guideline Development Group recommends antenatal...
A total of 475 patients were enrolled with 55 of these patients receiving early, low-dose corticosteroids. Methylprednisolone 20 or 40 mg IV daily was administered to 50 of these patients for 3-5 days, and oral prednisone 20 mg daily (equivalent dosage to methylprednisolone) was administered to 5 such patients for 3 days. Corticosteroid therapy was initiated within a median of 2 days following hospital admission. A total of 420 patients received standard therapy (no corticosteroids); using propensity score matching, 55 of these patients were selected as matched controls. The primary outcome was the rate of patients who developed severe disease and mortality. In the corticosteroid treatment arm, 12.7% of patients developed severe disease compared with 1.8% of patients in the control group. There was one death in the group receiving methylprednisolone and none in the control group. Regarding secondary outcomes, duration of fever, virus clearance time, and length of hospital stay were all significantly longer in patients receiving corticosteroids compared with no corticosteroid therapy. Because of the finding that early, low-dose, short-term systemic corticosteroid therapy was associated with worse clinical outcomes in hospitalized adult patients with non-severe COVID-19 pneumonia, the authors concluded that the study results do not support the use of corticosteroids in this population. However, it is difficult to interpret these results because of potential confounding factors inherent in the nonrandomized study design. It is unclear if the results of this study apply to corticosteroids other than methylprednisolone.

Methylprednisolone multicenter quasi-experimental study with single pretest and posttest (NCT04374071): This trial was conducted to evaluate the efficacy of early, short-term therapy with systemic methylprednisolone in hospitalized adults with confirmed moderate to severe COVID-19 from a multicenter health system in Michigan. A total of 213 patients were enrolled with 132 patients receiving early therapy with IV methylprednisolone at dosages of 0.5-1 mg/kg daily in 2 divided corticosteroid therapy for pregnant women at risk of preterm birth from 24-34 weeks’ gestation when there is no clinical evidence of maternal infection and adequate maternal and newborn care are available. In cases where a pregnant woman presents with mild or moderate COVID-19, the clinical benefits of antenatal corticosteroids may outweigh the risk of potential harm to the woman. The balance of benefits and risks for the woman and preterm infant should be considered during the informed decision-making process.

**Pediatric use:** The safety and efficacy of dexamethasone or other corticosteroids for COVID-19 treatment have not been sufficiently evaluated in pediatric patients. Therefore, caution is warranted when extrapolating recommendations for adults to patients <18 years of age. Importantly, the RECOVERY trial did not include a significant number of pediatric patients, and mortality rates are significantly lower for pediatric patients with COVID-19 than for adult patients with the disease. Therefore, results of this trial should be interpreted with caution for patients <18 years of age. The NIH COVID-19 Treatment Guidelines Panel recommends use of dexamethasone for hospitalized pediatric patients with COVID-19 who are receiving high-flow oxygen, noninvasive ventilation, invasive mechanical ventilation, or ECMO. Dexamethasone is generally not recommended for pediatric patients who require only low levels of oxygen support (i.e., nasal cannula only). For pediatric patients with COVID-19, the NIH panel recommends dexamethasone at a dosage of 0.15 mg/kg (maximum dose 6 mg) once daily for up to 10 days. If dexamethasone is not available, alternative corticosteroids such as hydrocortisone, methylprednisolone, or prednisone may be considered. Additional studies are needed to evaluate the use of corticosteroids for the treatment of COVID-19 in pediatric patients, including in those with multisystem inflammatory syndrome in children (MIS-C). Although

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>A total of 475 patients were enrolled with 55 of these patients receiving early, low-dose corticosteroids. Methylprednisolone 20 or 40 mg IV daily was administered to 50 of these patients for 3-5 days, and oral prednisone 20 mg daily (equivalent dosage to methylprednisolone) was administered to 5 such patients for 3 days. Corticosteroid therapy was initiated within a median of 2 days following hospital admission. A total of 420 patients received standard therapy (no corticosteroids); using propensity score matching, 55 of these patients were selected as matched controls. The primary outcome was the rate of patients who developed severe disease and mortality. In the corticosteroid treatment arm, 12.7% of patients developed severe disease compared with 1.8% of patients in the control group. There was one death in the group receiving methylprednisolone and none in the control group. Regarding secondary outcomes, duration of fever, virus clearance time, and length of hospital stay were all significantly longer in patients receiving corticosteroids compared with no corticosteroid therapy. Because of the finding that early, low-dose, short-term systemic corticosteroid therapy was associated with worse clinical outcomes in hospitalized adult patients with non-severe COVID-19 pneumonia, the authors concluded that the study results do not support the use of corticosteroids in this population. However, it is difficult to interpret these results because of potential confounding factors inherent in the nonrandomized study design. It is unclear if the results of this study apply to corticosteroids other than methylprednisolone.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>------------------------------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td></td>
<td></td>
<td>doses for 3 days plus standard care and 81 patients receiving early therapy with standard care alone. The primary end point was a composite based on the need for ICU transfer, progression to respiratory failure requiring mechanical ventilation, or in-hospital all-cause mortality. The primary composite end point occurred at a significantly lower rate in the group receiving early corticosteroid therapy (34.9%) compared with the group receiving early therapy with standard care alone (54.3%). The early corticosteroid group had a median time to initiation of methylprednisolone of 2 days compared with 5 days for the standard care group. The median hospital length of stay was significantly reduced from 8 to 5 days in patients receiving early corticosteroid therapy compared with those receiving early therapy with standard care alone. ARDS occurred in 26.6% of patients receiving early corticosteroid therapy compared with 38.3% of those in the standard care group. The authors concluded that early, short-term therapy with methylprednisolone in patients with moderate to severe COVID-19 may prevent disease progression and improve clinical outcomes. <strong>Note:</strong> Limitations of this study include the following: differences were noted in the baseline characteristics of the comparator groups; some patients in the standard care group received corticosteroids, but initiation of therapy was significantly later than in the early corticosteroid group; and patient follow-up for both treatment groups was limited to 14 days. 51</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone open-label, multicenter, randomized, controlled study ([NCT04244591])</td>
<td></td>
<td></td>
<td>This recently completed trial compared use of methylprednisolone in conjunction with standard care in patients with confirmed COVID-19 infection that progressed to acute respiratory failure; results have not yet been posted. 23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retrospective, observational study of systemic corticosteroid use in patients with COVID-19 from a New York hospital (Keller et al)</td>
<td></td>
<td></td>
<td>Data are available for 1806 patients hospitalized with COVID-19 between Mar 11 and Apr 13, 2020. Patients included in immune globulin IV (IGIV) and/or corticosteroids generally have been used as first-line therapy in pediatric patients with MIS-C, the NIH COVID-19 Treatment Guidelines Panel recommends consultation with a multidisciplinary team when considering and managing immunomodulating therapy for children with this condition. The optimal choice and combination of immunomodulating therapies for children with MIS-C have not been definitely established. 24</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
the analysis were those treated with systemic corticosteroids (e.g., dexamethasone, hydrocortisone, methylprednisolone, prednisone) within the first 48 hours of hospital admission (140 patients) and those not treated with corticosteroids (1666 patients) as the control group. Treatment and control groups were similar except that corticosteroid-treated patients were more likely to have a history of COPD, asthma, rheumatoid arthritis, or lupus, or to have received corticosteroids in the year prior to admission. Primary goal of the study was to determine whether early systemic corticosteroid treatment was associated with reduced mortality or need for mechanical ventilation. Overall, early use of systemic corticosteroids was not associated with in-hospital mortality or mechanical ventilation. However, there was a significant treatment effect based on C-reactive protein (CRP) levels. Early use of corticosteroids in patients with initial CRP levels of ≥20 mg/dL was associated with a significantly reduced risk of mortality or need for mechanical ventilation (odds ratio: 0.23). Conversely, such treatment in patients with initial CRP levels of <10 mg/dL was associated with a significantly increased risk of mortality or need for mechanical ventilation (odds ratio: 2.64). The authors state that these findings suggest that appropriate selection of COVID-19 patients for systemic corticosteroid treatment is critical to maximize the likelihood of benefit and minimize the risk of harm. Note: The limitations of the observational study design should be considered when interpreting these results. Corticosteroid dosages used in patients included in this study not provided. Further study is needed to determine the role of CRP levels in guiding the use of corticosteroid treatment in patients with COVID-19. 36

Retrospective study of systemic corticosteroids and/or other immunosuppressive therapies and their effect on COVID-19 infection in patients with chronic immune-mediated inflammatory arthritis (Favalli et al): This study evaluated the frequency and characteristics of symptomatic COVID-19 infection in relation to use of different

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
</table>

Note: The limitations of the observational study design should be considered when interpreting these results. Corticosteroid dosages used in patients included in this study not provided. Further study is needed to determine the role of CRP levels in guiding the use of corticosteroid treatment in patients with COVID-19. 36

Retrospective study of systemic corticosteroids and/or other immunosuppressive therapies and their effect on COVID-19 infection in patients with chronic immune-mediated inflammatory arthritis (Favalli et al): This study evaluated the frequency and characteristics of symptomatic COVID-19 infection in relation to use of different
immunosuppressive agents in such patients. Data are available from a cross-sectional survey administered to 2050 adults receiving follow-up care at arthritis outpatient clinics of 2 large academic hospitals in Italy. Patients surveyed had arthritis of long duration (median of 10 years) and 62% were receiving therapy with biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) alone or in combination with conventional synthetic DMARDs; approximately one-third of these patients were also receiving concomitant long-term treatment with systemic corticosteroids. Laboratory-confirmed COVID-19 or highly suspected infection (based on close contact with a confirmed COVID-19 case within 14 days prior to onset of symptoms) was reported in 1.1 or 1.4% of patients, respectively. In this study, corticosteroid treatment was independently associated with an increased risk of COVID-19 infection, especially at prednisone dosages ≥ 2.5 mg daily. The use of corticosteroids was confirmed to independently predict increased risk of COVID-19 infection regardless of comorbidities, precautions taken to prevent infection, and contacts with COVID-19 cases. Conversely, treatment with biologic/targeted synthetic DMARDs was associated with a reduced risk of COVID-19 infection. Limitations of this study include its retrospective nature and the definition of COVID-19 cases based on patient survey results. The authors state these data should not result in indiscriminate discontinuance of systemic corticosteroids in patients with chronic immune-mediated inflammatory arthritis, but underscore the importance of a benefit-risk assessment in individual patients.

**Randomized, single-center, phase 2 trial (NCT03852537):** The SMART trial is evaluating the role of a biomarker-based corticosteroid dosing algorithm using methylprednisolone compared with usual care in hospitalized adults with COVID-19 and acute respiratory failure. Primary outcome measure: feasibility of the timely initiation of corticosteroids and implementation of biomarker-titrated corticosteroid dosing based on CRP concentrations. Clinical trial completed; results not yet published.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone, hydrocortisone, methylprednisolone, or prednisone studies for treatment of COVID-19 pneumonia or ARDS: Registered clinical trials that have been initiated or underway include: 22 NCT04263402 NCT04329650 NCT04344730 NCT04348305</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone non-randomized pilot study (NCT04355247): Trial has been initiated to evaluate use of the drug for the prevention of COVID-19 cytokine storm and progression to respiratory failure. 22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage</td>
<td>Comments</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td>Corticosteroids (inhaled)</td>
<td>68:04 Adrenals</td>
<td>Inhaled corticosteroids may mitigate local inflammation and inhibit virus proliferation.</td>
<td>There are currently limited results from randomized controlled studies specifically evaluating use of inhaled corticosteroids in patients with COVID-19.</td>
<td>In the STOIC trial, inhaled budesonide was administered as a dry powder inhaler at a dosage of 800 mcg twice daily for 4-10 days.</td>
<td>NIH COVID-19 Treatment Guidelines Panel recommends that inhaled corticosteroids used daily for the management of asthma and COPD to control airway inflammation should not be discontinued in patients with COVID-19 unless discontinuation is otherwise warranted based on their clinical condition. The panel also states that no studies to date have investigated the relationship between inhaled corticosteroids in these clinical settings and virus acquisition, severity of illness, or viral transmission.</td>
</tr>
</tbody>
</table>

**Updated 5/13/21**

Early reports of an unexpectedly low prevalence of chronic respiratory conditions among outpatients and hospitalized COVID-19 patients resulted in speculation that respiratory treatments, specifically inhaled corticosteroids, may have a protective effect against SARS-CoV-2 infection. 

Retrospective, observational study of inhaled corticosteroid use in patients with COPD or asthma and associated risk of COVID-19-related death in the UK (Schultze et al): 

This study was designed to assess the role of routine use of inhaled corticosteroids on COVID-19-related mortality. Data were extracted from primary care electronic health records and linked with mortality data for a cohort of patients with COPD (n = 148,557) and another cohort with asthma (n = 818,490) who were prescribed standard respiratory treatments within the 4 months prior to the index date. In patients with COPD, an increased risk of COVID-19-related death (hazard ratio: 1.39) was reported after adjusting for age and comorbidities among those who were prescribed inhaled corticosteroids combined with a long-acting β-agonist and/or long-acting antimuscarinic compared with those prescribed a long-acting β-agonist and long-acting antimuscarinic. In patients with asthma, an increased risk of COVID-19-related death (hazard ratio: 1.55) was reported in patients who were prescribed high-dose inhaled corticosteroids compared with those prescribed a short-acting β-agonist only; however, there was no increased risk of death (hazard ratio: 1.14) in asthma patients receiving low- or medium-dose inhaled corticosteroids compared with nonusers of inhaled corticosteroids. Sensitivity analyses suggest there may be other factors driving the increased risk of death observed with use of inhaled corticosteroids, including underlying disease differences between individuals that are not captured in the health records. The results of this study do not support evidence of benefit or harm with routine use of inhaled corticosteroids, including underlying disease differences between individuals that are not captured in the health records. 

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
of inhaled corticosteroids on COVID-19-related mortality among individuals with COPD or asthma. 44, 45

**Phase 2, randomized, controlled, open-label, parallel group study evaluating the use of inhaled budesonide in adults with early COVID-19 (NCT04416399; STOIC):** This trial was conducted to evaluate the use of inhaled budesonide compared with usual care in 146 nonhospitalized adults from the UK within 7 days of the onset of mild symptoms suggestive of COVID-19. COVID-19 infection was later confirmed by RT-PCR in 94% of these patients. Prior to randomization, the median duration of symptoms was 3 days. Total of 70 patients were randomized to receive inhaled budesonide as a dry powder inhaler at a dosage of 800 mcg twice daily and 69 patients were randomized to receive usual care, with a total of 139 patients included in the per-protocol analysis. In the budesonide group, the drug was administered for a median duration of 7 days. The primary end point was defined as an urgent care visit, emergency department assessment, or hospitalization. This outcome occurred in 10 patients (14%) from the usual care group compared with 1 patient (1%) from the budesonide group. In addition, fewer patients receiving inhaled budesonide had persistent symptoms at days 14 and 28 compared with those receiving usual care. Study results suggest that early administration of inhaled budesonide reduces the likelihood of needing urgent medical care, emergency department consultation, or hospitalization in patients with early COVID-19 illness. Use of inhaled budesonide was also associated with self-reported reduced time to symptom resolution from COVID-19 infection. 53

**Multicenter, randomized, controlled, open-label, adaptive platform study (not peer reviewed) evaluating the use of inhaled budesonide in adults in the community with suspected COVID-19 at higher risk of adverse outcomes (PRINCIPLE):** This trial compared the use of standard care alone, standard care plus inhaled budesonide, or standard care plus other interventions in nonhospitalized adults in the UK who had
suspected COVID-19 and were ≥65 years of age or ≥50 years of age with comorbidities. COVID-19 infection was later confirmed in 2617 (56%) of these patients, of which 2422 had follow-up data and, therefore, were included in the primary analysis. Patients were randomized to receive standard care alone (n=1028), standard care plus inhaled budesonide at a dosage of 800 mcg twice daily for 14 days (n=751), or standard care plus other interventions (n=643). The coprimary end points were time to first self-reported recovery and COVID-19-related hospitalization or death (both end points measured within 28 days after randomization). Inhaled budesonide appeared to reduce time to recovery by a median of 3 days in adults with COVID-19 who had comorbidities that put them at higher risk for complications. Among patients in the inhaled budesonide group who had 28 days of follow-up data, a lower rate of COVID-19-related hospitalization or death was observed compared with patients in the standard care group (8.5 versus 10.3%, respectively). Final data analysis is pending completion of 28-day follow-up for all patients randomized to receive inhaled budesonide.

A small case series from Japan observed possible clinical benefit in 3 patients with mild to moderate COVID-19 pneumonia following oral inhalation of ciclesonide; however, without a control group, it is not known whether the patients would have improved spontaneously.

Various clinical trials evaluating the use of inhaled corticosteroids (e.g., budesonide, ciclesonide) in patients with COVID-19 are registered at clinicaltrials.gov.

In patients with ARDS, various dosages of inhaled epoprostenol have been used; dosages up to 50 ng/kg per minute (titrated to response) have been used in clinical studies. It is not clear whether or how COVID-19-associated ARDS differs from ARDS related to other etiologies.

The Surviving Sepsis Campaign states that due to the lack of adequately powered randomized controlled studies, a recommendation cannot be made for or against the use of inhaled prostacyclins in COVID-19 patients with severe ARDS.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interferons</td>
<td>8:18.20 Interferons</td>
<td><em>Inhaled</em> epoprostenol has been suggested as an alternative to inhaled nitric oxide due to similar efficacy, lower potential for systemic adverse effects, lower cost, and ease of delivery. Experience with inhaled iloprost is more limited, but the drug is thought to have a similar theoretical benefit as epoprostenol in patients with ARDS.</td>
<td>with COVID-19 and refractory hypoxemia did not show significant improvement in oxygenation metrics following treatment with inhaled epoprostenol or inhaled nitric oxide. In this study, 38 patients initially received inhaled epoprostenol (starting dose of 0.05 mcg/kg per minute, continued based on PaO₂ response); 11 patients who did not respond to epoprostenol were transitioned to inhaled nitric oxide (starting dose of 20 ppm, titrated up to 80 ppm based on PaO₂ response). Although 42.1% of patients who received epoprostenol and 63.6% of patients who received nitric oxide were considered responders (defined as an increase in PaO₂/FiO₂ by &gt;10%), there were no significant changes in other oxygenation parameters or clinical outcomes. In another retrospective observational study in 80 mechanically ventilated COVID-19 patients, clinically significant improvement in PaO₂/FiO₂ (defined as an increase by 10% from baseline values) was observed in 50% of the patients following treatment with inhaled epoprostenol (initial dose of 50 ng/kg per minute delivered through the ventilator tubing); however, the benefit was generally modest and there was wide variability in response. Numerous limitations of the observational studies described above preclude definitive conclusions. Inhaled prostacyclins may be included in some COVID-19 clinical trials registered at clinicaltrials.gov.</td>
<td>In several observational studies in mechanically ventilated patients with COVID-19, inhaled epoprostenol was administered at an initial dosage of 50 ng/kg per minute (based on ideal body weight).</td>
<td>The NIH COVID-19 Treatment Guidelines Panel and the Surviving Sepsis Campaign state that a trial of inhaled pulmonary vasodilator may be considered as rescue therapy in mechanically ventilated adults with COVID-19, severe ARDS, and hypoxemia; if no rapid improvement in oxygenation is observed, the patient should be tapered off treatment.</td>
</tr>
<tr>
<td>Interferons</td>
<td>10:00 Antineoplastic Agents</td>
<td>Interferons (IFNs) modulate immune responses to some viral infections, in vitro studies indicate only weak induction of IFN following SARS-CoV-2 infection, and a possible role for IFNs in prophylaxis or early treatment of COVID-19 has been suggested to compensate for possibly insufficient endogenous IFN production.</td>
<td>Only limited clinical trial data available to date specifically evaluating efficacy of IFNs for treatment of COVID-19; for information on additional studies including IFN alfa or IFN beta as a component of combination therapy (e.g., background regimen), see antiviral entries in this Evidence Table. Various clinical trials evaluating IFN beta-1a, IFN beta-1b, or peginterferon [pegIFN] beta-1a, generally added to other antivirals, for treatment of COVID-19 are registered at clinicaltrials.gov. PegIFN beta-1a also is being evaluated for postexposure prophylaxis of SARS-CoV-2 infection.</td>
<td>IFN beta: Various sub-Q dosages of IFN beta-1a and IFN beta-1b are being evaluated for treatment of COVID-19. IFN beta-1a has been administered IV in some patients (IV preparation not commercially available in US). Sub-Q and IV routes of administration may not be equivalent. Bioavailability is lower following sub-Q injection, suggesting potential for less efficient distribution to central target organs, especially in critically ill patients. Efficacy and safety of IFNs for treatment or prevention of COVID-19 not established. Relative effectiveness of different IFNs against SARS-CoV-2 not established. NIH COVID-19 Treatment Guidelines Panel recommends against use of IFNs for treatment of severe or critical COVID-19, except in the context of a clinical trial. The panel also states there are insufficient data to recommend either for or against use of IFN beta for the treatment of early (i.e., &lt;7 days from infection).</td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage*</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Type 1 IFNs (IFN alfa and IFN beta)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>are active in vitro against MERS-CoV in Vero and LLCMK2 cells and in rhesus macaque model of MERS-CoV infection; type 1 IFNs also active in vitro against SARS-CoV-1 in Vero, fRhK-4, and human cell lines; IFN beta is more active than IFN alfa in vitro against SARS-CoV-1 and MERS-CoV.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN alfa and IFN beta are active in vitro against SARS-CoV-2 in Vero cells at clinically relevant concentrations; in vitro study suggests SARS-CoV-2 is more sensitive than SARS-CoV-1 to IFN alfa.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>However, lack of clinical benefit observed with use of type 1 IFNs, generally in combination with ribavirin, for treatment of SARS and MERS.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV IFN beta-1a did not reduce ventilator dependence or mortality in a placebo-controlled trial in patients with acute respiratory distress syndrome (ARDS).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 3 IFNs (IFN lambda)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>are thought to provide important immunologic defense against respiratory viral infections and may have less potential than type 1 IFNs to produce systemic inflammatory response, including inflammatory effects on respiratory tract; IFN lambda receptor is expressed mainly on epithelial (including respiratory epithelial) cells and</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Open-label, randomized study in Hong Kong in hospitalized adults with COVID-19, mainly mild disease (NCT04276688): Combination regimen of LPV/RTV, ribavirin, and sub-Q IFN beta-1b (IFN beta-1b was omitted to avoid proinflammatory effects when treatment was initiated 7-14 days after symptom onset) was associated with shorter median time from treatment initiation to negative RT-PCR result in nasopharyngeal swab (7 vs 12 days), earlier resolution of symptoms (4 vs 8 days), and shorter hospital stay (9 vs 14.5 days) compared with control (LPV/RTV). In the subset of patients initiating treatment 7 or more days after symptom onset (i.e., those not treated with IFN beta-1b), there was no significant difference in time to negative RT-PCR result, time to resolution of symptoms, or duration of hospital stay between the combination regimen (LPV/RTV and ribavirin) and control (LPV/RTV). IFN beta-1b (8 million units on alternate days) was administered for 1, 2, or 3 doses when initiated on day 5-6, 3-4, or 1-2, respectively, following symptom onset (median of 2 IFN beta-1b doses given); 52 of 86 patients (60%) randomized to combination regimen received all 3 drugs, and 41 patients received control LPV/RTV.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In an open-label, randomized study in hospitalized adults with severe COVID-19, IFN beta-1b 250 mcg was given sub-Q every other day for 2 weeks.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Open-label, randomized study in hospitalized adults with COVID-19, mainly mild disease (NCT04276688): IFN beta-1b 8 million units was given sub-Q on alternate days for 1, 2, or 3 doses (when initiated on day 5-6, 3-4, or 1-2, respectively, following symptom onset) in conjunction with 14-day regimen of LPV/RTV and ribavirin.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In an open-label, randomized study in hospitalized adults with severe COVID-19, IFN beta-1b 12 million units was given sub-Q 3 times weekly for 10 days.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN alfa:</td>
<td>National guidelines from China suggest IFN alfa dosage of 5 million units (or equivalent) twice daily via inhalation for up to 10 days for treatment of COVID-19.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PegIFN lambda-1a:</td>
<td>For treatment of COVID-19 in adults (NCT04354259): a single 180-mcg sub-Q dose of pegIFN lambda-1a was given.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For postexposure prophylaxis of CoV-2 infection in adults (NCT04344600): Two 180-mcg sub-Q doses of peginterferon lambda-1a given 1 week apart.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Interferon alfa via inhalation is included in national guidelines from China as a possible option for treatment of COVID-19.
neutrophils, and is distinct from the ubiquitous type 1 IFN receptor;\textsuperscript{2, 4, 7, 19} despite different receptors and expression patterns, type 1 and type 3 IFNs activate similar signaling cascades;\textsuperscript{4, 7, 19} unknown whether limited receptor distribution might also affect efficacy\textsuperscript{4}

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage\textsuperscript{a}</th>
<th>Comments</th>
</tr>
</thead>
</table>
| IFN group than in the control group (9 vs 11 days). A smaller proportion of IFN-treated patients required ICU admission (42 vs 67%). There was no difference in duration of hospitalization, intubation rate, length of ICU stay, or all-cause 28-day mortality.\textsuperscript{20}  
**Open-label, randomized study in** Iran in hospitalized adults with severe suspected or RT-PCR-confirmed COVID-19: **IFN beta-1a** (12 million units sub-Q 3 times weekly for 2 weeks) plus standard care (7- to 10-day regimen of hydroxychloroquine plus lopinavir/ritonavir or atazanavir/ritonavir) (n = 42) was compared with standard care (control; n = 39). Time to clinical response (primary outcome; defined as hospital discharge or 2-score improvement in a 6-category ordinal scale) did not differ significantly between the IFN beta-1a group and the control group (9.7 vs 8.3 days); durations of hospital stay, ICU stay, and mechanical ventilation also did not differ between the groups. Discharge rate on day 14 (67% vs 44%) was higher and 28-day overall mortality rate (19 vs 44%) was significantly lower with IFN beta-1a compared with control; early initiation of IFN beta-1a (<10 days after symptom onset), but not late initiation of the drug (≥10 days after symptom onset), was associated with reduced mortality. **NOTE:** Total of 92 patients were randomized; results are based on the 42 IFN beta-1a-treated patients and 39 control patients who completed the study. Diagnosis of COVID-19 was based on RT-PCR testing (64%) or clinical manifestations/imaging findings (36%). Other concomitant therapies included corticosteroids and immune globulin (IFN beta-1a group: 62 and 36%, respectively; control group: 44 and 26%, respectively). Patients were recruited from general, intermediate, and ICU wards; 45% of the IFN beta-1a-treated patients and 59% of the control patients were admitted to ICU; 36 and 44%, respectively, required invasive mechanical ventilation. Mean time from symptom onset to treatment initiation was 11.7 days for the IFN beta-1a group and 9.3 days for the control group.\textsuperscript{20} |
Large, multinational, open-label, randomized, adaptive trial launched by the World Health Organization (WHO) to evaluate effects of 4 different treatments compared with local standard of care in adults hospitalized with COVID-19 and not previously treated with any of the study drugs (SOLIDARITY; NCT04315948): The protocol-specified primary outcome is in-hospital mortality; protocol-specified secondary outcomes are initiation of ventilation and duration of hospitalization. **Interim results have been reported, including results for the IFN beta-1a treatment arm.** From March 22 to October 4, 2020, 2063 patients were randomized to receive IFN (given in conjunction with lopinavir and ritonavir \( n = 651 \) or standard of care \( n = 1412 \)) and 2064 patients were randomized to IFN control (either lopinavir and ritonavir or standard of care, for the respective IFN regimens). Most IFN-treated patients received three 44-mcg doses of IFN beta-1a sub-Q over 6 days; where IV IFN was available, patients on high-flow oxygen, ventilators, or ECMO received 10 mcg IV once daily for 6 days. Preliminary data analysis for the intention-to-treat (ITT) population indicated that IFN did not reduce in-hospital mortality (either overall or in any subgroup defined by age or ventilation status at study entry) and did not reduce the need for initiation of ventilation or the duration of hospitalization. The log-rank death rate ratio for IFN in the ITT population was 1.16; 243/2050 patients treated with IFN (12.9%) and 216/2050 control patients (11%) died. About one-half of the patients randomized to receive IFN or IFN control received corticosteroids; this did not appear to affect the death rate ratio. The clinical relevance of the difference in the pharmacokinetic profiles of sub-Q and IV IFN is unclear. 23, 28

**Phase 2, randomized, double-blind, multi-center, placebo-controlled study** (NCT04385095; SG016) evaluating SNG001 (inhaled IFN beta-1a) in adults with COVID-19: In the in-hospital portion of the study, patients received SNG001 (IFN beta-1a 6 million units via nebulizer once daily for up to 14 days) plus standard care or placebo.
plus standard care. The intention-to-treat population for the interim analysis included 48 patients treated with SNG001 and 50 patients given placebo. More patients in the SNG001 group had hypertension (69 vs 41%) and received oxygen at baseline (77 vs 58%), while more patients in the control group had diabetes mellitus (33 vs 12%) or cardiovascular disease (30 vs 19%). Median duration of symptoms before initiation of treatment was 10 days. Clinical outcomes were assessed on the WHO ordinal scale for clinical improvement; statistical models were adjusted for baseline and demographic factors. Hazard ratio for time to recovery (2.19) during the 14-day treatment period and odds ratios for recovery (3.19) and for improvement (2.32) on day 15 or 16 favored SNG001 over placebo. The study has been extended to include 120 patients in the home setting.\textsuperscript{16, 22, 27, 29}

Aerosolized IFN alfa (not commercially available in U.S.) has been used in China in children and adults for treatment of COVID-19,\textsuperscript{13, 14, 15} but limited clinical data presented to date.\textsuperscript{11} In a retrospective study of 77 hospitalized adults with moderate COVID-19 disease who received aerosolized IFN alfa-2b (5 million units twice daily) (n = 7), umifenovir (Arbidol\textsuperscript{®}) (n = 24), or both drugs (n = 46), time from symptom onset to negative RT-PCR result in throat swab appeared to be shorter in those receiving IFN alfa-2b alone or in combination with umifenovir compared with those receiving umifenovir alone; this exploratory study was small and nonrandomized, and treatment groups were of unequal size and demographically unbalanced in age, comorbidities, and time from symptom onset to treatment.\textsuperscript{15}

Retrospective cohort study in 446 hospitalized patients who received antiviral therapy for COVID-19 suggested that early IFN alfa-2b therapy (within first 5 days of hospitalization) was associated with reduced in-hospital mortality while late IFN alfa-2b therapy was associated with increased mortality and delayed recovery. In this study, 48.4% of patients received early IFN therapy, 6% received late IFN therapy, and
46% received no IFN. Median time from symptom onset to admission was 6 days, and median time from admission to first IFN dose was 2 or 8.5 days in the early or late IFN group, respectively. Median duration of IFN therapy was 10 or 8.5 days in the early or late IFN group, respectively.  

Preliminary, retrospective, single-center, matched case-control study in 104 patients hospitalized with COVID-19 suggested that **IFN alfa-2b therapy** (100,000 units by inhalation 4 times daily for 7 days) **did not reduce the duration of viral shedding**. Duration of viral shedding (based on 2 consecutive negative RT-PCR results) was not significantly different between the matched-pair groups (12 days in 32 IFN-treated patients vs 15 days in 32 control patients [no IFN treatment]).

**Randomized, double-blind, placebo-controlled trial** (NCT04354259) in 60 adults with confirmed SARS-CoV-2 infection: Patients who received **pegIFN lambda-1a** (single 180-mcg sub-Q injection) within 7 days of symptom onset or first positive nasal swab test (if asymptomatic) had **greater reduction in viral load** compared with those receiving placebo. By day 7 after treatment, 80% of pegIFN lambda-1a recipients and 63% of placebo recipients had undetectable SARS-CoV-2 RNA. After controlling for a higher baseline viral load in the pegIFN lambda-1a group compared with the placebo group (6.16 vs 4.87 log10 copies/mL; 5 vs 10 patients in these respective groups had undetectable SARS-CoV-2 RNA on day of randomization), patients in the pegIFN lambda-1a group were more likely to have undetectable viral RNA by day 7 after treatment (odds ratio 4.12; 95% CI 1.15-16.73). At low viral loads, viral clearance tended to occur rapidly regardless of treatment assignment. Studies establishing clinical benefit (e.g., effects on morbidity, mortality, or virus transmission) still required.

**Other trials evaluating sub-Q pegIFN lambda-1a** (not commercially available in U.S.) for **treatment or postexposure prophylaxis** of SARS-CoV-2 infection are registered at clinicaltrials.gov.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitric oxide (inhaled)</td>
<td>48:48 Vasodilating Agent</td>
<td>Selective pulmonary vasodilator with bronchodilatory and vasodilatory effects in addition to other systemic effects mediated through cGMP-dependent or independent mechanisms; may be useful for supportive treatment of acute respiratory distress syndrome (ARDS), a complication of COVID-19. Also has been shown to have antiviral effects. In vitro evidence of direct antiviral activity against severe acute respiratory syndrome coronavirus (SARS-CoV) has been demonstrated.</td>
<td>The available evidence indicates that inhaled nitric oxide can modestly improve oxygenation in patients with ARDS, but has no mortality benefit and may cause possible harm (e.g., renal impairment). It is not clear whether or how COVID-19-associated ARDS differs from ARDS related to other etiologies. Evidence supporting the use of inhaled nitric oxide in COVID-19 patients is currently limited. Various case reports, case series, and observational studies have described the use of inhaled nitric oxide in mechanically ventilated patients with COVID-19. Findings generally have been inconsistent, with some improvement in oxygenation reported in some studies and minimal to no improvement in others; various dosages of inhaled nitric oxide were used and patients were receiving other therapies confounding interpretation of the data. In a small cohort (n=6) of pregnant women with hypoxic respiratory failure secondary to COVID-19, intermittent twice-daily treatments with high-dose inhaled nitric oxide (160-200 ppm for 30 minutes to 1 hour administered to spontaneously breathing patients using a mask) improved systemic oxygenation. The decision to use a high dose of inhaled nitric oxide was based on prior reports showing broad antimicrobial effects of such high doses. However, fetal parameters and the development of acute kidney injury (a known complication of nitric oxide therapy) were not monitored. Results of a retrospective, single-center, observational study in intubated patients with COVID-19 and refractory hypoxemia did not show significant improvement in oxygenation metrics following treatment with inhaled epoprostenol or inhaled nitric oxide. In this study, 38 patients initially received inhaled epoprostenol (starting dose of 0.05 mcg/kg per minute, continued based on PaO2 response); 11 patients who did not respond to epoprostenol were transitioned to inhaled nitric oxide (starting dose of 20 ppm, titrated up to 80 ppm based on PaO2 response). Although 42.1%</td>
<td>In the Chen et al. study in severe SARS patients, inhaled nitric oxide therapy was given for ≥3 days (30 ppm on day 1, followed by 20 and 10 ppm on days 2 and 3, respectively, then weaned on day 4; therapy was resumed at 10 ppm if deteriorating oxygenation occurred). Dosages of inhaled nitric oxide used in patients with COVID-19 have varied. (See Trials or Clinical Experience.)</td>
<td>The NIH COVID-19 Treatment Guidelines Panel and the Surviving Sepsis Campaign recommend against the routine use of inhaled nitric oxide in mechanically ventilated adults with COVID-19 and ARDS. These experts state that a trial of inhaled pulmonary vasodilator may be considered as rescue therapy in mechanically ventilated adults with COVID-19, severe ARDS, and hypoxemia; however, if no rapid improvement in oxygenation is observed, the patient should be tapered off treatment.</td>
</tr>
</tbody>
</table>

Updated 1/28/21

Copyright © 2021, American Society of Health-System Pharmacists, Inc. All rights reserved. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International
of patients who received epoprostenol and 63.6% of patients who received nitric oxide were considered responders (defined as an increase in PaO$_2$/FiO$_2$ by >10%), there were no significant changes in other oxygenation parameters or clinical outcomes. Limitations of the study include its retrospective nature and small sample size.  

In a report describing administration of inhaled nitric oxide (initial dose 30 ppm; mean duration of therapy 2.1 days) to 39 spontaneously breathing patients with laboratory-confirmed COVID-19 (29 were initially admitted to the general medical floor and 24 of these patients later required transfer to the ICU), approximately half of the patients did not require invasive mechanical ventilation after treatment. These findings suggest a role of inhaled nitric oxide in preventing progression of hypoxic respiratory failure; however, randomized controlled studies are needed.  

In a single-center prospective study, 34 critically ill adults with COVID-19 received inhaled nitric oxide (10 ppm administered through the inspiratory limb of the ventilator tubing when PaO$_2$/FiO$_2$ <150). A response (defined as improvement in PaO$_2$/FiO$_2$ of >20% during the 30 minutes following administration) was achieved in 65% of the patients.  

Nitric oxide may be included in some COVID-19 clinical trials registered at clinicaltrials.gov.  

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruxolitinib (Jakafi®)</td>
<td>10:00 Antineoplastic Agents</td>
<td>Janus kinase (JAK) 1 and 2 inhibitor; may potentially combat cytokine release syndrome (CRS) in severely ill patients. May reduce inflammation via JAK inhibition, but study based on artificial intelligence (AI)-derived methodology suggests that clinically tolerated concentrations of ruxolitinib may be unlikely to reduce viral infectivity by disrupting</td>
<td>Although some small studies have suggested possibility of benefit from ruxolitinib in patients with COVID-19, 2 placebo-controlled, phase 3 trials have failed to meet key end points. Single-hospital retrospective chart review: Based on the hospital’s COVID-19 treatment algorithm, patients with severe COVID-19 were prospectively stratified using a newly developed clinical inflammation score (CIS; maximum score = 16); those identified as being at high risk for systemic inflammation (CIS ≥10, without sepsis) were evaluated for ruxolitinib treatment; Various dosages are being evaluated</td>
<td>NIH COVID-19 Treatment Guidelines Panel recommends against use of JAK inhibitors other than baricitinib (see Baricitinib entry in this table) for the treatment of COVID-19 except in the context of a clinical trial.</td>
<td></td>
</tr>
</tbody>
</table>
regulators of endocytosis (e.g., AP2-associated protein kinase 1 [AAK1]).  
(See Baricitinib entry in this table.)

Ability to inhibit a variety of proinflammatory cytokines, including interferon, has been raised as a possible concern with the use of JAK inhibitors in the management of hyperinflammation resulting from viral infections such as COVID-19.  

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
</table>
|         |            |           | 14 patients received ruxolitinib (median cumulative dose: 135 mg [52.5-285 mg], median treatment duration: 9 days [5-17 days]) initiated at a median of 15.5 days (5-24 days) after symptom onset. A decrease in CIS of ≥25% from baseline to day 7 was observed in 12 of 14 patients. At baseline, 10 required noninvasive ventilation, 3 required supplemental oxygen, and 1 required invasive ventilation.  
Prospective, randomized, single-blind, placebo-controlled study in adults with severe COVID-19: Patients received ruxolitinib (5 mg orally twice daily) plus standard care (n = 20) or placebo (ascorbic acid 100 mg orally twice daily) plus standard care (n = 21); no significant difference observed between ruxolitinib and placebo in time to clinical improvement (defined as hospital discharge or a 2-point improvement on a 7-category ordinal scale) although median time to improvement was numerically shorter with ruxolitinib (12 vs 15 days). Chest CT improvement observed at day 14 in greater proportion of ruxolitinib-treated vs placebo-treated patients (90 vs 62%). By day 28, 3 patients had died (all 3 in placebo group). Note: Median time from symptom onset to randomization was 20 days; most patients in both treatment groups received systemic corticosteroids (71%) and antivirals (90%). Study excluded critically ill and ventilator-dependent patients. Interpretation is limited by small sample size.  
Compassionate use of ruxolitinib in mainly older adults with RT-PCRConfirmed COVID-19 with severe respiratory manifestations but not requiring invasive mechanical ventilation in Italy: Patients (n = 34) received ruxolitinib (5 mg twice daily, increased to 10 mg twice daily or 25 mg daily if respiratory function not improved); ruxolitinib was initiated at a median of 8 days after symptom onset; median dose was 20 mg daily and median treatment duration was 13 days. Median patient age was 80.5 years (53% were ≥80 years of age and 35% were 60-79 years of age); 85% of patients had ≥2 comorbidities. Concomitant therapies included hydroxychloroquine (91%), | second patient; these cases differed in the timing of ruxolitinib initiation and the severity of COVID-19 illness.  
However, clinical trials have identified no substantial safety concerns with ruxolitinib in patients with COVID-19.  |
antimicrobials (77%), antivirals (62%), and corticosteroids (29%). Cumulative incidence of clinical improvement (decrease of ≥2 categories on a 7-category ordinal scale within 28 days) was 82%; overall survival at day 28 was 94%. Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with $\text{PaO}_2/\text{FiO}_2$ ratio <200. 17

**Compassionate use of ruxolitinib in combination with eculizumab** (a terminal complement inhibitor) in adults with RT-PCR-confirmed COVID-19 and associated pneumonia or acute respiratory distress syndrome (ARDS) in Italy: Consecutive patients received ruxolitinib (10 mg twice daily for 14 days) and eculizumab (900 mg IV once weekly for 2 or 3 doses) (n = 7) or best available therapy (n = 10; control). Greater improvement in median $\text{PaO}_2$ and $\text{PaO}_2/\text{FiO}_2$ ratio and greater increase in platelet count observed on day 7 in patients receiving ruxolitinib and eculizumab compared with control patients. All patients received antibiotic prophylaxis (azithromycin) and all patients except 2 in control group received hydroxychloroquine; greater proportion of patients in the ruxolitinib and eculizumab group compared with the control group received low-dose corticosteroids (5/7 vs 3/10) and sub-Q heparin (7/7 vs 5/10). Randomized, controlled trials needed to confirm these preliminary data. 15

**Small retrospective cohort study of adults with RT-PCR-confirmed COVID-19 and associated ARDS:** Total of 18 patients with $\text{PaO}_2/\text{FiO}_2$ ratio of 100 to <200 and rapid clinical worsening of respiratory function received ruxolitinib (20 mg twice daily for initial 48 hours, with subsequent stepwise dosage reductions based on response, for a maximum of 14 days of treatment); ruxolitinib was initiated at a median of 9 days after symptom onset. Other therapies were used according to local practice. Clinical improvements in respiratory function within 48 hours and avoidance of mechanical ventilation reported in 16 patients; spontaneous breathing with $\text{pO}_2$ >98% reported on day 7 in 11 patients; no response reported in 2 patients. No patients died. 18

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>antimicrobials (77%), antivirals (62%), and corticosteroids (29%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Compassionate use of ruxolitinib in combination with eculizumab</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Small retrospective cohort study of adults with RT-PCR-confirmed COVID-19 and associated ARDS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Phase 3 randomized, double-blind, placebo-controlled, global clinical trial (NCT04362137; RUXCOVID) failed to confirm efficacy of ruxolitinib in 432 patients ≥12 years of age with COVID-19-associated cytokine storm (sponsored by Novartis/Incyte). Manufacturer announced results (not peer reviewed) indicating that ruxolitinib (5 mg orally twice daily for 14 days, with possible extension to 28 days) plus standard care did not reduce the proportion of patients experiencing severe complications (death, respiratory failure requiring mechanical ventilation, or ICU admission) by day 29, compared with standard care alone (12 vs. 11.8%); in addition, no clinically relevant benefits were observed among secondary or exploratory end points, including mortality rate by day 29 and time to recovery.

Phase 3, randomized, double-blind, placebo-controlled clinical trial (NCT04377620; RUXCOVID-DEVENT; 369 DEVENT) failed to confirm the primary efficacy end point for ruxolitinib in 211 patients ≥12 years of age with COVID-19-associated acute respiratory distress syndrome (ARDS) who required mechanical ventilation (sponsored by Incyte). Manufacturer announced results (not peer reviewed) indicating that ruxolitinib (5 or 15 mg orally twice daily) plus standard care did not reduce all-cause mortality (adjusted for ARDS severity) through day 29 compared with placebo plus standard care (5 mg vs. placebo: 55.2 vs. 74.3%; 15 mg vs. placebo: 51.8 vs. 69.6%). Manufacturer announced that a mortality benefit was observed when data for both dosages were pooled; a mortality benefit also was observed for both the 5- and 15-mg dosages in the subset of patients enrolled in the U.S. (n = 191). Most patients received concurrent or prior therapy with remdesivir (55%) and corticosteroids (90%). The study was terminated at the time of the above planned interim analysis. Initial targeted enrollment was 500 patients.

Expanded-access (managed-access, compassionate use) program (NCT04337359) for adults and children ≥6 years of age with COVID-19 associated acute respiratory distress syndrome (ARDS).
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarilumab (Kevzara®)</td>
<td>92:36 Disease-modifying Anti-rheumatic Drug</td>
<td>Recombinant humanized monoclonal antibody specific for the interleukin-6 (IL-6) receptor; IL-6 is a proinflammatory cytokine. Sarilumab may potentially combat cytokine release syndrome (CRS) and pulmonary symptoms in severely ill patients</td>
<td>Results from randomized clinical trials evaluating efficacy of sarilumab in the treatment of patients with COVID-19 have been conflicting. Based on encouraging results in China with a similar drug, tocilizumab, a large, U.S.-based, phase 2/3, randomized, double-blind, placebo-controlled, adaptively designed study (NCT04315298) evaluating efficacy and safety of sarilumab in patients hospitalized with severe COVID-19 was performed. Patients in this study were randomized (2:2:1) to receive sarilumab 400 mg, sarilumab 200 mg, or placebo. Randomization was stratified by severity of illness (e.g., severe, critical, multisystem organ dysfunction) and use of systemic corticosteroids. In the phase 2 part of the study, sarilumab at both dosages reduced C-reactive protein (CRP) levels. The primary efficacy outcome measure in phase 3 was the change on a 7-point scale; this phase was modified to focus on the 400-mg dose of sarilumab in the critically ill patient group. During the course of the trial, there were many amendments that increased the sample size and modified the dosing strategies, and multiple interim analyses were performed. The results did not demonstrate a clinical benefit of sarilumab for any of the disease severity subgroups or dosing strategies studied. A second manufacturer-sponsored phase 3 clinical trial was conducted in countries outside the U.S. (Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Spain) in 420 severely or critically ill patients hospitalized with COVID-19 did not show a clinical benefit of sarilumab for any of the disease severity subgroups or dosing strategies studied. A second manufacturer-sponsored phase 3 clinical trial was conducted in countries outside the U.S. (Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Spain) in 420 severely or critically ill patients hospitalized with COVID-19 did not show a clinical benefit of sarilumab for any of the disease severity subgroups or dosing strategies studied.</td>
<td>Large US-based controlled study (NCT04315298): Dosage of 400 mg IV as a single dose or multiple doses (based on protocol criteria); the lower-dose (200-mg) treatment arm was discontinued following a preliminary analysis of study results (see Trials or Clinical Experience) In the REMAP-CAP trial, patients received a single 400-mg IV dose</td>
<td>NIH COVID-19 Treatment Guidelines Panel states that there are insufficient data for the Panel to recommend either for or against use of sarilumab for hospitalized patients with COVID-19 who are within 24 hours of admission to the ICU and who require invasive mechanical ventilation, noninvasive ventilation, or high-flow oxygen (&gt;0.4 FiO₂/30 L/min oxygen flow) (see Tocilizumab in this Evidence Table.) No new safety findings observed with use in COVID-19 patients</td>
</tr>
</tbody>
</table>
meet its primary endpoint and key secondary endpoint when sarilumab was compared with placebo in addition to usual hospital care. Although not statistically significant, trends were observed toward a decrease in duration of hospital stay, an acceleration in time to improved clinical outcomes, reduced mortality in the critically ill patient group not seen in the severely ill group, and a shortened time to discharge. 9, 11

Multicenter, ongoing, international open-label trial using a randomized, embedded multifactorial adaptive platform (NCT02735707; REMAP-CAP): This trial randomized patients to multiple interventions within multiple domains. In the COVID-19 immune modulation therapy domain, adults with suspected or confirmed COVID-19 following admission to an ICU for respiratory or cardiovascular organ support were randomized to receive either tocilizumab (353 patients; 8 mg/kg by IV infusion over 1 hour; dose may be repeated 12-24 hours later) or sarilumab (48 patients; single 400-mg dose by IV infusion over 1 hour) or standard care (402 patients; control group; corticosteroids were included as standard of care) within 24 hours of commencing organ support in an intensive care unit. Over 80% of the patients in the study received corticosteroids. The primary outcome was an ordinal scale combining in-hospital mortality and days free of organ support to day 21. Compared with standard care, treatment with sarilumab or tocilizumab decreased in-hospital mortality (mortality was 22% for sarilumab and 28% for tocilizumab vs 36% for the standard of care). Compared with standard of care, sarilumab and tocilizumab also improved in-hospital survival and increased the number of organ support-free days. 7, 13

Italian case series (Benucci et al.) describes 8 patients hospitalized with COVID-19 pneumonia at one hospital in Florence treated with sarilumab (initial 400-mg IV dose followed by 200-mg IV doses after 48 and 96 hours) in addition to standard therapy (hydroxychloroquine, azithromycin, darunavir, cobicistat, enoxaparin).
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Siltuximab (Sylvant®)</td>
<td>10:00 Antineoplastic agents</td>
<td>Recombinant chimeric monoclonal antibody specific for the interleukin-6 (IL-6) receptor; may potentially combat cytokine release syndrome (CRS) symptoms (e.g., fever, organ failure, death) in severely ill patients 1-5</td>
<td>Only limited, unpublished data available describing efficacy in patients with COVID-19.</td>
<td>In the SISCO study in Italy, patients received an initial dose of siltuximab 11 mg/kg by IV infusion over 1 hour; a second dose could be administered at the physician’s discretion 4.</td>
<td>Efficacy and safety of siltuximab in the treatment of COVID-19 not established. NIH COVID-19 Treatment Guidelines Panel recommends against use of siltuximab in the treatment of COVID-19, except in a clinical trial 9. Pediatric use: Safety and efficacy of siltuximab have not been established in pediatric patients 4, 9.</td>
</tr>
</tbody>
</table>

**Various clinical trials evaluating siltuximab for the treatment of COVID-19** are registered at clinicaltrials.gov. 10

Siltuximab was used in these patients because of a lack of tocilizumab at this institution. Seven of the patients demonstrated an improvement in oxygenation and lung echo score and were discharged within 14 days; the remaining patient died in 13 days. 8

Various clinical trials evaluating siltuximab for the treatment of COVID-19 are registered at clinicaltrials.gov. 10

| Sirolimus (Rapamune®) | 92:44 Immunosuppressive agent; mammalian target of rapamycin (mTOR) inhibitor | mTOR complex 1 (mTORC1) is involved in the replication of various viruses, including coronavirus 1, 2, 5. | A few clinical trials evaluating sirolimus for the treatment of COVID-19 are registered at clinicaltrials.gov. | Various dosing regimens are being evaluated in registered trials 11. | Although possible clinical application, current data not specific to COVID-19; additional study needed 11. |

**Various clinical trials evaluating sirolimus for the treatment of COVID-19** are registered at clinicaltrials.gov. 10

Sirolimus was used in these patients because of a lack of tocilizumab at this institution. Seven of the patients demonstrated an improvement in oxygenation and lung echo score and were discharged within 14 days; the remaining patient died in 13 days. 8
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tocilizumab (Actemra®)</td>
<td>92:36 Disease-modifying Anti-rheumatic Drug</td>
<td>Recombinant humanized monoclonal antibody specific for the interleukin-6 (IL-6) receptor; IL-6 is a proinflammatory cytokine. Tocilizumab may potentially combat cytokine release syndrome (CRS) and pulmonary symptoms in severely ill COVID-19 patients.</td>
<td>Results from randomized clinical trials evaluating efficacy of tocilizumab in the treatment of patients with COVID-19 have been conflicting, but suggest possible efficacy. In preliminary data from a non-peer-reviewed, single-arm, observational Chinese trial (Xu et al.) involving 21 patients with severe or critical COVID-19 infection, patients demonstrated rapid fever reduction and a reduced need for supplemental oxygen within several days after receiving tocilizumab (initially given as a single 400-mg dose by IV infusion; this dose was repeated within 12 hours in 3 patients because of continued fever).</td>
<td>Tocilizumab is typically given IV to treat cytokine release syndrome (CRS) and in patients with COVID-19; however, the drug has been given subcutaneously in some patients.</td>
<td>Emergency use authorization (EUA) for tocilizumab: FDA issued an EUA on June 24, 2021 that permits use of tocilizumab for treatment of COVID-19 in hospitalized adults and pediatric patients ≥2 years of age who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). FDA states that, based on review of data from an open-label, controlled, platform trial (NCT04381936; RECOVERY); a double-blind, placebo-controlled trial (NCT04320615; COVACTA); a double-blind, placebo-controlled trial (NCT04372186; EMPACTA); and a double-blind, placebo-controlled trial (NCT04409262; REMDAC); it is reasonable to believe that tocilizumab may be effective for the treatment of COVID-19 in the patient population specified in the tocilizumab EUA and, when used under the conditions described in the EUA, the known and potential benefits of tocilizumab when used to treat COVID-19 in such patients outweigh the known and potential risks.</td>
</tr>
</tbody>
</table>

**Updated 7/15/21**

- In one study, treatment with sirolimus 2 mg daily in conjunction with corticosteroids for 14 days was associated with improved patient outcomes (e.g., shortened duration of mechanical ventilation, improved hypoxia and multiorgan function).
- T cell dysregulation has been observed in patients with severe COVID-19 and is thought to be a possible cause of cytokine storm; when given early prior to the cytokine storm phase, sirolimus may prevent progression to severe COVID-19 by restoring T-cell functionality.
- This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMPACTA</td>
<td></td>
<td></td>
<td>In the REMAP-CAP trial, patients received a single dose of 8 mg/kg based on actual body weight (up to a maximum of 800 mg) by IV infusion; this dose could be repeated 12–24 hours later at the discretion of the treating clinician.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**A single-center, retrospective observational study of 20 kidney transplant recipients in Italy with COVID-19 hospitalized for pneumonia included 6 patients who received tocilizumab.** Half of the patients experienced reduced oxygen requirements and 2 (33%) showed improved radiologic findings following administration; 2 (33%) of the 6 tocilizumab-treated patients died. 12

**Italy:** A prospective, open, single-arm, multicenter study evaluated use of tocilizumab in 63 hospitalized adults with severe COVID-19. Patients received either tocilizumab IV (8 mg/kg) or SQ (324 mg) based on drug availability; a second dose given within 24 hours was administered to 52 of the 63 patients. Following tocilizumab administration, fevers resolved in all but one patient within 24 hours and C-reactive protein (CRP), ferritin, and D-dimer levels declined from baseline to day 14. The PaO₂/Fio₂ ratio improved between admission and Day 7. Overall mortality was 11%. Tocilizumab appeared to be well tolerated. 13

Zhang et al. from China reported on a patient with COVID-19 and multiple myeloma who appeared to be successfully treated with tocilizumab. 13

**France:** An investigator-initiated, multicenter, open-label, randomized clinical trial (CORIMUNO-TOCI, NCT04331808) evaluated tocilizumab in patients hospitalized at Assistance Publique – Hôpitaux de Paris hospitals in Paris. 15, 16, 20 Sixty-four out of 131 adults with moderate to severe COVID-19 pneumonia not requiring intensive care upon admission were randomized to receive tocilizumab 8 mg/kg (1–2 doses) along with standard of care, and 67 patients were randomized to receive standard of care alone. Tocilizumab did not reduce scores on the World Health Organization 10-point Clinical Progression Scale (WHO-CPS) to <5 on day 4 but may have reduced the risk of noninvasive ventilation, mechanical ventilation, or death by day 14. No difference in day 28 mortality was found. 20

In the REMAP-CAP trial, patients received a single dose of 8 mg/kg based on actual body weight (up to a maximum of 800 mg) by IV infusion; this dose could be repeated 12–24 hours later at the discretion of the treating clinician. 21

Based on the results from the REMAP-CAP and RECOVERY trials, the NIH COVID-19 Treatment Guidelines Panel recommends a single 8-mg/kg dose (based on actual body weight) of tocilizumab by IV infusion (up to a maximum of 800 mg) in addition to dexamethasone (6 mg daily for ≤10 days) in certain patients (see Comments column). An alternative corticosteroid to dexamethasone may be used in a therapeutically-equivalent dosage. The Panel states that data are insufficient to determine which patients, if any, would benefit from an additional dose of tocilizumab. 19

**US/Global randomized, placebo-controlled trial (manufacturer sponsored; COVACTA):** Evaluated an initial IV infusion of 8 mg/kg (up to a maximum dose of 800 mg); one additional dose was given if symptoms worsened or showed no improvement. 18

**Boston Area COVID-19 Consortium (BACC) Bay Tocilizumab Trial** used a single 8-mg/kg IV dose (up to a maximum dose of 800 mg). 19

**EMPACTA trial** used an initial IV infusion of 8 mg/kg (up to a maximum dose of 800 mg); an additional dose was given 8–24 hours later if symptoms worsened or showed no improvement. 26

Consult the tocilizumab EUA letter of authorization, 23 EUA fact sheet for healthcare providers, 24 and EUA fact sheet for patients, parents and caregivers 25 for additional information.

NIH COVID-19 Treatment Guidelines Panel has revised recommendations regarding the use of tocilizumab in patients with COVID-19 based on the collective evidence from clinical trials reported to date. 9

The Panel recommends use of tocilizumab (single IV dose of 8 mg/kg of actual body weight, up to 800 mg) in combination with dexamethasone (6 mg daily for ≤10 days) in certain hospitalized patients who are exhibiting rapid respiratory decompensation caused by COVID-19. 9

1) Recently hospitalized patients (e.g., within 3 days) admitted to the ICU within the prior 24 hours and who require invasive mechanical ventilation, noninvasive ventilation, or high-flow oxygen (>0.4 FIO₂/30 l/min oxygen flow) by nasal cannula. 9

2) Recently hospitalized patients (e.g., within 3 days) not admitted to the ICU with rapidly increasing oxygen needs who require noninvasive ventilation or high-flow nasal cannula oxygen and who have significant inflammatory markers of inflammation (CRP ≥75 mg/L). 9

For hospitalized patients with hypoxemia who require conventional oxygen therapy, the Panel states that there is currently insufficient evidence to specify which of these patients would benefit from the addition of tocilizumab. Some Panel members would also use tocilizumab in patients exhibiting rapidly increasing oxygen needs while on dexamethasone and who have a CRP ≥75 mg/L, but who do not yet require noninvasive ventilation or high-flow oxygen as described above. 9
US/Global randomized, placebo-controlled trial: Manufacturer (Roche) conducted a randomized, double-blind, placebo-controlled phase 3 trial (COVACTA; NCT04320615) in collaboration with the US Health and Human Services’ Biomedical Advanced Research Development Authority (BARDA). The study evaluated safety and efficacy of tocilizumab in combination with standard of care compared with placebo in adults hospitalized with severe COVID-19 pneumonia. The trial failed to meet its primary endpoint of improved clinical status at week 4 (determined using a 7-point scale to assess clinical status based on need for intensive care and/or ventilator use and requirement for supplemental oxygen) and several key secondary endpoints, including the key secondary endpoint of reduced patient mortality.18

Boston Area COVID-19 Consortium (BACC) Bay Tocilizumab Trial: In this investigator-driven, randomized, placebo-controlled trial (NCT04356937), 243 adults with confirmed severe COVID-19, hyperinflammatory states, and at least 2 of the following signs: fever (body temperature >38°C), pulmonary infiltrates, or need for supplemental oxygen in order to maintain SpO2 >92% were randomly assigned in a 2:1 ratio to receive standard care plus a single IV dose of either tocilizumab (8 mg/kg) or placebo. The primary outcome was intubation or death, assessed in a time-to-event analysis. Secondary efficacy outcomes were clinical worsening and discontinuation of supplemental O2 among patients who had been receiving it at baseline, both assessed in time-to-event analyses. 58% of the enrolled patients were men, median age was 59.8 years (range: 21.7 to 85.4 years), and 45% of patients were Hispanic or Latino. The hazard ratio for intubation or death in the tocilizumab group compared with the placebo group was 0.83 (P = 0.64), and the hazard ratio for disease worsening was 1.11 (P = 0.73). At 14 days, 18% of the pts in the tocilizumab group and 14.9% of those in the placebo group had worsening of disease. Median time to discontinuation of supplemental O2 was 5 days in the tocilizumab group and 4.9 days in the placebo group.

The Panel states that use of tocilizumab should be avoided in patients with significant immunosuppression, particularly in those with a history of recent use of biologic immunomodulating drugs; alanine transaminase levels >5 times the upper limit of normal; high risk for GI perforation; uncontrolled, serious bacterial, fungal, or non-SARS-CoV-2 viral infection; or absolute neutrophil count <500 cells/µL; platelet count <50,000 cells/µL, or known hypersensitivity to tocilizumab.9

In addition, the Panel states the following:

Tocilizumab should only be given in combination with dexamethasone (or another corticosteroid at an equivalent dose).9

Some clinicians may assess a patient’s clinical response to dexamethasone first before deciding whether tocilizumab is needed.9

Although some patients in the REMAP-CAP and RECOVERY trials received a second dose of tocilizumab at the treating physician’s discretion, there are insufficient data to determine which patients, if any, would benefit from an additional dose of the drug.9

Cases of severe and disseminated strongyloidiasis reported with the use of tocilizumab and corticosteroids in patients with COVID-19. Prophylactic ivermectin should be considered for individuals who are from areas where strongyloidiasis is endemic.9

Pediatric use: There are insufficient data to recommend either for or against tocilizumab for the treatment of hospitalized children with COVID-19 or multi-system inflammatory syndrome of children (MIS-C). Tocilizumab has been used in children to treat cytokine release syndrome associated with CAR-T
group (P = 0.69). At 14 days, 24.6% of patients in the tocilizumab group and 21.2% of those in the placebo group were still receiving supplemental O₂. Patients who received tocilizumab had fewer serious infections than patients who received placebo. Tocilizumab was not found to be effective for preventing intubation or death in moderately ill hospitalized patients with COVID-19 in this study. Some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide. 19

**Multicenter, ongoing, international open-label trial using a randomized, embedded multifactorial adaptive platform (NCT02735707; REMAP-CAP):** This trial randomized patients to multiple interventions within multiple domains. In the COVID-19 immune modulation therapy domain, adults with suspected or confirmed COVID-19 following admission to an ICU for respiratory or cardiovascular organ support were randomized to receive either tocilizumab (353 patients; 8 mg/kg by IV infusion over 1 hour; dose may be repeated 12-24 hours later) or sarilumab (48 patients; single 400-mg dose by IV infusion over 1 hour) or standard care (402 patients; control group; corticosteroids were included as standard of care) within 24 hours of commencing organ support in an intensive care unit. Over 80% of the patients in the study received corticosteroids. The primary outcome was an ordinal scale combining in-hospital mortality and days free of organ support to day 21. Compared with standard care, treatment with sarilumab or tocilizumab decreased in-hospital mortality (mortality was 22% for sarilumab and 28% for tocilizumab vs 36% for the standard of care). Compared with standard of care, sarilumab and tocilizumab also improved in-hospital survival and increased the number of organ support-free days. 9, 21

**Randomized, controlled, open-label, platform trial (NCT04381936; RECOVERY):** The RECOVERY trial is assessing several possible treatments in patients hospitalized with COVID-19 in hospitals throughout the UK. Up to 21 days following the

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>cell therapy and systemic and polyarticular juvenile idiopathic arthritis. 9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The role of routine cytokine measurements (e.g., IL-6, CRP) in determining the severity of and treating COVID-19 requires further study. 14</td>
</tr>
</tbody>
</table>
initial (main) randomization and regardless of the initial treatment allocation, participants in the RECOVERY trial with clinical evidence of progressive COVID-19 characterized by hypoxia ($O_2$ saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (CRP concentrations \(\geq 75\) mg/L) could be considered for randomization in a 1:1 ratio to tocilizumab (400-800 mg, based on weight, by IV infusion; a second dose could be given within 12-24 hours) plus usual care or usual care alone. Between April 23, 2020 and January 24, 2021, 4116 adults of 21,550 patients enrolled in the RECOVERY trial were included in the assessment of tocilizumab, including 3385 patients (82%) who were receiving systemic corticosteroid therapy. The mean age of enrolled patients was 63.6 years. The primary outcome measure was 28-day mortality; 621 of 2022 patients (31%) in the tocilizumab group died within 28 days compared with 729 of 2094 patients (35%) in the standard of care group. Patients who received tocilizumab also were more likely to be discharged from the hospital alive within 28 days than those receiving standard of care alone (57 versus 50%, respectively). Among patients not receiving invasive mechanical ventilation at baseline, tocilizumab was associated with a substantially lower risk of progressing to invasive mechanical ventilation or death compared with standard of care alone (35 versus 42%, respectively). These benefits were seen in all prespecified patient subgroups, including those receiving invasive mechanical ventilation, non-invasive respiratory support, or no respiratory support other than simple oxygen. Patients concurrently receiving corticosteroids and tocilizumab showed a clear benefit. There was no evidence that tocilizumab had any effect on the chance of successful cessation of invasive mechanical ventilation. 22

Global, randomized, double-blind, placebo-controlled, phase 3 trial (NCT04372186; Evaluating Minority Patients with Actemra [EMPACTA]): The EMPACTA trial assessed efficacy and safety of IV tocilizumab combined with standard of care (e.g., antivirals,
corticosteroids, supportive care) in adults hospitalized with COVID-19 pneumonia who were not receiving mechanical ventilation. Enrollment of patients from high-risk and racial and ethnic minority populations was emphasized in this study. Overall, 389 patients from 6 countries were randomized in a 2:1 ratio to receive IV tocilizumab (1 or 2 doses of 8 mg/kg up to a maximum of 800 mg per dose) plus standard care or placebo plus standard care. More than 25% of the patients were >65 years of age and more than 75% had at least one coexisting condition; more than 80% of the patients were in a minority racial or ethnic group (Hispanic or Latino, Black, or American Indian or Alaska Native). The primary efficacy outcome was a composite of invasive mechanical ventilation or death by day 28, and favored tocilizumab over placebo (12 versus 19.3% in the tocilizumab and placebo groups, respectively; p = 0.04). However, there was no difference between the groups in all-cause mortality at day 28. Various clinical trials evaluating tocilizumab for the treatment of COVID-19 are registered at clinicaltrials.gov.  

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>------------------------------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td>Vitamin D Updated 4/30/21</td>
<td>88:16 Vitamin D</td>
<td>Vitamin D receptor is expressed on immune cells (e.g., B cells, T cells, antigen-presenting cells); these cells can synthesize and respond to active vitamin D. 10,13</td>
<td>Only limited prospective clinical trial evidence regarding efficacy of vitamin D supplementation for treatment or prevention of COVID-19.</td>
<td>Various dosages of vitamin D are being evaluated for prevention or treatment of COVID-19. 4</td>
<td>Efficacy of vitamin D supplementation in the prevention or treatment of COVID-19 has not been established. 1,2,3 Some experts recommend maintaining recommended levels of vitamin D intake during the COVID-19 pandemic to maintain bone and muscle health and avoid deficiency. 2,1,14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vitamin D modulates innate and adaptive immune responses; may downregulate proinflammatory cytokines and upregulate anti-inflammatory cytokines, increase T regulatory cell activity, and reduce cytokine storm induced by innate immune system. 10,12,13</td>
<td>Prevention of respiratory infections: Efficacy of vitamin D supplementation for prevention of influenza or other respiratory infections is unclear. 10 Meta-analysis of 25 randomized, double-blind, placebo-controlled trials including a total of 11,321 participants, either healthy or with comorbidities, indicated a protective effect for oral vitamin D supplementation against acute respiratory infection. 5 A second systematic review and meta-analysis of 15 randomized controlled trials involving approximately 7000 healthy individuals found that vitamin D supplementation did not reduce the risk of respiratory infections compared with placebo or no treatment. 11</td>
<td>High concentrations of vitamin D may cause hypercalcemia and nephrocalcinosis; 1 currently no convincing scientific evidence that very high intake of vitamin D will be beneficial in preventing or treating COVID-19. 14</td>
<td>NIH COVID-19 Treatment Guidelines Panel states that there are insufficient data to recommend either for or against use of vitamin D for prevention or treatment of COVID-19. 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In an animal model of gram-negative bacterial-induced acute lung injury (ALI), vitamin D modulated expression of renin, angiotensin II, angiotensin-converting enzyme (ACE) 1, and ACE2, and attenuated ALI; studies needed to determine relevance to SARS-CoV-2 infection. 12,31</td>
<td>Outcomes in critically ill patients: Results of 2 randomized, double-blind, placebo-controlled clinical trials (VIOLET, VITdAL-ICU) in critically ill patients with vitamin D deficiency (but not with COVID-19) indicated that high-dose vitamin D supplementation did not reduce hospital stay or mortality compared with placebo. Patients in both studies received a single enteral dose of 540,000 international units (IU; units) of vitamin D₃; patients in VITdAL-ICU also received oral maintenance doses (90,000 units monthly for 5 months). 6,7</td>
<td>National Academy of Sciences (NAS) guidelines for adequate dietary intake of vitamin D for bone health in US population: Estimated Average Requirement (EAR) in children and adults 1-70 years of age is 400 units (10 mcg) daily; Recommended Dietary Allowance (RDA) in these age groups is 600 units (15 mcg) daily. In adults &gt;70 years of age, EAR is 400 units (10 mcg) daily and RDA is 800 units (20 mcg). These reference values assume minimal sun exposure. 26</td>
<td>Joint guidance from the American Society for Bone and Mineral Research (ASBMR), American Association of Clinical Endocrinologists (AACE), Endocrine Society, European Calcified Tissue Society (ECTS), National Osteoporosis Foundation (NOF), and International Osteoporosis Foundation (IOF) emphasizes importance of obtaining the recommended daily dosage of vitamin D; for those unable to obtain recommended durations of direct sun exposure during the pandemic, recommended intake of vitamin D can be obtained through supplemental vitamin D. The joint guidance states that current data do not provide any evidence that vitamin D supplementation will help prevent or treat COVID-19. 7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vitamin D deficiency is associated with increased autoimmunity and increased susceptibility to infection. 10,13</td>
<td>Outcomes in patients with COVID-19: Retrospective study (NCT04560608) in frail geriatric patients (mean age: 88 years; range: 78-100 years) hospitalized with COVID-19 suggested lower frequency of severe COVID-19 disease and lower 14-day mortality in those who received regular oral vitamin D supplementation (50,000 units monthly or 80,000 or 100,000 units every 2–3 months) over the prior year (n = 29) compared with those who received no supplementation, either over the prior year or following COVID-19 diagnosis (n = 32).</td>
<td>NAS states that data indicate that a serum 25-hydroxyvitamin D concentration of 50 nmol/L is sufficient to meet the needs of 97.5% of the population and concentrations &lt;30 nmol/L are associated with clinical deficiency. 26</td>
<td>Recommendations from the UK National Institute for Health and Care Excellence (NICE) state that there is insufficient evidence to recommend use of vitamin D supplements solely to prevent or treat COVID-19, except as part of a clinical trial. However, all individuals should continue to follow current recommendations on daily vitamin D supplementation to maintain bone and muscle health during the pandemic. 8</td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage*</td>
<td>Comments</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Vitamine D deficiency also is more common in older patients and patients with obesity and hypertension (factors potentially associated with worse COVID-19 outcomes).&lt;sup&gt;1, 20, 21, 23-25, 27&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Association also suggested between vitamin D and diabetes mellitus (a condition also associated with worse COVID-19 outcomes).&lt;sup&gt;20, 22, 27&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical trials are evaluating the relationship between vitamin D concentration and COVID-19 disease severity and mortality;&lt;sup&gt;4&lt;/sup&gt; some retrospective observational data suggest an association between vitamin D concentration and COVID-19 risk or severity/mortality,&lt;sup&gt;15-18, 28, 32&lt;/sup&gt; but may not account for potential confounding factors.&lt;sup&gt;17, 19, 25&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meta-analysis of 26 observational studies reporting vitamin D concentrations in adults and elderly patients with COVID-19 suggested an association between vitamin D deficiency and COVID-19 severity; however, potential for bias in most of the studies was considered high.&lt;sup&gt;30&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prospective observational study in non-elderly adults admitted to a COVID-19 care center indicated higher prevalence of vitamin D deficiency (defined as serum 25-hydroxyvitamin D concentration &lt;20 ng/mL) on admission (97 versus 32%) in patients with severe COVID-19 disease requiring ICU admission.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supplemental oral vitamin D (single 80,000-unit dose) given shortly after COVID-19 diagnosis (&lt;i&gt;n&lt;/i&gt; = 16) did not improve outcomes.&lt;sup&gt;25&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**App-based community survey, conducted mainly in the UK: COVID-19 Symptom Study app subscribers in the UK who self-reported regular use of vitamin D supplements (>3 times/week for ≥3 months) had a modest 9% lower risk of testing positive for SARS-CoV-2 than those who did not report regular use; stratification of data by sex showed an association in women but not in men. The analysis included data for 372,720 UK app users who reported having had a SARS-CoV-2 test and completed a dietary supplement questionnaire. The overall finding of an association between vitamin D supplementation and lower risk of testing positive for SARS-CoV-2 was replicated in smaller numbers of US and Swedish app users; however, findings based on sex varied in the different cohorts.<sup>39</sup>**

**Randomized, open label, pilot study in hospitalized adults with confirmed COVID-19: Total of 76 patients were randomized 2:1 to receive oral calcifediol (0.532 mg on day of admission, then 0.266 mg on days 3 and 7 followed by 0.266 mg weekly until discharge or ICU admission) in conjunction with standard care (including 6-day hydroxychloroquine regimen and 5-day azithromycin regimen) or standard care alone (control). ICU admission was reported for 1/50 calcifediol-treated patients (2%) and 13/26 control patients (50%). All calcifediol-treated patients were discharged; 24 control patients were discharged and 2 died. The odds ratio for ICU admission in calcifediol-treated patients vs control patients was 0.02; odds ratio was 0.03 after adjustment for the higher prevalence of hypertension and type 2 diabetes mellitus in the control group. Data on serum vitamin D concentrations were not available. Larger placebo-controlled trials with well-matched groups are needed to confirm these pilot results.<sup>33</sup>**

**Randomized, double-blind, placebo-controlled trial (NCT04449718) in 240**
### Drug(s)

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc</td>
<td></td>
<td>Trace mineral involved in immune function, including antibody and white blood cell production; an important cofactor for many enzymes; may improve wound healing</td>
<td>No evidence from controlled trials that zinc is effective in the prevention or treatment of COVID-19</td>
<td>Zinc Recommended Dietary Allowance (RDA): Adult males: 11 mg/day; adult females: 8 mg/day</td>
<td>Despite some anecdotal claims in the media that zinc is effective in treating COVID-19, it remains unclear whether zinc supplementation is beneficial in the prophylaxis and/or treatment of COVID-19; further study is needed.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zinc deficiency increases proinflammatory cytokine</td>
<td>Retrospective observational study in New York City (Carlucci et al; non-peer-reviewed): Data were collected from electronic medical records to compare outcomes between hospitalized patients with COVID-19 who received hydroxychloroquine, azithromycin, and zinc (411 patients)</td>
<td></td>
<td>NIH COVID-19 Treatment Guidelines Panel states that there are insufficient clinical data to recommend either for</td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>----------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Zinc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rationale</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zinc</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Enhances</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>cytotoxicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>induces</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>apoptosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>when used</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>in vitro</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>with a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>zinc ionophore (e.g., chloroquine):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chloroquine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>can enhance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>intracellular</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>zinc uptake</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>in vitro</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elderly patients and patients with</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>certain concurrent medical conditions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>are at higher risk of zinc deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>and those who received hydroxychloroquine and azithromycin alone (521 patients). Zinc was given as a zinc sulfate 220-mg capsule (50 mg of elemental zinc) twice daily for 5 days. The addition of zinc did not affect the length of hospitalization, duration of ventilation, or duration of ICU stay, but patients in the treatment group that included zinc were discharged home more frequently and the need for ventilation, ICU admission, and mortality or transfer to hospice for patients not admitted to the ICU were all reduced in univariate analyses. After adjusting for the timing of when zinc was added to the protocol, findings remained significant for increased frequency of being discharged home and reduction in mortality or transfer to hospice in the zinc-treated patients. Because of the study design and its limitations, the authors state that this study should not be used to guide clinical practice, but that the observations do support initiation of randomized controlled trials investigating zinc in patients with COVID-19.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multicenter, retrospective, cohort study in New York City hospitals (Yao et al; non-peer-reviewed): This study reviewed the records of 3473 hospitalized adults with laboratory-confirmed COVID-19 who were admitted to 4 New York City hospitals between March 10 and May 20, 2020. The primary aim of the study was to compare rates of in-hospital mortality among patients who received zinc plus hydroxychloroquine and those not receiving this combination. Out of 3473 patients, 1006 (29%) received zinc and hydroxychloroquine in combination and 2467 (71%) received hydroxychloroquine without zinc. Zinc plus hydroxychloroquine was associated with a 24% reduced risk of in-hospital mortality compared with patients who did not receive the combination (12 versus 17% respectively; p&lt;0.001). In addition, hospital discharge rates were substantially higher in patients receiving the combination versus those who did not (72 versus 67%; p=0.003). Neither zinc nor hydroxychloroquine alone were associated with decreased mortality rates. There are several limitations to this study. It was a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Appropriate dosage regimens not established in either the prophylaxis or treatment of COVID-19; various supplementation regimens being evaluated in clinical trials, with a maximum dosage of zinc sulfate of 220 mg (50 mg of elemental zinc) twice daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NIH COVID-19 Treatment Guidelines Panel recommends against using zinc supplementation above the RDA for the prevention of COVID-19, except in a clinical trial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zinc concentrations are difficult to measure accurately since it is distributed as a component of various proteins and nucleic acids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adverse effects may include nausea (possibly dose dependent), vomiting, and changes in taste</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Long-term zinc supplementation may cause copper deficiency with adverse hematologic (e.g., anemia, leukopenia) and neurologic effects (e.g., myelopathy, paresthesia, ataxia, spasticity); zinc supplementation for as little as 10 months has been associated with copper deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intranasal administration should be avoided because of reports of prolonged or permanent loss of the sense of smell; intranasal zinc formulations are no longer commercially available in the US</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Potential for interactions with iron and copper, certain antibiotics (e.g., quinolones, tetracyclines), and other medications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>retrospective in design and patients were not randomized to treatments. In addition, it was not known whether patients were taking zinc and/or hydroxychloroquine prior to admission. The treatment groups were not balanced; patients receiving zinc plus hydroxychloroquine were more likely to be male and Black and to have a higher body mass index and diabetes. Patients receiving zinc plus hydroxychloroquine were also treated more often with corticosteroids and azithromycin and less often with lopinavir/ritonavir than those who did not receive this combination.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Randomized, open-label study (NCT04342728; COVID A to Z) in an outpatient setting in 214 adults with confirmed SARS-CoV-2 infection: A 10-day oral regimen of ascorbic acid (8 g daily given in 2 or 3 divided doses with meals), zinc gluconate (50 mg at bedtime), or both supplements in combination failed to reduce the time required to achieve a 50% reduction in symptom severity, as compared with usual care alone. The mean number of days from peak symptom score to 50% resolution of symptoms (including fever/chills, cough, shortness of breath, and fatigue, each rated on a 4-point scale) was 5.5 days with ascorbic acid, 5.9 days with zinc, 5.5 days with ascorbic acid and zinc, or 6.7 days with usual care alone. Target enrollment was 520 patients; the study was stopped early for futility.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Randomized clinical trial conducted at 3 major university hospitals in Egypt (NCT04447534): 191 patients with a laboratory-confirmed diagnosis of COVID-19 were randomized to receive either zinc sulfate 220 mg (50 mg of elemental zinc) twice daily in combination with hydroxychloroquine or hydroxychloroquine alone for 5 days; patients in both treatment groups also received standard of care therapy. Hydroxychloroquine was given in a dosage of 400 mg twice daily on the first day, then 200 mg twice daily for 5 days. The primary efficacy endpoints were recovery within 28 days, the need for mechanical ventilation, and death. No significant differences were found between the 2 groups of patients in the percentage of patients who</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-----------------------------</td>
<td>----------------------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>recovered within 28 days (79.2% in the zinc plus hydroxychloroquine group and 77.9% in the hydroxychloroquine group), the need for mechanical ventilation, or overall mortality.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Retrospective observational study at a single institution (Hoboken University Medical Center): This study collected data on 242 patients with laboratory-confirmed COVID-19 who were admitted to the hospital. 196 of the patients (81%) received a total daily dosage of zinc sulfate 440 mg (100 mg of elemental zinc); 191 of these patients (97%) also received hydroxychloroquine. The primary outcome was days from admission to in-hospital mortality. The primary analysis explored the causal relationship between zinc administration and patient survival. There were no significant differences in baseline characteristics between the 2 groups of patients. 73 patients (37.2%) died in the zinc group compared with 21 patients (45.7%) in the control group. In the primary analysis, which used inverse probability weighting (IPW), the effect estimate of zinc therapy was an additional 0.84 days of survival. This finding was considered imprecise. On multivariate Cox regression analysis with IPW, zinc therapy was not significantly associated with a change in the risk of in-hospital mortality and the use of interleukin-6 inhibitors was associated with reduced mortality. Older patients, male patients, and those with severe or critical disease were significantly associated with increased mortality.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Zinc is being evaluated in a number of clinical trials in both the prophylaxis and treatment of COVID-19, sometimes in combination with other supplements (including vitamin C and vitamin D) and drugs (including hydroxychloroquine)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosagea</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>------------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| **ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs)**  
*Updated 4/30/21* | 24:32 Renin-Angiotensin-Aldosterone System Inhibitor | **Hypothetical harm:** Human pathogenic coronaviruses bind to their target cells through angiotensin-converting enzyme 2 (ACE2).  
1, 4, 7 Expression of ACE2 may be increased in patients treated with ACE inhibitors or ARBs.  
1, 4, 8 Increased expression of ACE2 may potentially facilitate COVID-19 infections.  
**Hypothetical benefit:** ACE inhibitors or ARBs may have a protective effect against lung damage or may have paradoxical effect in terms of virus binding.  
1, 2, 6 | Only limited data available to date evaluating the effect of these drugs on COVID-19 infection.  
1, 3, 9, 15-18 Large, observational study analyzed a cohort of pts tested for COVID-19 to evaluate the relationship between previous treatment with 5 common classes of anti-hypertensive agents (including ACE inhibitors, ARBs) and the likelihood of a positive or negative test result for COVID-19 as well as the likelihood of severe COVID-19 illness among pts who tested positive: Study included data obtained from a large health network in New York City for 12,594 pts who were tested for COVID-19 from Mar 1 to Apr 15, 2020. Among these pts, 4357 (34.6%) had a history of hypertension. Of these patients, 2573 (59.1%) tested positive for COVID-19. Among the 2573 pts with hypertension and positive results for COVID-19, 634 pts (24.6%) had severe disease (i.e., indicated by ICU admission, mechanical ventilation, or death). Results of COVID-19 testing were stratified in propensity-score-matched patients with hypertension according to previous treatment with selected antihypertensive agents. Propensity-score matching was based on age, sex, race, BMI, medical history, various comorbidities, and other classes of medications. The authors stated that no substantial increase was observed in the likelihood of a positive test for COVID-19 or in the risk of severe COVID-19 among patients who tested positive in association with any single antihypertensive class (including ACE inhibitors, ARBs).  
13 Large, population-based case-control study was conducted to evaluate the association between the use of RAAS blockers (including ACE inhibitors, ARBs) and the risk of COVID-19: Study included data obtained from a regional healthcare database in the Lombardy region of Italy for 6272 case pts with confirmed severe COVID-19 acute respiratory syndrome from Feb 21 to Mar 11, 2020 who were | | American Heart Association (AHA), American College of Cardiology (ACC), Heart Failure Society of America (HFSA), and European Society of Cardiology (ESC) recommend continuation of treatment with renin-angiotensin-aldosterone system (RAAS) antagonists in those patients who are currently prescribed such agents.  
2, 3 These experts state there is a lack of experimental or clinical data demonstrating beneficial or adverse outcomes among COVID-19 patients receiving ACE inhibitors or ARBs. Further study is needed.  
4, 3 NIH COVID-19 Treatment Guidelines Panel states patients who are receiving an ACE inhibitor or ARB for cardiovascular disease (or other non-COVID-19 indications) should not discontinue these drugs during acute management of COVID-19 unless discontinuation is otherwise warranted by their clinical condition. The panel recommends against use of ACE inhibitors or ARBs for the treatment of COVID-19 except in the context of a clinical trial. These experts state that it is unclear whether use of ACE inhibitors or ARBs has a positive or negative impact on the treatment and clinical outcomes of COVID-19. Meta-analyses and ongoing reviews have not found an association between the use of such medications and the likelihood of a positive result from SARS-CoV-2 testing or on the severity or outcomes of COVID-19 infection.  
9 Patients with cardiovascular disease are at an increased risk of severe COVID-19.  
4, 9 Abrupt withdrawal of RAAS inhibitors in high-risk patients (e.g., heart failure patients, patients with prior myocardial infarction) may lead to clinical instability and adverse health outcomes.  
8 |
matched to 30,759 controls based on sex, age, and place of residence. Information about use of selected drugs and clinical profiles was obtained from regional healthcare databases. Use of ACE inhibitors or ARBs was more frequent in patients with COVID-19 than among controls because of their higher prevalence of cardiovascular disease. Percentage of patients receiving ACE inhibitors was 23.9% for case pts and 21.4% for controls. Percentage of patients receiving ARBs was 22.2% and 19.2% for case and control pts, respectively. The authors concluded that there was no evidence that treatment with ACE inhibitors or ARBs significantly affected the risk of COVID-19 or altered the course of infection or resulted in more severe disease.

Large, multinational, retrospective study analyzed outcome data for hospitalized pts with confirmed COVID-19 to evaluate the relationship between cardiovascular disease and preexisting treatment with ACE inhibitors or ARBs with COVID-19 (Mehra et al; now retracted): Original publication included multinational data for 8910 pts hospitalized with COVID-19 between Dec 20, 2019 and Mar 15, 2020 that were obtained from a global healthcare data collaborative. The authors concluded that those data confirmed previous observations suggesting that underlying cardiovascular disease is independently associated with an increased risk of death in hospitalized pts with COVID-19. They also stated that they were not able to confirm previous concerns regarding a potential harmful association of ACE inhibitors or ARBs with in-hospital mortality.  

Note: This published study has now been retracted by the publisher at the request of the original authors. Concerns were raised with respect to the veracity of the data and analyses that were the basis of the authors’ conclusions.

Multicenter, prospective study in a cohort of hospitalized pts with confirmed COVID-19 infection to evaluate the association of antihypertensive therapy with ACE inhibitors or ARBs and the risk of severe COVID-19 or worsening of clinical outcomes.
Trials or Clinical Experience

(NCT04357535; Hakeam et al): Data are available for 338 patients from 4 hospitals in Saudi Arabia. On the day of hospital admission, 245 of these patients (72.5%) were receiving ACE inhibitors or ARBs; 197 of these patients continued such antihypertensive therapy during hospitalization. On the day of hospital admission, 93 patients (27.5%) were receiving antihypertensive therapy (e.g., calcium-channel blockers, β-blockers, thiazide diuretics) that did not include either ACE inhibitors or ARBs. The primary study end point was the rate of developing severe COVID-19 on the day of hospitalization. The key secondary end point was a composite of mechanical ventilation and in-hospital mortality. In the study cohort, 98 patients (29%) met the WHO criteria for severe COVID-19 on the day of hospitalization. However, use of ACE inhibitors or ARBs was not associated with development of severe COVID-19 (odds ratio: 1.17). Use of ACE inhibitors or ARBs prior to hospitalization also was not associated with ICU admission, mechanical ventilation, or in-hospital mortality. In addition, continuing such antihypertensive therapy during non-ICU hospitalization was associated with decreased mortality (odds ratio: 0.22). The authors concluded that patients with hypertension or cardiovascular disease receiving therapy with ACE inhibitors or ARBs prior to hospitalization for COVID-19 do not appear to be at increased risk for severe infection upon hospital admission. In addition, ICU admission, mechanical ventilation, and mortality are not associated with use of ACE inhibitors or ARBs prior to hospitalization. Because of a lower risk of mortality, the authors advise that ACE inhibitor or ARB therapy be continued in pts with COVID-19 during hospitalization. However, because of study limitations, randomized controlled trials are needed for further assessment of the effects of ACE inhibitors or ARBs on COVID-19.  

Multicenter, open-label, randomized study in hospitalized pts with mild to moderate COVID-19 to evaluate the effect of discontinuation versus continuation of ACE inhibitors or ARBs on clinical outcomes (NCT04364893; Lopes et al): Data are
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
</table>
|         |            |           | available for 659 adults from 29 hospitals in Brazil who were receiving ACE inhibitors or ARBs prior to hospitalization. In the primary analysis, 334 of these patients were randomized to discontinue ACE inhibitors or ARBs and 325 patients were assigned to continue use of such medication for 30 days. The primary study end point was the number of days alive and out of the hospital from randomization through 30 days. Key secondary end points included death during the 30-day follow-up period, cardiovascular death, and COVID-19 progression. No significant difference was observed in the mean number of days alive and out of the hospital for patients in the discontinuation group (21.9 days) compared with patients in the continuation group (22.9 days). There were also no significant differences between the discontinuation and the continuation groups in the incidence of death (2.7 versus 2.8%, respectively), cardiovascular death (0.6 versus 0.3%, respectively), or COVID-19 progression (38.3 versus 32.3%, respectively). The authors concluded that these findings do not support the routine discontinuation of ACE inhibitors or ARBs among hospitalized patients with mild to moderate COVID-19 when there is an indication for such use. Limitations of this trial include the open-label study design and the lack of generalizability of results to COVID-19 patients in other settings. The study also was not designed to evaluate the effect of ACE inhibitors or ARBs on susceptibility to COVID-19.  


Other clinical trials evaluating the effect of continuing or discontinuing treatment with ACE inhibitors or ARBs on clinical outcomes in patients with COVID-19 are registered at clinicaltrials.gov. |       |          |
Anticoagulants

**Updated 5/13/21**

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticoagulants</td>
<td>20:12.04 Anti-coagulants</td>
<td>Patients with COVID-19, particularly those with severe disease, may develop a hypercoagulable state, which can contribute to poor outcomes (e.g., progressive respiratory failure, acute respiratory distress syndrome [ARDS], death).</td>
<td>Retrospective study in China: Reduced mortality was observed in COVID-19 patients with severe sepsis-induced coagulopathy or markedly elevated D-dimer levels (&gt;6 x ULN) who received prophylactic anticoagulation (low molecular weight heparin [LMWH] or unfractionated heparin [UFH]).</td>
<td>See Comments column for available dosage-related information.</td>
<td>The available evidence to inform the clinical management of COVID-19-associated coagulopathy is continuously evolving.</td>
</tr>
</tbody>
</table>

Most common pattern of coagulopathy is characterized by elevated D-dimer levels, high fibrinogen levels, minimal prolongation of aPTT and/or PT, and mild thrombocytopenia; microvascular and macrovascular thrombosis also have been reported. In addition, high rates of VTE have been observed in critically ill patients with COVID-19.

Pathogenesis of COVID-19-related coagulopathy not completely known, but may be associated with endothelial cell activation and other factors contributing to an uncontrolled immunothrombotic response to the virus.

Lupus anticoagulants have been detected in some patients with COVID-19 who present with prolonged aPTT. However, clinical significance of these antibodies is not known.

Such thrombotic findings are the basis for anticoagulant therapy in COVID-19 patients; some anticoagulant agents also may have antiviral and anti-inflammatory properties.

Observational cohort study using data (n=4297) from the US VA system: Early initiation of prophylactic anticoagulation (within 24 hours of admission for COVID-19) was associated with a 27% decreased risk of 30-day mortality compared with no anticoagulation; post-hoc analysis indicated that evidence of benefit appeared to be most pronounced in patients who did not require ICU care within the first 24 hours of admission. Results of this study provide some evidence to support recommendations for use of prophylactic anticoagulation in hospitalized COVID-19 patients (see Comments column).

Several retrospective studies suggest that high-intensity prophylactic anticoagulation or therapeutic anticoagulation may be associated with lower mortality compared with standard VTE prophylaxis in severe COVID-19 patients.

Retrospective study in a large cohort (n=786) of hospitalized patients with COVID-19: Systemic anticoagulation was associated with reduced risk of mortality; in the subgroup of patients who required mechanical ventilation, mortality rate was reduced with the use of therapeutic anticoagulation compared with no anticoagulation (29 versus 63%; median survival of 21 versus 9 days).

Subsequent retrospective study involving a larger cohort of patients (n=4389) from the same health system: Use of prophylactic or therapeutic anticoagulation was associated with lower in-hospital mortality compared with no anticoagulant therapy (adjusted hazard reductions of 50 and 47%, respectively). Overall bleeding rates were low, but higher in the therapeutic anticoagulation group (3%) compared with the prophylactic or no anticoagulation groups.

Several organizations (e.g., NIH, WHO, CDC, American Society of Hematology [ASH], International Society for Thrombosis and Haemostasis, Anticoagulation Forum, Surviving Sepsis Campaign, Mayo Clinic) have published interim guidance for anticoagulation management in patients with COVID-19. These experts agree that hospitalized patients with COVID-19 should receive prophylactic-dose anticoagulation to reduce the risk of thromboembolism unless there are contraindications.

However, many questions regarding the best prophylactic strategy in COVID-19 patients remain unanswered (e.g., type and intensity of anticoagulation, duration of anticoagulation, use of biomarkers for VTE risk stratification).

VTE risk should be assessed in all hospitalized patients with COVID-19.

While initial reports suggested that bleeding is infrequent in COVID-19 patients, more information regarding the risk of bleeding is emerging.

Standard risk factors for bleeding should be considered and patients should be individually assessed to balance risk of thrombosis with risk of bleeding.

The NIH COVID-19 Treatment Guidelines Panel issued the following recommendations for VTE prophylaxis in COVID-19 patients:

1) Hospitalized nonpregnant adults with COVID-19: Prophylactic-dose anticoagulation is recommended.

2) Pregnant patients hospitalized with severe COVID-19: Prophylactic-dose anticoagulation is recommended unless contraindicated; if antithrombotic therapy is prescribed prior to the diagnosis.
### Drug(s) | AHFS Class | Rationale | Trials or Clinical Experience | Dosage | Comments
--- | --- | --- | --- | --- | ---

Among 26 autopsies performed in this cohort of patients, 42% had evidence of thromboembolic disease not otherwise suspected premortem; the majority of these patients were not treated with therapeutic anticoagulation. 40

In other observational studies, intermediate-dose or therapeutic-dose anticoagulation in COVID-19 patients did not provide a mortality benefit over standard-dose prophylaxis and/or was associated with an increased risk of clinically significant adverse effects (e.g., bleeding). 46, 61, 62, 69

All of the aforementioned studies have important limitations such as their retrospective nature, small sample size, confounding variables (e.g., other treatments administered), and lack of information and consistency with regard to anticoagulation indication, doses, and regimens; therefore, confirmation of findings in randomized controlled studies is required. 26, 31, 38, 40, 42, 44, 45, 50, 52, 61, 62, 69

Some retrospective studies have evaluated the impact of a tailored anticoagulant approach (e.g., risk stratification based on D-dimer and other clinical and laboratory parameters) or an escalated-dose thromboprophylaxis approach based on severity of disease. 52, 57

**Phase 2 randomized open-label study (HESACOVID):** Administration of therapeutic-dose enoxaparin in 20 mechanically ventilated COVID-19 patients was associated with improved oxygenation (PaO2/FiO2 ratio), decreased D-dimer levels, and a higher rate of successful liberation from mechanical ventilation compared with prophylactic-dose anticoagulation. The study was insufficiently powered to assess mortality. 53

**Meta-analysis of 5 observational studies in critically ill or acutely ill COVID-19 patients conducted by the American Society of Hematology:** No difference was observed in risk of VTE and mortality between patients treated with prophylactic dose anticoagulation and those treated with higher doses of anticoagulation; critically ill patients who received intermediate- or of COVID-19 in a pregnant patient, such therapy should be continued. 28

3) **Hospitalized children with COVID-19:** Indications for VTE prophylaxis should be the same as those for children without COVID-19. 28

4) **Nonhospitalized patients with COVID-19:** Anticoagulants should not be initiated for the prevention of VTE or arterial thrombosis unless the patient has other indications for such therapy or is participating in a clinical trial. 28

LMWH is generally preferred for VTE prophylaxis; however, specific drug characteristics (e.g., pharmacokinetics, route of administration, drug interaction potential), patient-specific factors (e.g., renal function), and practical concerns (e.g., need for frequent monitoring, convenience of administration, risk of medical staff exposure) may influence choice of anticoagulant. 14, 15, 20, 27, 28, 30, 32, 44, 54, 59

There is currently debate about the appropriate intensity of anticoagulation for VTE prevention in COVID-19 patients. 43, 44 Because of the severity of coagulopathy in critically ill COVID-19 patients and reports of high rates of VTE despite routine prophylaxis, some clinicians suggest a more aggressive anticoagulation strategy using intermediate or therapeutic dosages of anticoagulants in such patients; however, current data is limited (see Trials or Clinical Experience Column) and well-designed randomized controlled studies are needed to evaluate these approaches. 8, 11, 14-17, 20-24, 26-28, 50-52, 54, 34, 36, 39, 43, 44, 48, 59

Based on expert opinion, interim guidance from the Anticoagulation Forum (published in July 2020) suggests increased doses of VTE prophylaxis (e.g., enoxaparin 40 mg BID, enoxaparin 0.5 mg/kg BID, heparin 7500 units sub-Q 3 times daily, or low-intensity heparin infusion) for critically ill patients (e.g., in the ICU) with confirmed or suspected COVID-19. 28
### Drug(s) | AHFS Class | Rationale | Trials or Clinical Experience | Dosage | Comments
--- | --- | --- | --- | --- | ---
| | | | therapeutic-dose anticoagulation had lower odds of PE (OR 0.09) but higher odds of major bleeding (OR 3.84). | | 

**Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4 trials):** NIH launched this series of adaptive platform trials to evaluate safety and efficacy of various anticoagulants in different COVID-19 patient populations including outpatient, inpatient, and convalescent.  

Large multipatform, adaptive-design trial that includes 3 global studies (REMAP-CAP, ATTACC, ACTIV-4A): This trial was initiated to address the question of whether more intensive anticoagulation is indicated in critically ill or moderately ill COVID-19 patients; the primary outcome of this trial is “organ-support-free days.” As of December 21, 2020, enrollment of patients requiring ICU-level care (defined as requiring high-flow nasal oxygen, invasive or noninvasive mechanical ventilation, vasopressor therapy, or ECMO support) was paused due to results of an interim pooled analysis demonstrating futility of full-dose anticoagulation in reducing the need for organ support and mortality compared with usual care prophylactic-dose anticoagulation. Enrollment is continuing for hospitalized patients not requiring ICU support (i.e., moderately ill patients) in these trials to determine whether there is any benefit from full-dose anticoagulation.  

On January 22, 2021, NIH reported interim results of the above multipatform trials in the moderately ill cohort. Based on data collected from more than 1000 moderately ill hospitalized patients with COVID-19 (identified as those not in the ICU and not receiving organ support such as mechanical ventilation at trial enrollment), preliminary findings showed that full-dose anticoagulation was superior to prophylactic doses in reducing mortality or the need for organ support. Peer-review of the finalized multipatform trial data is pending.  

Randomized open-label trial comparing intermediate-dose versus standard-dose prophylactic anticoagulation in patients

Based on more recent evidence (as of February 2021), ASH guideline panel issued the following recommendations for anticoagulation therapy in patients with COVID-19:

1) Patients with COVID-19-related critical illness (defined as those with an immediately life-threatening condition who would typically be admitted to the ICU, such as patients requiring hemodynamic support, ventilatory support, or renal replacement therapy) who do not have suspected or confirmed VTE: The ASH guideline panel suggests using prophylactic-intensity over intermediate- or therapeutic-intensity anticoagulation in these patients; however, a conditional recommendation is given based on very low certainty of evidence. (See information on the multipatform, adaptive-design trial that includes REMAP-CAP, ATTACC, and ACTIV-4A in the Clinical Trials and Experience column). ASH discourages the empiric use of full-dose heparin or LMWH outside a clinical trial in critically ill COVID-19 patients who do not have any other indication for therapeutic anticoagulation.

2) Hospitalized patients with COVID-19-related acute illness not requiring intensive care (e.g., those with dyspnea or mild to moderate hypoxia) who do not have suspected or confirmed VTE: ASH suggests the use of prophylactic-intensity over intermediate- or therapeutic-intensity anticoagulation; a conditional recommendation is given based on very low certainty of evidence. Although preliminary findings in the moderately ill patient cohort (those requiring hospitalization but not ICU-level care) suggest that full-dose anticoagulation is superior to usual prophylactic-dose anticoagulation in this population, ASH states that, until peer-reviewed data are available, clinicians should use clinical judgment when managing individual patients and carefully consider the benefits and harms of higher-intensity anticoagulation.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>with COVID-19 admitted to the ICU (INSPIRATION trial; NCT04486508):</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No evidence of benefit from intermediate-dose anticoagulation versus standard-dose prophylactic anticoagulation was observed based on a composite primary outcome of venous or arterial thrombosis, treatment with ECMO, or mortality within 30 days.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Patients in the intermediate-dose anticoagulation group received enoxaparin 1 mg/kg daily and patients in the standard-dose prophylactic anticoagulation group received enoxaparin 40 mg daily with modification according to body weight and renal function. Among 562 patients who were included in the efficacy analysis, the primary outcome occurred in 45.7% of patients in the intermediate-dose group and 44.1% of patients in the standard-dose prophylaxis group. Although bleeding events were rare, there was a small but nonsignificant increase in major bleeding in the intermediate-dose group (2.5 versus 1.4%). The authors state that these results do not support the routine empiric use of intermediate-dose prophylactic anticoagulation in unselected patients admitted to the ICU for COVID-19.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Additional VTE prophylaxis after hospital discharge is not routinely recommended in patients with COVID-19, but may be considered based on the same protocols and risk-benefit analysis as for patients without COVID-19.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Although a relationship between markedly elevated D-dimer levels and mortality has been shown, whether this can be applied to predicting or managing VTE risk is not known.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3) COVID-19 patients who experience recurrent clotting of access devices (e.g., central venous catheters, arterial lines): ASH states that, although of unproven benefit, it may be reasonable to increase the intensity of anticoagulation or switch to a different anticoagulant in these patients. 15

NIH states that there are currently insufficient data to recommend for or against the use of doses higher than the prophylactic dose of anticoagulation for VTE prophylaxis in hospitalized COVID-19 patients outside of a clinical trial setting. 28

The most recent guideline from WHO includes a conditional recommendation to administer standard thromboprophylaxis dosing of anticoagulation rather than therapeutic or intermediate dosing in patients with COVID-19 who do not have an established indication for higher dose anticoagulation; this recommendation was made based on a low certainty of evidence. 25

Extended VTE prophylaxis after hospital discharge is not routinely recommended in patients with COVID-19, but may be considered based on the same protocols and risk-benefit analysis as for patients without COVID-19. |                  |          |

Although a relationship between markedly elevated D-dimer levels and mortality has been shown, whether this can be applied to predicting or managing VTE risk is not known. 5, 6, 7, 30, 32, 33 |          |          |

15, 27, 28, 50, 52
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 Convalescent Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Updated 4/29/21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Plasma obtained from patients who have recovered from COVID-19 (i.e., COVID-19 convalescent plasma) that contains antibodies against SARS-CoV-2 may provide short-term passive immunity to the virus; theoretically, such immunity may prevent or contribute to recovery from the infection, possibly as the result of viral neutralization and/or other mechanisms. 1,5,24,25

Convalescent plasma therapy has been used in the treatment of other viral diseases with various degrees of success. 16, 20, 21, 24, 25 In patients with SARS-CoV-1 infection, use of convalescent plasma was reported to shorten the duration of hospitalization and decrease mortality; 6,8,37 SARS patients who received convalescent plasma less than 14 days after onset of symptoms had better outcomes than those who received such plasma later in the course of the disease. 1,2,6-8

While there is some evidence suggesting possible benefits of COVID-19 convalescent plasma in the treatment of COVID-19, the specific role of convalescent plasma for the treatment of COVID-19 in patients with or without humoral immunity is unclear and additional data are needed from well-controlled, adequately powered, randomized clinical trials. Data from case reports, case series, and a retrospective case-control study suggest benefit of convalescent plasma in patients with various primary and secondary humoral immunodeficiencies. 25

Randomized, controlled, open-label, adaptive, platform trial assessing several possible treatments in patients hospitalized with COVID-19 in the UK (NCT04381936; RECOVERY): Preliminary (non-peer-reviewed) data for 5763 patients randomized to receive standard care and 5795 patients randomized to receive standard care plus convalescent plasma demonstrated no significant differences in 28-day mortality between the two groups (risk ratio: 1.00). Convalescent plasma for this study was prepared using only plasma donations with sample to cut-off (S/CO) ratio of ≥6.0 as detected by the EUROIMMUN IgG ELISA test. 34

Study with retrospectively matched control in US (Liu et al): Preliminary (non-peer-reviewed) data from a study of 39 hospitalized adults with severe to life-threatening COVID-19 who received ABO-compatible COVID-19 convalescent plasma (2 units [total volume approximately 500 mL] infused IV over 1-2 hours), obtained from donors with a SARS-CoV-2 anti-spike antibody titer of 1:320 or greater, suggest that stable or improved supplemental oxygen requirements by post-transfusion day 14 were more likely in these convalescent plasma recipients than in the matched control group not treated with convalescent plasma (odds ratio: 0.86); this effect appeared to be confounded by use of therapeutic anticoagulants, but not by other types of drugs (i.e., azithromycin, broad-spectrum antibiotics, hydroxychloroquine, corticosteroids, antivirals, interleukin-1 [IL-1] and IL-6 inhibitors) or duration of therapy with rhIL-6 inhibitors. 11-13

Emergency use authorization (EUA) for COVID-19 convalescent plasma for the treatment of hospitalized patients and those with impaired humoral immunity: Consider initiating therapy with one high-titer unit (approximately 200 mL) of COVID-19 convalescent plasma given IV through a peripheral or central venous catheter according to standard institutional transfusion guidelines. Additional high-titer COVID-19 convalescent plasma units may be administered based on the prescribing physician’s medical judgment and the patient’s clinical response. 37, 38

Smaller volumes or prolonged transfusion times may be necessary in patients with impaired cardiac function and heart failure. 38

Efficacy and safety of COVID-19 convalescent plasma for the treatment of COVID-19 not established. 11,25 Several case reports indicate that patients with humoral immunity may experience persistent SARS-CoV-2 viral replication and, therefore, may be at risk for developing viral resistance to SARS-CoV-2 antibodies following therapy with convalescent plasma. 25

There are no convalescent blood products currently licensed by the FDA. COVID-19 convalescent plasma is regulated as an investigational product. 11,37

Emergency use authorization (EUA) for COVID-19 convalescent plasma: FDA issued an EUA on August 23, 2020 that permitted use of convalescent plasma for the treatment of hospitalized patients with COVID-19. This EUA was reissued in its entirety on February 4, 2021 to authorize the use of high-titer COVID-19 convalescent plasma for the treatment of hospitalized patients with COVID-19, early in the course of disease, and in those hospitalized with COVID-19 who have impaired humoral immunity. Use of low-titer COVID-19 convalescent plasma is no longer authorized under the EUA. This EUA is based on historical evidence using convalescent plasma in prior outbreaks of respiratory viruses, certain preclinical evidence, results from small clinical trials of convalescent plasma conducted during the current outbreak, data obtained from the ongoing National Expanded Access Treatment Protocol (EAP) for COVID-19 convalescent plasma sponsored by the Mayo Clinic, and additional studies (including randomized controlled trials). 37 The EUA requires healthcare providers to provide convalescent plasma recipients with the Fact Sheet for Patients and Parents/Caregivers and to inform recipients of the significant known and potential risks and benefits of emergency use of COVID-19 convalescent plasma. 37,38

Healthcare facilities and healthcare providers administering high-titer COVID-19 convalescent plasma must
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Symptoms before admission. Overall, survival was improved in patients in the convalescent plasma group compared to the control group; after adjusting for covariates, data suggest a significant improvement in survival in non-intubated patients (hazard ratio: 0.19) receiving convalescent plasma, but not in the small cohort of intubated patients (hazard ratio: 1.24). Subgroup analyses suggested a survival benefit of convalescent plasma among nonintubated patients, in those who received treatment earlier in the course of disease, and those who received therapeutic anticoagulation. No significant transfusion-related morbidity or mortality was observed in patients receiving convalescent plasma. 32</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Uncontrolled case series in US [Salazar et al]: 316 adults with severe and/or life-threatening COVID-19 disease received convalescent plasma (one or two units) in addition to multiple other treatments (e.g., antivirals, anti-inflammatory agents). 28, 48. At the time of an interim analysis, outcomes of 136 convalescent plasma recipients who reached day 28 post-transfusion were compared with two sets of propensity score-matched controls at 28 days after admission. 25, 48. These data suggested a trend toward benefit of convalescent plasma, particularly in patients who were transfused early (i.e., within 72 hours of admission) with high-titer convalescent plasma (i.e., anti-spike protein receptor binding domain titer ≥1:1350). 25, 48</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cochrane systematic review: Analysis of 19 published studies (2 RCT, 8 controlled non-randomized studies of interventions [NRSIs], 9 non-controlled NRSIs) evaluating convalescent plasma in adults with COVID-19 (total of 38,160 study participants, of whom 36,081 received COVID-19 convalescent plasma) found low to very low confidence in the efficacy and safety of this treatment approach. 42, 52</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Systematic review (Joyner et al; non-peer-reviewed): Analysis of pooled data (total of 804 COVID-19 patient outcomes) from 12 studies (3 RCT, 5 matched-control, 4 case series) evaluating convalescent plasma in hospitalized adults with severe or life-threatening COVID-19 found evidence</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>comply with certain mandatory record keeping and reporting requirements (including adverse event reporting). 38 Consult the EUA, 37 EUA fact sheet for healthcare providers, 38 and EUA fact sheet for patients and parents/caregivers 32 for additional information.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The EUA states that high-titer COVID-19 convalescent plasma should not be considered a new standard of care for the treatment of patients with COVID-19. FDA states that adequate and well-controlled randomized trials remain necessary to determine optimal product attributes and to identify appropriate subpopulations for its use and that ongoing clinical trials of COVID-19 convalescent plasma should not be amended based on issuance of the EUA. 37</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The NIH COVID-19 Treatment Guidelines Panel has made the following recommendations regarding the use of convalescent plasma for the treatment of COVID-19: 25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1. The panel recommends against the use of low-titer convalescent plasma. 25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. Hospitalized patients without impaired immunity: The panel recommends against the use of convalescent plasma in those requiring mechanical ventilation. In those not requiring mechanical ventilation, the panel recommends against use of high-titer convalescent plasma, except in a clinical trial. 25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3. Hospitalized patients with impaired immunity: The panel states that there are insufficient data to either recommend for or against the use of high-titer convalescent plasma. 25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4. Nonhospitalized patients: The panel states that there are insufficient data to recommend either for or against the use of high-titer convalescent plasma. 25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The Surviving Sepsis Campaign COVID-19 subcommittee suggests that convalescent plasma not be used routinely in</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>---------------------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Favoring efficacy of this therapeutic approach. The risk of death was substantially reduced in hospitalized COVID-19 patients transfused with convalescent plasma compared to matched patients receiving standard therapy (OR: 0.43, p &lt;0.001). <strong>Note:</strong> There were several limitations to this analysis including aggregating mortality data across study populations that varied by dose and timing of convalescent plasma administration, geographic region, and duration of follow-up.**&lt;sup&gt;16&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Open-label, randomized, controlled study in Netherlands (Gharbharan et al; Con-COVID study):</strong> Preliminary (non-peer-reviewed) data from a study of 86 hospitalized adults with COVID-19 found no significant difference in mortality, duration of hospital stay, or disease severity on day 15 in patients treated with convalescent plasma (300 mL of convalescent plasma containing anti-SARS-CoV-2 neutralizing antibody titers of ≥1:80 as determined by a SARS-CoV-2 plaque reduction neutralization test) compared with standard of care.**&lt;sup&gt;44&lt;/sup&gt; <strong>Note:</strong> Anti-SARS-CoV-2 antibodies were detected at baseline in 53/66 patients who had been symptomatic for 10 days prior to study enrollment. Neutralizing antibodies were detected in 44/56 (79%) patients tested with median titers comparable to the donors (1:160). These findings raised concerns about the potential benefit of convalescent plasma in the study population and the study was terminated.*&lt;sup&gt;44&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Open-label, randomized, controlled study in China (Li et al):</strong> Results of this study in 103 adults with severe or life-threatening COVID-19 found no significant difference in time to clinical improvement within 28 days, mortality, or time to hospital discharge in patients treated with convalescent plasma (containing a high titer of antibody to SARS-CoV-2) plus standard of care compared with standard of care alone.<strong>&lt;sup&gt;28&lt;/sup&gt; Convalescent plasma therapy was well tolerated by the majority of patients; 2 cases of transfusion-associated adverse events were reported.</strong>&lt;sup&gt;28&lt;/sup&gt; There was a signal of possible benefit in the subgroup of patients with severe COVID-19 disease.**&lt;sup&gt;28, 29&lt;/sup&gt; However, the study had several limitations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*critically ill adults with COVID-19 because efficacy and safety not established and uncertainty surrounding optimal preparation of convalescent plasma.**<sup>30</sup>

**Appropriate criteria for selection of patients to receive investigational COVID-19 convalescent plasma, optimal time during the course of the disease to receive such therapy, and appropriate dosage (e.g., volume, number of doses) not determined.**<sup>1-5,9</sup> Current data suggest clinical benefit is associated with transfusion of high-titer convalescent plasma early in the course of the disease (e.g., prior to respiratory failure requiring intubation and mechanical ventilation) and in those with impaired humoral immunity.**<sup>1,2,16,17,20,24,25,36-38</sup> Limited clinical evidence suggests the potential therapeutic window following symptom onset may be longer in patients with suppressed or deficient humoral immunity.**<sup>38</sup>

Available data suggest that serious adverse effects following administration of COVID-19 convalescent plasma are infrequent and consistent with the risks associated with plasma infusions for other indications. Risks associated with COVID-19 convalescent plasma therapy include inadvertent transmission of other infectious agents, allergic reactions, thrombotic complications, transfusion-associated circulatory overload, transfusion-related acute lung injury (TRALI), antibody-dependent enhancement of infection, febrile nonhemolytic reactions, hemolytic reactions, hypothermia, metabolic complications, and post-transfusion purpura. Theoretical risks of COVID-19 convalescent plasma therapy include antibody-dependent enhancement of SARS-CoV-2 infection and long-term immunosuppression.**<sup>23</sup>

May be contraindicated in patients with a history of severe allergic reactions or anaphylaxis to plasma transfusions.**<sup>38</sup> The NIH COVID-19 Treatment Guidelines Panel recommends consulting a transfusion medicine specialist for...
that preclude any definite conclusions, including the possibility of being underpowered as the result of early termination because of the lack of available patients. In addition, most patients received convalescent plasma treatment at least 14 days after symptom onset and it is unclear whether earlier treatment would have resulted in greater benefit.

Open-label, single-arm, phase 2 study (Ibrahim et al): Data from a study of 38 severely or critically ill hospitalized adults with COVID-19 who received convalescent plasma (up to 2 transfusions of 200 mL of convalescent plasma containing IgG titers of 1:320) found a significant reduction in mortality (13 versus 55%, respectively) and hospital length of stay (15.4 versus 33 days, respectively) in those who were severely ill compared with those who were critically ill. Note: Severely ill patients received convalescent plasma approximately 4.6 days following hospital admission and 12.6 days following symptom onset while on high-flow oxygen supplementation without evidence of acute respiratory distress syndrome (ARDS). Critically ill patients received convalescent plasma approximately 16.4 days following hospital admission and 23.1 days following symptom onset after developing ARDS; these patients also had been on ventilation support for an average of 10.6 days prior to transfusion of convalescent plasma. Transient transfusion reaction (fever and hematuria) was observed within 2 hours of transfusion of convalescent plasma in one patient with severe illness.

Open-label, randomized, controlled study in India (Agarwal et al; PLACID trial): Preliminary (non-peer-reviewed) data from a study of 464 moderately ill adults hospitalized with COVID-19 found no significant difference in 28-day mortality or progression to severe disease in patients treated with convalescent plasma (2 transfusions of 200 mL) plus standard of care compared with standard of care alone. Convalescent plasma therapy was well tolerated by the majority of patients; adverse effects included local infusion site reaction, chills, nausea, bradycardia, dizziness, pyrexia, tachycardia, dyspnea, and IV catheter blockade.

patients with a history of severe allergic or anaphylactic transfusion reactions.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established; a decision to use high-titer convalescent plasma in patients <18 years of age should be based on an individualized assessment of risks and benefits in consultation with a pediatric infectious disease specialist. The NIH COVID-19 Treatment Guidelines Panel states that there are insufficient data to either recommend for or against the use of convalescent plasma for the treatment of COVID-19 in hospitalized children who do not require mechanical ventilation. The Panel recommends against use of convalescent plasma for the treatment of COVID-19 in mechanically ventilated pediatric patients.

Pregnancy: Safety and effectiveness of convalescent plasma during pregnancy have not been evaluated; however, pathogen-specific immunoglobulins are used clinically during pregnancy to prevent infection from varicella-zoster virus (VZV) and rabies virus.

FDA does not collect COVID-19 convalescent plasma and does not provide such plasma; healthcare providers and acute care facilities obtain convalescent plasma from FDA-registered or licensed blood establishments. Information on obtaining such plasma may be available at www.redcrossblood.org or www.aabb.org.

FDA issued a guidance for industry to provide recommendations to healthcare providers and investigators regarding COVID-19 convalescent plasma, which may be used under the EUA, and investigational COVID-19 convalescent plasma, which does not meet all conditions of the EUA and/or is being used under an investigational new drug application (IND). This guidance document includes recommendations regarding pathways available for administering or studying COVID-19.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open-label, randomized, controlled study in Chile (Balcells et al):</td>
<td></td>
<td></td>
<td>Preliminary (non-peer-reviewed) data from a study of 58 adults hospitalized within 7 days of COVID-19 symptom onset with risk factors for disease progression and without mechanical ventilation found no significant difference in composite outcome of death, mechanical ventilation, or prolonged hospital admission (&gt;14 days) in patients who received convalescent plasma (up to two transfusions of 200 mL) immediately following hospital admission compared with those who received convalescent plasma at clinical deterioration. Two patients developed severe respiratory deterioration within 6 hours after transfusion of convalescent plasma and were categorized as possible transfusion-associated acute lung injury (TRALI) type II.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expanded access IND protocol in US (Joyner et al):</td>
<td></td>
<td></td>
<td>Analysis of 35,322 adults hospitalized with laboratory-confirmed SARS-CoV-2 infection who had or were considered at high risk of progression to severe or life-threatening COVID-19 who participated in a US FDA Expanded Access Program (NCT04338360) suggests that 7-and 30-day mortality rates are substantially reduced in patients transfused with convalescent plasma within 3 days of COVID-19 diagnosis. Patients received at least one unit (approximately 200 mL) of ABO-compatible COVID-19 convalescent plasma IV according to institutional transfusion guidelines. A statistically significant difference in crude 7-day mortality was observed between patients transfused with convalescent plasma within 3 days of COVID-19 diagnosis compared with those transfused with convalescent plasma 4 or more days after COVID-19 diagnosis (8.7 vs 11.9%). Similar findings were observed for 30-day mortality rate (21.6 vs 26.7%). A reduction in 7- and 30-day mortality rate also was observed in patients transfused with convalescent plasma containing higher IgG antibody levels (&gt;18.45 signal-to-cut-off [S/Co] ratio) compared with those transfused with convalescent plasma containing IgG antibody levels ≤18.45 S/Co. Analysis of key safety indicators in 20,000 adults who participated in this Expanded Access Program</td>
<td></td>
<td>convalescent plasma, collection of such plasma (including donor eligibility and qualifications, testing such plasma for anti-SARS-CoV-2 antibodies, product labeling, and recordkeeping.</td>
</tr>
<tr>
<td>Additional pathways (outside of the EUA) for administering or studying the use of investigational COVID-19 convalescent plasma:</td>
<td></td>
<td></td>
<td>1). Clinical Trials: Requests to study use of COVID-19 convalescent plasma should be submitted to FDA under the traditional IND regulatory pathway. 2). Intermediate-size Population Expanded Access IND: FDA is accepting requests for expanded access INDs for use of COVID-19 convalescent plasma in patients with serious or immediately life-threatening COVID-19 who are not eligible or are unable to participate in randomized clinical trials. Consult the FDA guidance document for specific information on applying for an expanded access IND for more than a single patient. 3). Single Patient Emergency Expanded Access IND (IND): Licensed physicians seeking to administer COVID-19 convalescent plasma to individual patients with serious or life-threatening COVID-19 may request an individual patient expanded access IND from the FDA. Consult the FDA guidance document for specific information on applying for a single patient IND.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donor eligibility:</td>
<td></td>
<td></td>
<td>The FDA guidance states that COVID-19 convalescent plasma for use under the EUA or for use under an IND may be collected from individuals who meet the following qualifications:</td>
<td></td>
<td>1). Laboratory-confirmed evidence of COVID-19 infection in individuals who had symptoms or laboratory-confirmed evidence from 2 different tests in those who did not have a prior positive diagnostic test and/or never had symptoms of COVID-19.</td>
</tr>
</tbody>
</table>
suggests that IV transfusion of convalescent plasma is safe in hospitalized patients with COVID-19. Within the first 4 hours after transfusion, 146 serious adverse events (i.e., transfusion-associated circulatory overload, transfusion-related acute lung injury [TRALI], severe allergic transfusion reaction) were reported (incidence of <1% of all transfusions with a mortality rate of 0.3%); however, only 13/146 serious adverse events were judged by the treating clinician as related to convalescent plasma transfusion. Within 7 days after transfusion, 1136 other serious adverse events were reported (i.e., thromboembolic or thrombotic event, sustained hypotensive event requiring IV vasopressor, cardiac event); however, 55/87 thromboembolic or thrombotic complications and 569/643 cardiac events were judged to be unrelated to convalescent plasma transfusion.

Retrospective subset analyses of Mayo Clinic expanded-access protocol in US: Retrospective analysis of a subset of 3082 hospitalized adults with COVID-19 who were treated with convalescent plasma at 680 acute care facilities in the US as part of an expanded-access program indicated 30-day mortality was improved following transfusion of high-titer COVID-19 convalescent plasma compared with low-titer convalescent plasma in patients who did not require mechanical ventilation prior to transfusion (relative risk: 0.66); however, no effect on mortality was observed in patients who required mechanical ventilation prior to transfusion of convalescent plasma (relative risk: 1.02). Randomized, embedded, multifactorial adaptive platform trial (REMAP-CAP): Preliminary analysis of 912 hospitalized adults with severe COVID-19 requiring ICU admission indicated that convalescent plasma was unlikely to benefit such patients; however, the study continues to recruit hospitalized patients who do not require ICU admission.

Open-label, prospective study (Madariaga et al): The relationship between clinical and serologic parameters in a group of COVID-19 convalescent plasma donors and

2. Complete resolution of symptoms for at least 14 days before donation (a negative result for COVID-19 by a diagnostic test is not necessary to qualify the donor).

3. Male donors, female donors who have never been pregnant, or female donors who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies.

To ensure that COVID-19 convalescent plasma collected from donors contains antibodies directly related to an immune response to SARS-CoV-2 infection, the FDA guidance states that COVID-19 convalescent plasma should not be collected from the following individuals: 1). Those who have received an investigational COVID-19 vaccine in a clinical trial or received an authorized or licensed COVID-19 vaccine, unless they had symptoms of COVID-19 and a positive test result from a diagnostic test approved, cleared, or authorized by FDA and received the COVID-19 vaccine after diagnosis of COVID-19 and are within 6 months after complete resolution of COVID-19 symptoms.

2). Those who received an investigational COVID-19 monoclonal antibody in a clinical trial or received an authorized or licensed COVID-19 monoclonal antibody (SARS-CoV-2-specific mAb), unless it is ≥3 months after receipt of such therapy.

SARS-CoV-2 antibody titers in donor plasma: COVID-19 convalescent plasma for use under the EUA or an IND must be tested to determine suitability before release. Information on tests acceptable for use in the manufacture of high-titer COVID-19 convalescent plasma and respective qualifying results may be found in the EUA.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
</table>
| antibody responses in recipients of convalescent plasma was evaluated. SARS-CoV-2 anti-receptor binding domain (anti-RBD) and anti-spike antibody titers ranged from 0 to 1:3892 and 0 to 1:3289, respectively, in 103 convalescent plasma donors; mean duration of COVID-19 symptoms in the plasma donors was 11.9 days and mean interval between symptom onset and convalescent plasma donation was 45.1 days; predictors of higher antibody titers in the donors included advanced age, fever, absence of myalgia, fatigue, ABO blood type, and previous hospitalization. In this study, 10 hospitalized adults with severe or life-threatening COVID-19 received 1 or 2 units (approximately 300 mL per unit administered IV over 4 hours) of ABO-compatible COVID-19 convalescent plasma (units had SARS-CoV-2 anti-RBD antibody titers of 1:73 to 1:3892 and anti-spike antibody titers of 1:69 to 1:2921) within 21 days after symptom onset and 80% of these patients had a significant increase in SARS-CoV-2 anti-spike and anti-RBD antibody titer by post-transfusion day 3 and were discharged after clinical improvement; antibody titers in the convalescent plasma recipients were independent of donor antibody titer. SARS-CoV-2 antibody titers in the convalescent plasma recipients continued to increase for up to 14 days in 4 recipients; however, 2 severely ill patients receiving extracorporeal membrane oxygenation (ECMO) who received convalescent plasma on day 20-21 of illness and had SARS-CoV-2 anti-spike antibody titers of up to 1:13,833 on day 0 had a decrease in antibody titer after receiving convalescent plasma. No convalescent plasma recipients experienced toxicity associated with the transfusion or clinical deterioration or worsening of disease status immediately related to plasma transfusion. Convalescent plasma transfusion was safe in high-risk individuals in this study (i.e., immunosuppressed, end-stage renal disease). Randomized, double-blind, placebo-controlled study in Argentina (Libster et al): Results of this study in 160 geriatric patients (≥75 years of age or 65–74 years of age with ≥1 coexisting condition) with mild COVID-19 who received convalescent plasma (250 mL with a SARS-CoV-2 anti-spike antibody titer of >1:1000) or placebo (250
Trials or Clinical Experience

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>mL of 0.9% sodium chloride injection) within 72 hours of symptom onset found a significant reduction in risk of progression to severe respiratory disease (16 versus 31%, respectively; relative risk 0.52). However, the study was terminated early because of the lack of available patients and, therefore, is likely underpowered.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Retrospective matched cohort study (Rogers et al; non-peer-reviewed)** of hospitalized COVID-19 patients at 3 Rhode Island medical centers indicated no significant difference in in-hospital mortality or rate of hospital discharge in patients who received convalescent plasma within a median of 7 days after symptom onset; however, subgroup analysis suggested a significantly increased hospital discharge rate among convalescent plasma recipients 65 years of age or older.

**Retrospective matched cohort study (Yoon et al; non-peer-reviewed)** of hospitalized COVID-19 patients at a New York medical center indicated no significant difference in all-cause mortality at 28 days in adults who received convalescent plasma (200 mL containing SARS-CoV-2 anti-spike antibody titers >1:2430) within 72 hours of admission. Subgroup analysis suggested a 4-fold decrease in mortality (8.8 vs 29.4%) and deterioration in oxygenation or mortality (11.8 vs 35.3%) in convalescent plasma recipients <65 years of age compared with propensity score-matched patients who did not receive convalescent plasma.

**Retrospective study (Salazar et al; non-peer-reviewed)** of adults diagnosed with COVID-19 and hospitalized with pneumonia in 215 hospitals in Argentina suggested clinical benefit of convalescent plasma in such patients; a significant reduction in 28-day unadjusted mortality was observed in convalescent plasma recipients compared with those who did not receive convalescent plasma (25.5 vs 38%).

**Multiple clinical trials are ongoing globally to evaluate use of COVID-19 convalescent plasma in various settings (e.g., postexposure prophylaxis, treatment of different stages of the disease); some are registered at clinicaltrials.gov.**
**Drug(s)** | **AHFS Class** | **Rationale** | **Trials or Clinical Experience** | **Dosage** | **Comments**
--- | --- | --- | --- | --- | ---
Famotidine | Updated 4/30/21 | 56:28.12 Histamine H₂ Antagonists | Computer-aided, structure-based, virtual screening of libraries of compounds against SARS-CoV-2 proteins suggested potential for famotidine to interact with viral proteases involved in coronavirus replication. 1 4 However, computer-aided modeling suggested binding affinity is weak and combined use with other antivirals would likely be required. 14 In vitro data suggest famotidine does not bind to SARS-CoV-2 proteases, although antiviral activity was not tested in cell lines that express H₂ receptors. 11, 12 No in vitro antiviral activity against SARS-CoV-2 observed in infected Vero E6 cells. 11 A possible role for dysfunctional mast cell activation and histamine release in mediating clinical manifestations of COVID-19 has been postulated; it is further postulated that the principal action of famotidine in COVID-19 may relate to activity at H₂ receptors. 10, 11 Anecdotal observations: Observations based on retrospective medical record review indicated that many Chinese COVID-19 survivors had received famotidine for chronic heartburn; mortality rate appeared to be lower in hospitalized COVID-19 patients receiving famotidine than in patients not receiving the drug. Currently no known published prospective clinical trial evidence supporting efficacy or safety for treatment of COVID-19.

**Randomized, double-blind, placebo-controlled, comparative trial (NCT04370262)** is evaluating high-dose IV famotidine plus standard care vs placebo plus standard care in hospitalized adults with moderate to severe COVID-19; targeted enrollment is at least 942 patients. 5 Other randomized clinical trials evaluating famotidine for treatment of COVID-19 may be registered at clinicaltrials.gov. 5

**Retrospective cohort study (NCT04389567)** of 10 outpatients self-medicating with high-dose famotidine following onset of symptoms consistent with COVID-19: No hospitalizations reported; all patients reported symptomatic improvement within 1-2 days, with continued improvement over 14-day period. Patients were symptomatic for 2-26 days before initiating famotidine. Total of 7 patients had PCR-confirmed COVID-19, 2 had serologic confirmation of antibodies against SARS-CoV-2, and 1 had clinical diagnosis only. Famotidine dosage of 80 mg 3 times daily was reported by 6 patients (range: 20-80 mg 3 times daily); median reported duration of use was 11 days (range: 5–21 days); high-dose famotidine generally was well tolerated. Data were collected by telephone interviews and written questionnaires. Patients retrospectively provided symptom scores on a 4-point ordinal scale. Potential exists for placebo effect, recall bias, and enrollment bias; symptomatic improvement also could reflect treatment-independent convalescence. 8

**Retrospective matched cohort study** of COVID-19 patients hospitalized, but not requiring intubation within the first 48 hrs, at a single New York medical center indicated that the risk for the composite outcome of death or intubation was reduced (mainly due to difference in mortality) in patients who received famotidine within 24 hours of hospital admission (n = 84) vs those who did not receive the drug.

Dosage in NCT04370262: Famotidine is being given IV in 120-mg doses (proposed total daily dosage of 360 mg) for maximum of 14 days or until hospital discharge, whichever comes first. 5

Proposed daily dosage in NCT04370262 is 9 times the usual manufacturer-recommended IV adult dosage; 9 the study excludes patients with creatinine clearance (Ccr) ≤50 mL/minute, including dialysis patients; 5 renal impaired patients may be at increased risk of adverse CNS effects since drug half-life is closely related to Ccr. 7

Safety and efficacy for treatment of COVID-19 not established.

IDSA suggests against using famotidine for the sole purpose of treating COVID-19 in hospitalized patients with severe COVID-19 outside of the context of a clinical trial. 9
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(14 vs 27%); observations did not control for possible confounding (e.g., socioeconomonic factors&lt;sup&gt;3&lt;/sup&gt;)</td>
<td>(n = 1536); overall, 21% of patients met the composite outcome (8.8% were intubated and 15% died); the finding appeared to be specific to the H&lt;sub&gt;2&lt;/sub&gt; antagonist and to COVID-19, as the investigators reported observing no protective effect with proton-pump inhibitors or in non-COVID-19 patients. Home use of famotidine was documented on admission in 15% of patients who received the drug in hospital vs 1% of those who did not; 28% of all famotidine doses were IV; 47% of doses were 20 mg, 35% were 40 mg, and 17% were 10 mg; the median duration of use was 5.8 days, and the total median dose was 136 mg (63-233 mg).&lt;sup&gt;7&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Retrospective, matched, single-center, observational study** in hospitalized patients with RT-PCR-confirmed COVID-19: In-hospital mortality (14.5 vs 26%) and the combined end point of death or intubation (7.2 vs 13.8%) were reduced in patients who received famotidine (n = 83) compared with a propensity score-matched group of patients who did not receive the drug (n = 689). Famotidine use was identified from electronic medical records and was defined as IV or oral use at any dosage within 7 days before or after COVID-19 screening and/or hospitalization; in the famotidine group, 66% received the drug in hospital only, and 29% received the drug both before and during hospitalization. Median total in-hospital dose was 80 mg (range: 40-160 mg) given over a median of 4 days (range: 2-8 days). There were no significant differences between the groups with respect to baseline demographics, comorbidities, or severity of illness or in concomitant use of hydroxychloroquine, remdesivir, azithromycin, or corticosteroids.<sup>10</sup>  

**Retrospective territory-wide cohort study** (not peer reviewed) in Hong Kong investigating the association between famotidine use and COVID-19 severity: In this cohort of 952 adults hospitalized with COVID-19, 51 patients (5.4%) had severe disease; 23 patients (2.4%) received famotidine and 4 patients (0.4%) received proton-pump inhibitors (PPIs), as determined on the day of
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
</table>
|         |            | admission. Multivariable logistic regression analysis showed no significant association between severe COVID-19 disease and use of famotidine or PPIs.  

Retrospective, matched, multiple-hospital study investigating the association between in-hospital famotidine use (within 24 hours of admission) and mortality in patients with confirmed COVID-19: Famotidine users and nonusers were matched by age, gender, race and ethnicity, body mass index, comorbidities, and in-hospital hydroxychloroquine use. Patients who died or required intubation within 48 hours of admission were excluded. The post-match cohort included 410 patients (35.5%) who received famotidine and 746 matched controls (64.5%). Multivariable logistic regression analysis within the matched cohort showed no association between in-hospital famotidine use and 30-day mortality after adjustment for WHO severity rating, smoking status, and use of antiviral and supportive therapies.  

Retrospective, multihospital, cohort study in hospitalized patients with an electronic health record (EHR) diagnosis of COVID-19: Famotidine use did not reduce mortality or the combined end point of death plus intensive intervention (mechanical ventilation, tracheostomy, or extracorporeal membrane oxygenation [ECMO]) at 30 days after admission compared with nonuse of famotidine or compared with use of proton-pump inhibitors (PPIs) or hydroxychloroquine. Medication use was determined from dispensing records on the day of admission; famotidine nonuse was defined as no history of exposure to the drug on or before the day of admission. Patients receiving intensive services on or within 30 days prior to admission were excluded. The study included 1816 famotidine users, 2193 PPI users, 5950 hydroxychloroquine users, and 26,820 nonusers of famotidine. Most famotidine users received the drug orally (64%) at a low dose of 20 mg (73%) on the day of admission. After propensity score stratification, the hazard ratio for death was 1.03, 1.14, or 1.03 for famotidine use vs. |
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluvoxamine (Luvox CR&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>28:16.04.20 Selective Serotonin-reuptake Inhibitors</td>
<td>Precise mechanism against SARS-CoV-2 not known; fluvoxamine is an antidepressant with high affinity at the sigma-1 receptor, which potentially could help prevent clinical deterioration in patients with COVID-19. 1,3 The sigma-1 receptor in the endoplasmic reticulum was essential for cytokine production in a mouse model of septic shock; fluvoxamine is associated with enhanced survival in mouse models of inflammation and sepsis and inhibition of the inflammatory response in human peripheral blood cells. 1,2,3</td>
<td>Randomized, double-blind, placebo-controlled, fully remote (contactless) trial (Lenze et al; NCT04342663) evaluated whether fluvoxamine could prevent clinical deterioration in adult outpatients with symptomatic (symptom onset within 7 days prior to randomization) and laboratory-confirmed COVID-19 with an O₂ saturation of ≥92%. Patients enrolled from the St Louis metropolitan area were randomly assigned to receive either fluvoxamine 100 mg or placebo orally 3 times daily for 15 days (see Dosage column). The primary efficacy outcome was clinical deterioration within 15 days of randomization, which was defined as meeting both of the following criteria: 1) shortness of breath or hospitalization for shortness of breath or pneumonia and 2) O₂ saturation &lt;92% on room air or need for supplemental oxygen to achieve an O₂ saturation of ≥92%. Out of 152 randomized patients, 115 (76%) completed the trial. Clinical deterioration occurred in 0 of 80</td>
<td>Fluvoxamine dosage in NCT04342663: 50 mg once in the evening on day 1, then dosage was increased to 100 mg twice daily as tolerated on days 2 and 3, then increased to 100 mg 3 times daily as tolerated through day 15. 3 Fluvoxamine dosage in NCT04668950: Initial dosage of 50 mg once daily then 100 mg twice daily for approximately 15 days; dosage can be adjusted based on tolerability. 4 Fluvoxamine dosage in the open-label cohort was initial dose of 50-100 mg, then 50 mg twice daily for 14 days. 5</td>
<td>NIH COVID-19 Treatment Guidelines Panel states that there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19. The panel states that results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of fluvoxamine in the treatment of COVID-19. 6 Some potential advantages of fluvoxamine include that it’s a relatively safe, inexpensive, and available drug that can be given orally. Unlike some selective serotonin-reuptake inhibitors, fluvoxamine is not associated with QT-interval prolongation. In addition, it has been widely used in children and adults and may help treat depressive and anxiety symptoms that may occur in patients with COVID-19. However, fluvoxamine...</td>
</tr>
</tbody>
</table>

**Notes:**
- No famotidine use, vs. PPI use, or vs. hydroxychloroquine use, respectively. Results for the combined end point were similar. 17
- **Meta-analysis** of the above 5 retrospective studies, 7,10,15-17 which included a total of 36,635 patients, found no significant protective effect for famotidine in reducing the risk of progression to severe illness, death, or intubation in patients with COVID-19 (odds ratio = 0.82 [95% CI = 0.52-1.3]). 18
- Uncontrolled series of hospitalized patients with COVID-19 receiving open-label, combined H<sub>2</sub> and H<sub>1</sub> antagonist therapy (famotidine and cetirizine) for ≥48 hours: Total of 110 patients at a single hospital received famotidine 20 mg and cetirizine hydrochloride 10 mg orally or IV every 12 hours; concomitant therapy included hydroxychloroquine (85%), tocilizumab (51%), methylprednisolone (31%), and convalescent plasma (30%). Findings included a 16.4% overall rate of intubation, 7.3% rate of intubation after ≥48 hours of treatment, 15.5% mortality rate, and 11-day average hospital stay. **Note:** Comparisons were limited to published outcome data from other locales for patients receiving “standard-of-care” regimens. 13

**Dosage**
- Fluvoxamine dosage in the open-label cohort was initial dose of 50-100 mg, then 50 mg twice daily for 14 days. 5
- Fluvoxamine dosage in NCT04342663: 50 mg once in the evening on day 1, then dosage was increased to 100 mg twice daily as tolerated on days 2 and 3, then increased to 100 mg 3 times daily as tolerated through day 15. 3
- NIH COVID-19 Treatment Guidelines Panel states that there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19. The panel states that results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of fluvoxamine in the treatment of COVID-19. 6

**References:**
- 1. Lenze EJ, et al; NCT04342663 evaluated whether fluvoxamine could prevent clinical deterioration in adult outpatients with symptomatic (symptom onset within 7 days prior to randomization) and laboratory-confirmed COVID-19 with an O₂ saturation of ≥92%. Patients enrolled from the St Louis metropolitan area were randomly assigned to receive either fluvoxamine 100 mg or placebo orally 3 times daily for 15 days (see Dosage column). The primary efficacy outcome was clinical deterioration within 15 days of randomization, which was defined as meeting both of the following criteria: 1) shortness of breath or hospitalization for shortness of breath or pneumonia and 2) O₂ saturation <92% on room air or need for supplemental oxygen to achieve an O₂ saturation of ≥92%. Out of 152 randomized patients, 115 (76%) completed the trial. Clinical deterioration occurred in 0 of 80 |
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Further studies needed to establish whether the anti-inflammatory effects of fluvoxamine observed in nonclinical studies also occur in humans and are clinically relevant in the COVID-19 setting.  &lt;sup&gt;5&lt;/sup&gt;</td>
<td>patients in the fluvoxamine group and in 6 of 72 patients (8.3%) in the placebo group. This preliminary study had several limitations, including a relatively small sample size, a single geographic area, a limited number of events occurred, and a short follow-up period. In addition, ascertaining clinical deterioration of patients was difficult because all assessments were made remotely.  &lt;sup&gt;3, 6&lt;/sup&gt; A larger, fully remote, randomized, placebo-controlled, phase 3 trial (the StopCovidTrial) evaluating fluvoxamine in adults with COVID-19 (expected enrollment 880) is currently under way by the same group of investigators as the Lenze et al study above (NCT04668950).  &lt;sup&gt;4&lt;/sup&gt; Seftel and Boulware reported on a prospective open-label cohort of patients in whom fluvoxamine was given during a mass COVID-19 outbreak at a horse racing track in California. A total of 65 patients with laboratory-confirmed COVID-19 chose to receive fluvoxamine (loading dose of 50-100 mg, then 50 mg twice daily for 14 days) and 48 patients declined the drug and received observed only. Hospitalization occurred in 0% of the fluvoxamine-treated patients compared with 12.5% of those receiving observation alone (2 of these patients required ICU treatment with mechanical ventilation and one of these patients died). At 14 days, residual symptoms persisted in none of the fluvoxamine-treated patients compared with 60% of those receiving observation alone. No serious adverse events were reported in the patients taking fluvoxamine. Limitations of this study include that it was a nonrandomized trial with a small sample size and limited data were collected during the course of the study.  &lt;sup&gt;5, 6&lt;/sup&gt; Other clinical trials evaluating use of fluvoxamine in patients with COVID-19 may be registered at clinicaltrials.gov.  &lt;sup&gt;5&lt;/sup&gt; may cause clinically important drug interactions because it is a potent inhibitor of CYP isoenzymes 1A2 and 2C19 and a moderate inhibitor of CYP isoenzymes 2C9, 2D6, and 3A4.  &lt;sup&gt;1, 3, 5, 6&lt;/sup&gt; <strong>Pediatric use:</strong> No data available to date on use of fluvoxamine for prevention or treatment of COVID-19 in pediatric patients.  &lt;sup&gt;6&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosagea</td>
<td>Comments</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>HMG-CoA Reductase Inhibitors (statins)</td>
<td>24:06</td>
<td>In addition to lipid-lowering effects, statins have anti-inflammatory and immunomodulatory</td>
<td>Data from randomized controlled trials are lacking on the use of statins in pts with COVID-19.</td>
<td></td>
<td>NIH COVID-19 Treatment Guidelines</td>
</tr>
<tr>
<td>Updated 4/30/21</td>
<td></td>
<td>effects, which may prevent acute lung injury.</td>
<td>Retrospective cohort studies:</td>
<td></td>
<td>Panel states pts who are receiving statin therapy for an underlying</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Statins affect ACE2 as part of their function in reducing endothelial dysfunction.</td>
<td>In a study of 13,981 pts in China hospitalized with COVID-19, statin use during hospitalization</td>
<td></td>
<td>medical condition should not discontinue such therapy unless</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>was associated with lower risk of mortality. The 28-day all-cause mortality was 22% lower in</td>
<td></td>
<td>discontinuation is otherwise warranted by their clinical condition.**</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>pts who received statins during hospitalization compared with pts who did not receive statins.</td>
<td></td>
<td>The panel <strong>recommends against</strong> use of statins for the treatment of</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Among propensity-score-matched pts (861 pts in the statin group vs 3444 matched pts in the</td>
<td></td>
<td>COVID-19 except in the context of a clinical trial. **</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>non-statin group), the risk of 28-day all-cause mortality was 42% lower in pts who received</td>
<td></td>
<td>Pts with cardiovascular disease are at an increased risk of serious</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>statins during hospitalization compared with those who did not receive statins. In addition,</td>
<td></td>
<td>COVID-19 infections. **</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>lower incidence of invasive mechanical ventilation was observed in the statin-treated pts.</td>
<td></td>
<td>In pts with active COVID-19 who may develop severe rhabdomyolysis, it</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The authors note that pts in the statin group were older and had a higher prevalence of</td>
<td></td>
<td>may be advisable to withhold statin therapy for a short period of time.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>comorbidities and more severe symptoms at baseline; matched non-statin pts therefore had more</td>
<td></td>
<td>Most statins are substrates for the CYP450 system; potential for drug</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>severe baseline symptoms and comorbidities than unmatched pts, which could account for the</td>
<td></td>
<td>interactions. **</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>increased mortality in the non-statin group after propensity score matching.</td>
<td></td>
<td>Clinicians should ensure that their high-risk primary prevention</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In a national registry-based cohort study in Denmark, statin use was <strong>not</strong> associated with</td>
<td></td>
<td>(for ASCVD) pts are on guideline-directed statin therapy. **</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>decreased risk of all-cause mortality or severe disease in patients with COVID-19. This study</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>captured data from 4842 pts with a hospital encounter (e.g., inpatient, outpatient, ED visit)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>and COVID-19: 17.4% were receiving statin therapy (defined as individuals having filled a</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>prescription for a statin within 6 months prior to COVID-19 diagnosis). After adjusting for</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>baseline characteristics, including comorbidities (e.g., history of ischemic heart disease,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>stroke, diabetes mellitus, hypertension, malignancy, chronic kidney disease, liver disease)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>and concomitant medications,</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**References:**
1. [Statins affect ACE2 as part of their function in reducing endothelial dysfunction.](#)
2. [Data from randomized controlled trials are lacking on the use of statins in pts with COVID-19.](#)
3. [Retrospective cohort studies in various settings and meta-analyses conducted using data from observational studies have yielded conflicting results regarding the benefit of statin treatment on disease severity or mortality and/or recovery time in pts with COVID-19.](#)
4. [10-16, 22-30 Retrospective cohort studies:](#)
5. [In a study of 13,981 pts in China hospitalized with COVID-19, statin use during hospitalization was associated with lower risk of mortality. The 28-day all-cause mortality was 22% lower in pts who received statins during hospitalization compared with pts who did not receive statins. Among propensity-score-matched pts (861 pts in the statin group vs 3444 matched pts in the non-statin group), the risk of 28-day all-cause mortality was 42% lower in pts who received statins during hospitalization compared with those who did not receive statins. In addition, lower incidence of invasive mechanical ventilation was observed in the statin-treated pts. The authors note that pts in the statin group were older and had a higher prevalence of comorbidities and more severe symptoms at baseline; matched non-statin pts therefore had more severe baseline symptoms and comorbidities than unmatched pts, which could account for the increased mortality in the non-statin group after propensity score matching.](#)
6. [In a national registry-based cohort study in Denmark, statin use was not associated with decreased risk of all-cause mortality or severe disease in patients with COVID-19. This study captured data from 4842 pts with a hospital encounter (e.g., inpatient, outpatient, ED visit) and COVID-19: 17.4% were receiving statin therapy (defined as individuals having filled a prescription for a statin within 6 months prior to COVID-19 diagnosis). After adjusting for baseline characteristics, including comorbidities (e.g., history of ischemic heart disease, stroke, diabetes mellitus, hypertension, malignancy, chronic kidney disease, liver disease) and concomitant medications,](#)

Additional notes:
- NIH COVID-19 Treatment Guidelines Panel states pts who are receiving statin therapy for an underlying medical condition should not discontinue such therapy unless discontinuation is otherwise warranted by their clinical condition.
- The panel **recommends against** use of statins for the treatment of COVID-19 except in the context of a clinical trial.
- Pts with cardiovascular disease are at an increased risk of serious COVID-19 infections.
- In pts with active COVID-19 who may develop severe rhabdomyolysis, it may be advisable to withhold statin therapy for a short period of time.
- Most statins are substrates for the CYP450 system; potential for drug interactions.
- Clinicians should ensure that their high-risk primary prevention (for ASCVD) pts are on guideline-directed statin therapy.
there was no difference between statin and non-statin pts in the 30-day risk of all-cause mortality, severe disease, and a composite of both outcomes. The study also found no differences in these outcomes among statin pts when stratified by specific statin or statin intensity.  

In a study of 2157 pts hospitalized with COVID-19 at multiple centers in Spain (NCT04407273; STACOV), statin use prior to hospitalization was associated with a lower in-hospital mortality rate compared with no statin use (19.8 vs 25.4%), particularly in pts who continued statin therapy during hospitalization (17.4%). Approximately 58% of the 581 pts receiving statins prior to hospitalization continued therapy at the same dosage during hospitalization. In this study, propensity matching failed to achieve similar baseline characteristics between statin and non-statin pts; pts were therefore matched using a genetic matching method.

A study of 2147 pts hospitalized with COVID-19 at 2 hospitals in China found an association between statin use and lower mortality and improved clinical outcomes compared with no statin use. In this study, 11.6% of patients were receiving statin therapy prior to admission that was continued during hospitalization. After propensity score matching, statin use was associated with a lower risk of death, ARDS, and ICU admission compared with no statin use (adjusted hazard ratios: 0.251, 0.232, and 0.381, respectively).

In a study of 842 pts hospitalized with COVID-19 at multiple centers in Italy, statin use was not associated with a difference in in-hospital mortality compared with no statin use. In this study, 21% of pts were receiving statin therapy prior to admission. After propensity score matching, although pts receiving statin therapy presented with worse disease severity (as assessed by the National Early Warning Score [NEWS]) and worse radiological features compared with non-statin pts, there was no difference in in-hospital mortality between statin and non-statin pts. The study also found that,
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
</table>
|         |            |           | although pts receiving high- or moderate-intensity statin therapy had worse clinical presentation of disease compared with those receiving low-intensity statin therapy, in-hospital mortality was similar between the groups.  

In a study of 170 pts hospitalized for COVID-19 at a single US center, statin use prior to admission was associated with reduced risk of developing severe disease and, among those without severe disease, faster time to recovery. In this study, 27% of pts reported using statins within 30 days prior to hospitalization for COVID-19. Statin use was associated with a 71% lower risk of severe outcome (i.e., death or ICU admission). In addition, rate of recovery in pts without severe disease was higher (hazard ratio for recovery: 2.69) and median time to recovery was shorter for those who received statins. The beneficial effect of statin use on reduction of severe outcomes in pts with COVID-19 was greater than that observed in a large control cohort of COVID-19-negative pts.

In a study of 249 pts hospitalized with COVID-19 at multiple US centers, statin use prior to hospitalization was associated with lower risk of invasive mechanical ventilation in some models, but there was no substantial association between statin use and in-hospital death or ICU admission.

In a cohort analysis of 541 pts hospitalized with COVID-19 at a single center in Italy, the association between statin use prior to hospitalization and reduced mortality or disease severity was not statistically significant.

Statin use was associated with a small, but statistically significant, decrease in mortality compared with no statin use in a multi-center US-based study comparing 2297 COVID-19 pts receiving statins (defined as pts with a medication order for a statin within 10 days before and 7 days after positive SARS-CoV-2 test) with 4594 propensity score-matched non-statin pts. In this study, the mortality rate was 16.1% in statin users and ranged from 18-20.6%, depending on |
propensity score iteration, in non-statin users.  

In a study using the Korean National Health Insurance Service database, prior statin use was associated with a lower risk of mortality in hospitalized COVID-19 pts. This study included 10,448 pts hospitalized for COVID-19 (5.1% were statin users based on prescription records). After propensity score matching, the risk of mortality was 36% lower in statin users compared with non-statin users.  

**Intensive care pts:** In a study of 87 pts admitted to the ICU with COVID-19 at a single US center, treatment with atorvastatin (40 mg daily) was associated with a reduced risk of death (adjusted hazard ratio: 0.38).  

**Non-hospitalized pts:** In a study of 154 nursing home residents in Belgium with clinically suspected COVID-19 and/or positive PCR test for SARS-CoV-2, statin use was associated with absence of symptoms (i.e., asymptomatic infection) in this cohort; 45% of the 31 pts receiving statin therapy remained asymptomatic compared with 22% of the 123 pts not receiving statins.  

In a retrospective cohort study in Korea, statin use was associated with lower odds of developing COVID-19 compared with no statin use. This study included 122,040 individuals without COVID-19 in the National Health Insurance Service database in Korea (18.5% were statin users based on prescription records). The primary endpoint was COVID-19 diagnosis. After propensity score matching, the odds of developing COVID-19 were 35% lower in statin users compared with non-statin users. However, among the 7780 pts diagnosed with COVID-19, there was no substantial difference in hospital mortality between statin users and those not receiving statins.  

**Meta-analyses:** Preliminary findings from a meta-analysis (Kow & Hasan) of 4 cohort or case-control studies which included a total of 8990 pts with COVID-19 suggest that statin use is...
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage^a</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>associated with a 30% reduction in risk of severe or fatal outcome in pts with COVID-19. (^{14}) However, another meta-analysis of 9 cohort or case-control studies (Hariyanto &amp; Kurniawan) did not find an association between statin use and improved severity or mortality outcomes in pts with COVID-19. This meta-analysis included a total of 3449 pts with COVID-19 and included 2 of the same studies used in the Kow &amp; Hasan analysis. (^{15}) A larger meta-analysis of observational studies (Scheen) found that statin use was not associated with reduced in-hospital mortality (13 studies with a total of 42,722 pts) or disease severity (11 studies with a total of 14,022 pts). In studies using multivariate analyses or adjusting for covariates, statin use was associated with lower rates of in-hospital mortality and reduced disease severity (adjusted odds ratio: 0.73). In addition, studies that utilized propensity-score matching for comparison found a statistically significant lower risk of in-hospital mortality in statin users compared with those not receiving statins (hazard ratios ranging from 0.48 to 0.88). The authors note that there was considerable heterogeneity between studies. (^{22}) Another meta-analysis (Pal et al.), which included 14 observational studies with a total of 19,988 pts, found that although analysis of unadjusted data indicated current and/or in-hospital statin use was not associated with differences in clinical outcomes (e.g., mortality, ICU admission), when analysis was limited to the 5 studies that reported adjusted odds and/or hazard ratios, statin use was associated with a 36-49% reduced risk of adverse clinical outcomes. (^{26}) Another meta-analysis (Permana et al.; 13 observational studies with a total of 52,122 pts) investigated whether in-hospital use of statins had an effect on mortality in patients with COVID-19. In 8 studies that specifically reported the use of statins during hospitalization, in-hospital statin use was associated with a 46% lower risk of mortality compared with no statin use.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage(^a)</td>
<td>Comments</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>In the remaining 5 studies where statin use</strong>&lt;br&gt;was discontinued or not explicitly stated as being continued during hospitalization, no difference in mortality was observed between pre-hospitalization statin use and no prior statin use.(^{17})</td>
<td></td>
<td><strong>In pts with diabetes mellitus</strong>&lt;br&gt;hospitalized with COVID-19, observational studies have also yielded conflicting results with regards to statin use.(^{17, 18, 19}) In a US single-center observational study, among 2266 pts with diabetes mellitus hospitalized with COVID-19, statin use during hospitalization was associated with reduced in-hospital mortality (hazard ratio 0.51).(^{19}) In addition, a large registry-based cohort study in England found an association between statin use (i.e., having a prescription for statins) and reduced COVID-19-related mortality in pts with type 2 diabetes mellitus.(^{17}) However, a cohort study of 2449 pts with type 2 diabetes mellitus hospitalized with COVID-19 at multiple centers in France (CORONADO study) found that statin use prior to hospitalization was associated with higher 7- and 28-day mortality compared with no statin use (odds ratio 1.74 and 1.46, respectively).(^{18})**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other respiratory conditions:</strong>&lt;br&gt;Preliminary findings have shown mixed results with other respiratory illnesses; some observational studies suggest statin therapy is associated with a reduction in various cardiovascular outcomes and possibly mortality in pts hospitalized with influenza and/or pneumonia.(^{3, 6}) Other clinical trials evaluating use of statins in pts with COVID-19 may be registered at clinicaltrials.gov.(^3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immune Globulin</strong>&lt;br&gt;Updated 10/28/20</td>
<td>80:04 Immune Globulin</td>
<td><strong>Commercially available immune globulin (non-SARS-CoV-2-specific IGIV, IVIG, γ-globulin):</strong> Immune globulin derived from pooled plasma containing many antibodies normally present in adult human blood; used for replacement therapy or treatment of various immune and inflammatory disorders</td>
<td><strong>Investigational Anti-SARS-CoV-2 Hyperimmunoglobulin (anti-SARS-CoV-2 hIgIV):</strong> Several manufacturers are collaborating to provide investigational anti-SARS-CoV-2 hIgIV on behalf of the CoVig-19 Plasma Alliance for the Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) study (NCT04546581). The ITAC study is an international, multi-center, randomized, double-blind, placebo-controlled, adaptive phase 3 study sponsored by the NIAID to commercially available immune globulin (non-SARS-CoV-2-specific IgIV): Dosage of 0.3-0.5 g/kg daily for 3-5 days has been used or is being investigated in patients with COVID-19(^3, 12, 20) Role of commercially available immune globulin (non-SARS-CoV-2-specific IgIV) and investigational anti-SARS-CoV-2 hyperimmune globulin (anti-SARS-CoV-2 hIgIV) in the treatment of COVID-19 is unclear.(^{36}) The NIH COVID-19 Treatment Guidelines Panel recommends against the use of commercially available IgIV (non-SARS-CoV-2-specific IgIV) for the treatment of COVID-19 except in the context</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Updated</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td>(e.g., primary or secondary humoral immunodeficiency, immune thrombocytopenic purpura) and also used to provide passive immunity to certain viral infections in other individuals. 1, 21, 22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercially available immune globulin (non-SARS-CoV-2-specific IGIV) may contain antibodies against some previously circulating coronaviruses. 2, 3, 13, 18 Antibodies that cross-react with SARS-CoV-1, MERS-CoV, and SARS-CoV-2 antigens have been detected in some currently available IGIV products; however, further evaluation is necessary to assess potential in vivo activity of such anti-SARS-CoV-2 antibodies using functional tests such as neutralization assays. 18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigational SARS-CoV-2 immune globulin (anti-SARS-CoV-2 hyperimmune globulin intravenous [hiGIV]): Concentrated immune globulin preparation containing specific antibody derived from pooled plasma of individuals who have recovered from COVID-19. 16, 23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigational anti-SARS-CoV-2 hiGIV preparations potentially could reduce dissemination and accelerate clearance of SARS-CoV-2 and theoretically may provide both immediate and long-term protection against the virus (e.g., for as long as one month). 2, 16, 23, 24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evaluate safety, tolerability, and efficacy of anti-SARS-CoV-2 hiGIV for treatment of hospitalized adults at risk for serious complications of COVID-19 disease. All enrolled patients will receive treatment with remdesivir. 12, 25 (See Remdesivir in this Evidence Table.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercially Available Immune Globulin (non-SARS-CoV-2-specific IGIV)</td>
<td>SARS Experience: IGIV has been used in the treatment of SARS. 4-7, 15 Benefits were unclear because of patient comorbidities, differences in stage of illness, and effect of other treatments; 5 IGIV may have contributed to hypercoagulable state and thrombotic complications in some patients. 6, 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Open-label, prospective, randomized, controlled study in the US (Sakoulas et al; NCT04411667): Preliminary (non-peer-reviewed) data from a study of 33 adults with COVID-19 and moderate to severe hypoxia (defined as SpO2 ≤96% requiring ≥4 liters O2 by nasal cannula) but not on mechanical ventilation found that IGIV significantly improved hypoxia and reduced hospital length of stay and progression to mechanical ventilation in patients with alveolar-arterial (A-a) gradient ≤200 mm Hg treated with IGIV (Octagam® 10% 0.5 g/kg daily for 3 days) plus standard of care compared with standard of care alone. All 16 patients in the IGIV group received premedication with methylprednisolone (40 mg IV) prior to each IGIV dose and 5 of these received additional glucocorticoid therapy; 10/17 patients in the standard of care group received some glucocorticoid therapy. 10-12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19 case reports in China (Cao et al): Treatment with IGIV at the early stage of clinical deterioration was reported to provide some clinical benefit in 3 adults with severe COVID-19; 2 patients also received antivirals and 1 patient also received short-term steroid treatment. Patients were afebrile within 1-2 days and breathing difficulties gradually improved within 3-5 days of IGIV administration.</td>
<td>of a clinical trial and states that current IGIV preparations are not likely to contain SARS-CoV-2 antibodies. 16 This does not preclude the use of IGIV when it is otherwise indicated for the treatment of complications arising during the course of COVID-19 disease. 16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIH states that there are insufficient data to recommend either for or against the use of investigational SARS-CoV-2 immune globulin (anti-SARS-CoV-2 hiGIV) for the treatment of COVID-19. 16</td>
<td>The Surviving Sepsis Campaign COVID-19 subcommittee suggests that commercially available IGIV not be used routinely in critically ill adults with COVID-19 because efficacy data not available, such preparations may not contain antibodies against SARS-CoV-2, and IGIV can be associated with increased risk of severe adverse effects (e.g., anaphylaxis, aseptic meningitis, renal failure, thromboembolism, hemolytic reactions, transfusion-related lung injury). 18</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 clinical experience in China: IGIV has been used as an adjunct in the treatment of COVID-19 and has been mentioned in Chinese guidelines as a possible treatment option for severe and critically ill children with COVID-19. 9,11,14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Multicenter retrospective study in China:** Among a cohort of 325 patients with severe or critical COVID-19 disease, no difference in 28-day or 60-day mortality was observed between patients who were treated with IGIV and those who were not treated with IGIV. However, patients who received IGIV were older and more likely to have coronary heart disease and critical status at study entry; patients also received numerous other treatments which limit interpretation of these findings. 16, 19

**Retrospective study in China:** 58 cases of severe or critical COVID-19 illness in ICU patients were reviewed. 17 Patients received IGIV in addition to other treatments (e.g., antiviral and anti-inflammatory agents). A statistically significant difference in 28-day mortality was observed between patients who received IGIV within 48 hours of admission compared with those who received IGIV after 48 hours (23 vs 57%). Treatment with IGIV within 48 hours also was associated with reduced duration of hospitalization and reduced ICU length of stay and need for mechanical ventilation. 17

**Efficacy data not available from controlled clinical studies to date.**

**Several clinical studies have been initiated to evaluate efficacy and safety of IGIV (non-SARS-CoV-2-specific IGIV) or anti-SARS-CoV-2 hyperimmune globulin (anti-SARS-CoV-2 hIGIV) in patients with COVID-19, including the following trials:** 12

- NCT04264858
- NCT04350580
- NCT04381858
- NCT04261426
- NCT04411667
- NCT04400058
- NCT04480424
- NCT04546581
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin (Stromectol®)</td>
<td>8:08</td>
<td>In vitro activity against some human and animal viruses 1-6</td>
<td>Limited published clinical data to date evaluating use in the treatment of COVID-19</td>
<td></td>
<td>No published data to date from randomized, controlled clinical trials to support use in the treatment or prevention of COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In vitro evidence of activity against SARS-CoV-2 in infected Vero-hSLAM cells reported with high concentrations of the drug 1</td>
<td>Pilot observational study comparing efficacy of add-on ivermectin in pts with mild to moderate COVID-19 (not peer reviewed): A total of 16 pts received a single dose of oral ivermectin (0.2 mg/kg) given on the day of hospital admission in addition to initiation of treatment with hydroxychloroquine and azithromycin, and results were compared with 71 pts who received hydroxychloroquine and azithromycin alone (matched controls). The primary outcome was percentage of pts cured (defined as symptoms free to be discharged from the hospital and 2 consecutive negative PCR tests from nasopharyngeal swabs at least 24 hours apart) within 23 days. The investigators reported that all 16 pts who received ivermectin were cured compared with 97% of pts who did not receive ivermectin and the mean duration of hospitalization was shorter in the ivermectin group (7.6 days) than in the control group (13.2 days). Note: These results need to be validated in a larger prospective trial. 11 Retrospective cohort study of COVID-19 pts treated with ivermectin (Rajter et al): Outcome data for 173 pts with confirmed COVID-19 who received oral ivermectin at any time during hospitalization (0.2-mg/kg dose; 13 pts received a second dose) in addition to usual care were compared with outcome data for 107 pts who received usual care. Usual care included hydroxychloroquine and/or azithromycin in most pts in both groups; use of these drugs and ivermectin was at the discretion of the treating physician. The primary outcome measure was all-cause in-hospital mortality; secondary outcome measures included mortality in the subgroup of pts with severe pulmonary involvement, length of hospital stay, and extubation rates in mechanically ventilated pts. For the unmatched cohort, overall mortality was lower in the ivermectin group (15%) than in the group not treated with ivermectin (25.2%); overall mortality in the matched cohort also was lower in the ivermectin group (13.3 vs 24.5%). Data for the manufacturer (Merck) states that, to date, there is no scientific basis from preclinical studies for a potential therapeutic effect of ivermectin against COVID-19, no meaningful evidence of clinical activity or clinical efficacy of the drug in patients with COVID-19, and a concerning lack of safety data in the majority of studies. In addition, available data do not support the safety and efficacy of ivermectin beyond the doses used in population studies.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>AHFS Class</td>
<td>Rationale</td>
<td>Trials or Clinical Experience</td>
<td>Dosage</td>
<td>Comments</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>subgroup of pts with severe pulmonary involvement also indicated lower mortality in the ivermectin group (38.8 vs 80.7%). There was no difference in duration of hospitalization between the groups in either the unmatched or matched cohorts (median of 7 days for both groups). There also was no significant difference in extubation rates between groups in either the unmatched or matched cohorts. <strong>Note:</strong> The effect of ivermectin on viral load was not evaluated and the impact of confounding factors in these patients (e.g., time from diagnosis to initiation of treatment, differences in drugs used for standard care and variances in clinical benefits of such drugs) is not known.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Randomized, double-blind, placebo-controlled trial in hospitalized adults (Ahmed et al):** A total of 72 adults with COVID-19 were randomized to receive ivermectin (12 mg orally once daily for 5 days), ivermectin (single 12-mg oral dose) with doxycycline (200 mg orally on day 1, then 100 mg every 12 hours for 4 days), or placebo. The primary end points were time required for virologic clearance (i.e., negative RT-PCR on nasopharyngeal swab) and remission of fever and cough within 7 days. The mean time to viral clearance was 9.7 days in the 5-day ivermectin group, 11.5 days in the ivermectin with doxycycline group, and 12.7 days in the placebo group. There was no significant difference between groups in remission of fever and cough.

**Randomized, double-blind, placebo-controlled trial in adults with mild COVID-19 (López-Medina et al; NCT04405843):** A total of 476 adults (hospitalized or outpatients) with mild disease and symptom onset within the previous 7 days were randomized 1:1 to receive a 5-day regimen of ivermectin (300 mcg/kg daily as an oral solution) or placebo. The primary outcome was the time from randomization to complete resolution of symptoms within the 21-day follow-up. The primary efficacy analysis population included 398 pts (200 received ivermectin and 198 received placebo). Baseline demographic and disease population indicated in regulatory agency-approved prescribing information.  

Ivermectin plasma concentrations attained with dosages recommended for treatment of parasitic infections are substantially lower than concentrations associated with in vitro inhibition of SARS-CoV-2; pharmacokinetic modeling predicts that plasma concentrations attained with dosages up to 10 times higher than usual dosage also are substantially lower than concentrations associated with in vitro inhibition of the virus.

FDA issued a warning concerning possible inappropriate use of ivermectin products intended for animals as an attempt to self-medicate for the treatment of COVID-19. |        |          | and populations indicated in regulatory agency-approved prescribing information. |        |          |
characteristics were well balanced between groups. **Ivermectin treatment did not significantly improve time to resolution of symptoms** in pts with mild COVID-19 (median of 10 or 12 days in the ivermectin or placebo group, respectively). At day 21, 82 or 79% of the ivermectin or placebo group, respectively, had complete resolution of symptoms. 21

**Randomized, double-blind, placebo-controlled pilot study to evaluate ivermectin for reduction of SARS-CoV-2 transmission (Chaccour et al):** Twelve adults with nonsevere COVID-19 who had no risk factors and symptom onset within the last 72 hours were randomized 1:1 to receive ivermectin (single dose of 400 mcg/kg) or placebo. The primary outcome measure was the proportion of patients with detectable SARS-CoV-2 RNA by PCR from nasopharyngeal swab at day 7. Results indicated no difference in the proportion of PCR-positive patients between the ivermectin group and placebo group at day 7 (100% of pts in both groups still had positive PCR). 15

Various clinical trials evaluating ivermectin used alone or in conjunction with other drugs for the treatment or prevention of COVID-19 are registered at clinicaltrials.gov. 10

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage(^a)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nebulized drugs</td>
<td></td>
<td>Potential harm: Concern that use of nebulized drugs (e.g., albuterol) for the management of respiratory conditions in patients with COVID-19 infection may distribute the virus into the air and expose close contacts. 1, 2, 4, 5, 7, 8</td>
<td>Nebulizer treatment used in clinical practice to treat influenza and other respiratory infections is thought to generate droplets or aerosols. In one study, nebulized saline delivered droplets in the small- and medium-size aerosol/droplet range. These results may have infection control implications for airborne infections, including severe acute respiratory syndrome and pandemic influenza infection. 9</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

American College of Allergy, Asthma & Immunology (ACAAI) recommends that nebulized albuterol should be administered in a location that minimizes exposure to close contacts who do not have COVID-19 infection. In the home, choose a location where air is not recirculated (e.g., porch, patio, or garage) or areas where surfaces can be cleaned easily or may not need cleaning. 2, 5

In hospitals, clinicians typically use nebulizers to deliver medications such as albuterol, but are being encouraged to switch to use of metered-dose or dry powder inhalers in patients who are awake and who can perform specific breathing techniques because of the risk of the virus becoming airborne when treating patients infected with COVID-19. 2, 5, 7
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Niclosamide</td>
<td>8:08 Anthelminic</td>
<td>Antiparasitic agent that also has broad antiviral activity&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Currently no known published clinical trial data regarding efficacy or safety in the treatment of COVID-19 Niclosamide may be included in some COVID-19 clinical trials registered at clinicaltrials.gov&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Protocol in one ongoing trial (NCT04399356) specifies a niclosamide dosage of 2 g orally once daily for 7 days for treatment of mild to moderate COVID-19 in adults&lt;sup&gt;3&lt;/sup&gt; Protocol in one ongoing trial (NCT04603924) specifies a niclosamide dosage of 1 g orally twice daily for 7 days for treatment of moderate or severe COVID-19 in hospitalized adults&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Not commercially available in the US Although suggested as a potential treatment for COVID-19 based on its broad antiviral activity, including in vitro activity against coronaviruses, &lt;sup&gt;1&lt;/sup&gt; there are no data to support the use of niclosamide in the treatment of COVID-19</td>
</tr>
</tbody>
</table>

There is a lack of published information and guidance on the optimal administration of aerosolized drugs in the treatment of patients with COVID-19. The safe and effective delivery of aerosol therapy to such patients may require modifications in dosage, frequency, and delivery techniques, as well as use of protective measures.<sup>5,7</sup>

WHO states there is insufficient evidence to classify nebulizer therapy as an aerosol-generating procedure associated with COVID-19 transmission and that further study is needed.<sup>6</sup>

CDC states that it is unclear whether the potential association between nebulizer therapy and increased risk of transmission of COVID-19 infection is related to the aerosol-generating procedure or to increased contact between those administering the nebulized therapy and infected patients.<sup>8</sup> If clinicians need to be present during nebulizer use among patients who have symptoms or a diagnosis of COVID-19, recommended infection control precautions (e.g., social distancing, use of negative-pressure rooms, discarding or disinfecting personal protective equipment after each use) should be followed when aerosol-generating procedures are performed.<sup>7,8</sup>
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Nitazoxanide (Alinia®) | 8:30.92 Antiprotozoal | In vitro activity against various viruses, including coronaviruses \(^4,5\); Structurally similar to niclosamide \(^3,5\); In vitro evidence of activity against SARS-CoV-2 \(^1,14\); In vitro activity against MERS-CoV \(^4\); Suppresses production of proinflammatory cytokines in peripheral blood mononuclear cells; suppresses IL-6 in mice \(^4\); Some in vitro evidence of potential synergism between nitazoxanide and remdesivir and between nitazoxanide and umifenovir against SARS-CoV-2; \(^1\) | Only very limited data available regarding efficacy or safety in the treatment or prevention of COVID-19  
**Experience in treating influenza:** In a randomized, placebo-controlled study in 624 otherwise healthy adult and adolescent patients with acute uncomplicated influenza, treatment with nitazoxanide reduced duration of symptoms by approximately 1 day \(^6\)  
**Experience in treating influenza-like illness:** In two studies for the treatment of influenza-like illness symptoms associated with viral respiratory infection in 186 adults and pediatric pts, treatment with nitazoxanide reduced duration of symptoms (4 days versus ≥7 days with placebo) \(^7\); In another study in 260 adults and pediatric pts hospitalized with influenza-like illness (≥25%) with pneumonia at presentation, treatment with nitazoxanide did not reduce the duration of hospital stay (primary end point) or duration of symptoms \(^7\)  
**Randomized, double-blind, placebo-controlled trial in adults with mild COVID-19 (Rocco et al; NCT04552483):** Total of 392 outpatients were randomized 1:1 to receive nitazoxanide (500 mg 3 times daily) or placebo for 5 days; median time from symptom onset to first dose was 5 days. Percentage of pts experiencing complete resolution of symptoms (i.e., dry cough, fever, fatigue) at 5 days did not differ between pts treated with nitazoxanide or placebo. Nitazoxanide significantly reduced SARS-CoV-2 viral load at 5 days compared with placebo. \(^13\)  
**Randomized, double-blind, placebo-controlled trial in outpatients with mild or moderate COVID-19 (Rossignol et al; NCT04486313; not peer reviewed):** Eligible pts were ≥12 years of age with laboratory-confirmed COVID-19 and onset of symptoms ≤72 hours before randomization to treatment with nitazoxanide (600 mg orally twice daily for 5 days) or placebo. The primary end point was time to sustained response (symptoms were self-reported by the pts); key secondary end point was rate of viral suppression \(^18\) | Dosage of nitazoxanide investigated for treatment of influenza and influenza-like illness or being investigated for other viral infections in adults and adolescents ≥12 years of age: 500 or 600 mg orally twice daily for 5 days \(^5,7,8\)  
Dosage of nitazoxanide specified in protocols of various trials evaluating the drug for treatment of COVID-19 in adults and adolescents ≥12 years of age: 500 or 600 mg two, three, or four times daily for 5-14 days or 1 g twice daily for 7 or 14 days \(^8,13,15,19\)  
Protocol in two trials sponsored by the manufacturer (NCT04343248, NCT04359680) to evaluate nitazoxanide for preexposure and/or postexposure prophylaxis of COVID-19 and other viral respiratory illnesses specifies a dosage of 600 mg orally twice daily for 6 weeks in adults; \(^8\) other studies (NCT04435314, NCT04788407) specify a dosage of 600 mg 3 times daily for 7 days for postexposure prophylaxis in adults \(^8\) | Investigated as a potential treatment for COVID-19 based on its broad antiviral activity, including in vitro activity against SARS-CoV-2 and MERS-CoV \(^1,4,5\); however, data to date are insufficient to support use of nitazoxanide in the treatment of COVID-19. \(^11,16\)  
NIH COVID-19 Treatment Guidelines Panel **recommends against** the use of nitazoxanide for the treatment of COVID-19, except in a clinical trial. \(^11\)  
While nitazoxanide is one of several agents being investigated for postexposure prophylaxis, \(^8\) NIH COVID-19 Treatment Guidelines Panel **recommends against** the use of any agents for postexposure prophylaxis for prevention of SARS-CoV-2 infection, except in a clinical trial. \(^11\) |
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage(^a)</th>
<th>Comments</th>
</tr>
</thead>
</table>
| of progression to severe COVID-19 (defined as shortness of breath at rest and \(\text{SpO}_2 \leq 93\%\) on room air or \(\text{PaO}_2/\text{FiO}_2 < 300\)). Results of efficacy analysis of the modified intention-to-treat population (184 received nitazoxanide and 195 received placebo) indicated that the time to sustained response was not reduced by nitazoxanide compared with placebo (median of 13.28 and 12.35 days, respectively). Subgroup analysis for pts considered at high risk for progression to severe COVID-19 according to CDC criteria suggested that nitazoxanide reduced progression to severe illness compared with placebo; 1 of 112 such pts in the nitazoxanide group (0.9%) and 7 of 126 such pts in the placebo group (5.6%) progressed to severe COVID-19 as defined in the protocol.\(^1\) Note: The study may have been underpowered to detect differences in progression to severe COVID-19 between the nitazoxanide and placebo groups.\(^1\)

**Two randomized, double-blind, placebo-controlled clinical trials** were initiated by the manufacturer (Romark) to evaluate efficacy and safety for preexposure and postexposure prophylaxis of COVID-19 and other viral respiratory illnesses in healthcare workers and others at increased risk of SARS-CoV-2 infection (NCT04359680) or postexposure prophylaxis of COVID-19 and other viral respiratory illnesses in elderly residents of long-term care facilities (NCT04343248)\(^8\)

Nitazoxanide, alone or in combination with other drugs, may be included in some COVID-19 clinical trials registered at clinicaltrials.gov\(^8\)

**Nonsteroidal Anti-inflammatory Agents (NSAIAs)**

**Updated 4/29/21**

| Ibuprofen: Speculative link between ibuprofen and increased ACE2 expression, which possibly could lead to worse outcomes in COVID-19 patients\(^1\) |
| Indomethacin: In vitro antiviral activity in SARS-CoV-2 pseudovirus-infected Vero E6 cells;\(^7\) also has in vitro activity |
| Results from large cohort studies have not found associations between NSAIA use and increased risk of COVID-19 incidence or severity.\(^14\)\(^-)\(^17\)

In a national *registry-based cohort study* in Denmark, NSAIA use was not associated with increased 30-day mortality, hospitalization, ICU admission, mechanical ventilation, or renal replacement therapy in individuals who tested positive for SARS-CoV-2. In this study, of the 9236 individuals who had a positive PCR test for SARS-CoV-2, concerns that anti-inflammatory drugs such as ibuprofen may worsen COVID-19 circulated widely in the early months of the pandemic.\(^5\)\(^,\)\(^12\)\(^,\)\(^14\) These reports were based largely on a letter published in *The Lancet Respir Med* stating that increased expression of ACE2 could facilitate infection with COVID-19 and that ibuprofen can increase ACE2.\(^1\)\(^,\)\(^4\) In addition, there were unconfirmed reports of younger, healthy patients who had used ibuprofen to treat early symptoms of COVID-19 and later experienced...
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Comments</th>
</tr>
</thead>
</table>
|         |            | against other coronaviruses: SARS-CoV-1 (in Vero E6 and human pulmonary epithelial [A549] cells) and canine coronavirus; also has in vivo activity against canine coronavirus in dogs, interferes with viral RNA synthesis<sup>6,8</sup> | 2.7% had used NSAIAAs (defined as individuals having filled a prescription for an NSAIA within 30 days prior to a positive SARS-CoV-2 test) based on national community pharmacy records. The authors note that in Denmark, NSAIAAs are available only by prescription with the exception of low-dose ibuprofen (200 mg) sold over the counter (OTC) in packages of no more than 20 tablets, and such OTC purchases of ibuprofen constituted 15% of total ibuprofen sales and a smaller proportion of total NSAIA sales. This definition of NSAIA use was a major limitation of the study<sup>14</sup> | NSAIA use was not associated with increased incidence of COVID-19 (suspected or confirmed) or all-cause mortality in a UK database-based study comparing 13,202 pts with osteoarthritis who were prescribed NSAIAAs with 12,457 propensity-matched pts who were prescribed comparator analgesics (acetaminophen and codeine/dihydrocodeine).<sup>16</sup> In addition, 2 other large UK database-based cohort studies did not find an association between NSAIA use and increased risk of COVID-19-related death in the general population or in pts with rheumatoid arthritis or osteoarthritis. These studies defined current NSAIA users as individuals with a prescription for an NSAIA within 4 months prior to study entry and compared 536,423 current NSAIA users with 1,927,284 NSAIA nonusers from the general population; among pts with rheumatoid arthritis or osteoarthritis, 175,495 current NSAIA users were compared with 1,533,286 NSAIA nonusers. In multivariate analyses, an increased risk of COVID-19-related death was not observed in NSAIA users.<sup>17</sup> Ibuprofen: In a retrospective cohort study of 403 hospitalized patients with COVID-19 at a single center in Israel, use of ibuprofen (1 week prior to diagnosis or during the course of disease) was not associated with increased mortality or the need for respiratory support compared with acetaminophen or no antipyretic drug.<sup>15</sup> | severe outcomes.<sup>10,12,24</sup> A statement attributed to the WHO recommending paracetamol and avoiding ibuprofen as a self-medication was widely circulated in the media; however, such a position by the WHO has not been substantiated. WHO subsequently performed a rapid review of the literature and concluded that there was no evidence at that time of severe adverse events or effects on acute health care utilization, long-term survival, or quality of life in patients with COVID-19 as a result of the use of NSAIAAs.<sup>9</sup> FDA has stated that it is not aware of scientific evidence connecting the use of NSAIAAs, such as ibuprofen, with worsening COVID-19 symptoms and will communicate publicly when more information is available. FDA also noted that all prescription NSAIA labels warn that by reducing inflammation, and possibly fever, these drugs may diminish the utility of diagnostic signs in detecting infections.<sup>11</sup> Although there currently is no compelling evidence to support an association between ibuprofen and negative outcomes in patients with COVID-19, some experts have recommended preferentially using acetaminophen for treatment of fever.<sup>7,8,10</sup> NIH-COVID-19 Treatment Guidelines Panel states that patients who are receiving NSAIAAs for an underlying medical condition should not discontinue such therapy unless discontinuation is otherwise warranted by their clinical condition; the panel also states that antiviral strategy (e.g., use of acetaminophen or NSAIAAs) in patients with COVID-19 should remain similar to the approaches used in other patients.<sup>5</sup> The Surviving Sepsis Campaign COVID-19 guidelines state that, for critically ill adults with COVID-19 who develop fever, use of acetaminophen over no
### Thrombolytic Agents (t-PA [alteplase], tenecteplase)

**Updated 5/13/21**

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosage(^a)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombolytic Agents (t-PA [alteplase], tenecteplase)</td>
<td>20.12.20 Thrombolytic agents</td>
<td>A consistent finding in patients with severe COVID-19 is a hypercoagulable state, which has been shown to contribute to poor outcomes (e.g., progressive respiratory failure, acute respiratory distress syndrome [ARDS], death).(^1), (^3), (^5), (^9), (^14), (^16), (^18), (^19)</td>
<td>Results of a small phase 1 study suggested possible benefit of plasminogen activators in the treatment of ARDS.(^1) In this study, 20 patients with ARDS secondary to trauma and/or sepsis who failed to respond to standard ventilator therapy and were not expected to survive were treated with urokinase or streptokinase; such therapy improved PaO(_2) and also appeared to improve survival.(^1)–(^3)</td>
<td>t-PA (alteplase): Various IV dosage regimens of t-PA (alteplase) are being evaluated in patients with COVID-19; the optimum dose, route of administration, and duration of treatment remain to be determined.(^2), (^5), (^9), (^12), (^14), (^20)</td>
<td>t-PA has been proposed as a salvage treatment for COVID-19 patients (e.g., those with decompensating respiratory function who are not responding to or do not have access to mechanical ventilation or extracorporeal membrane oxygenation [ECMO]).(^1), (^3), (^14), (^22), (^29)</td>
</tr>
</tbody>
</table>

Coagulation abnormalities observed include prothrombotic disseminated intravascular coagulation (DIC), elevated D-dimer levels, high fibrinogen levels, and microvascular and macrovascular thrombosis.\(^1\), \(^2\), \(^5\)–\(^10\), \(^13\), \(^14\), \(^16\)  
A consistent finding in patients with ARDS (regardless of the cause) is fibrin deposition and microthrombi formation in the alveoli and pulmonary vasculature.\(^1\), \(^11\), \(^14\)  
Many patients are found to have increased dead-space ventilation, a clinical feature of pulmonary embolism and diffuse pulmonary microemboli.\(^27\), \(^28\)  
Dysregulation of the clotting system in ARDS is a result of both enhanced activation of coagulation

Tenecteplase: A low-dose IV bolus of tenecteplase (0.25 mg/kg or 0.5 mg/kg) is being evaluated in the registered NCT04505592 trial.\(^12\)  

---

**Indomethacin:** In vitro studies and animal models only;\(^6\), \(^7\) currently no published studies evaluating use specifically in COVID-19 patients

Indomethacin: Additional data needed to determine whether in vitro activity against SARS-CoV-2 corresponds with clinical efficacy in the treatment of COVID-19

---

\(^a\) The current version of this document can be found on the ASHP COVID-19 Resource Center.
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>AHFS Class</th>
<th>Rationale</th>
<th>Trials or Clinical Experience</th>
<th>Dosagea</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>and suppression of fibrinolysis. 12,19</td>
<td>Other case reports or case series have described the use of t-PA in COVID-19 patients with severe respiratory failure or ARDS who were rapidly deteriorating and were either already on mechanical ventilation or likely to require intubation. Following IV infusion of t-PA (dosages varied), the majority of patients responded with rapid improvement in oxygenation. 21, 24, 28, 30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>fibrinolysis shutdown, as evidenced by complete failure of clot lysis on thromboelastography, has been observed in critically ill patients with COVID-19. 23</td>
<td>In these case reports, multiple confounding factors (including the use of various other treatments) were present, limiting interpretation of findings. 21, 24, 28, 29</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thrombolytic therapy may restore microvascular patency and limit progression of ARDS in patients with COVID-19. 1,14, 15, 22</td>
<td>Multiple clinical trials are ongoing to evaluate thrombolytic agents (alteplase, tenecteplase) in patients with COVID-19; some are registered at clinicaltrials.gov. 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>As of December 16, 2020, there were 6 randomized controlled trials of thrombolytic agents in patients with COVID-19 registered at clinicaltrials.gov or the World Health Organization clinical trials registry. 12, 32 Most of these studies include patients with severe disease (e.g., severe ARDS, elevated troponin levels, elevated D-dimer levels) and are evaluating improvement in PaO₂/FiO₂ ratio or ventilator-free days as the primary efficacy end point. 12, 32</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A phase 2 open-label, nonrandomized pilot study (NCT04356833) is being conducted to evaluate an inhaled formulation of t-PA (via nebulization) in patients with ARDS due to COVID-19; 12 the inhaled formulation of t-PA is investigational at this time 13</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The Anticoagulation Forum recommends against the use of thrombolytic agents in COVID-19 patients outside the setting of a clinical trial unless there is another clinical indication (e.g., STEMI, acute ischemic stroke, high-risk [massive] PE with hemodynamic compromise); in general, thrombolytic therapy is not recommended in the vast majority of patients with PE given limited efficacy data in patients who are hemodynamically stable. 26

The American Society of Hematology states that treatment of the underlying pathology is paramount in COVID-19 patients with coagulopathies; standard risk factors for bleeding should be considered. 8

---

a See US prescribing information for additional information on dosage and administration of drugs commercially available in the US for other labeled indications.
REFERENCES

ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs)


Anakinra:


Anticoagulants


Ascorbic acid:

Azithromycin:


Copyright © 2021, American Society of Health-System Pharmacists, Inc. All rights reserved.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


**Baloxavir:**


**Baricitinib:**


Copyright © 2021, American Society of Health-System Pharmacists, Inc. All rights reserved. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International


**Chloroquine and Hydroxychloroquine:**


Colchicine:


Colchicine:


Corticosteroids (systemic) and Corticosteroids (inhaled):


Updated 08-19-2021. The current version of this document can be found on the ASHP COVID-19 Resource Center.
COVID-19 Convalescent Plasma:


**Favipiravir**


Fluvoxamine:

HIV Protease Inhibitors:


HMG-CoA Reductase Inhibitors (statins)


Copyright © 2021, American Society of Health-System Pharmacists, Inc. All rights reserved.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


j.clim.2020.108459.


**Inhaled Prostacyclins:**


Interferons:


JVI.00272-10. PMID: 32748578.
Ivermectin:
Neuraminidase Inhibitors (e.g., oseltamivir):


Niclosamide:


Nitazoxanide:


Nitric Oxide (inhaled):


NSAIs, including ibuprofen:


**Remdesivir:**


46. Gilead Sciences. Veklury® (remdesivir) for injection and injection prescribing information. Foster City, CA; 2021 Feb.


Ruxolitinib


Sarilumab:


SARS-CoV-2-Specific Monoclonal Antibodies

7. Ojha PK, Kar S, Krishna JG et al. Therapeutics for COVID-19: from computation to practices – where we are, where we are heading to. Mol Divers. 2020 Sep 2;1:35. PMID: 32880078 DOI: 10.1007/s11030-020-10134-x.


Siltuximab:


Sirolimus:


Thrombolytic Agents (t-PA [alteplase], tenecteplase):


Copyright © 2021, American Society of Health-System Pharmacists, Inc. All rights reserved.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


### Tocilizumab:


Umifenovir:

Vitamin D:

Copyright © 2021, American Society of Health-System Pharmacists, Inc. All rights reserved.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International


Zinc:


The information contained in this evidence table is emerging and rapidly evolving because of ongoing research and is subject to the professional judgment and interpretation of the practitioner due to the uniqueness of each medical facility’s approach to the care of patients with COVID-19 and the needs of individual patients. ASHP provides this evidence table to help practitioners better understand current approaches related to treatment and care. ASHP has made reasonable efforts to ensure the accuracy and appropriateness of the information presented. However, any reader of this information is advised ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the evidence table in any and all practice settings. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this evidence table and will bear no responsibility or liability for the results or consequences of its use.